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Background and aims: The World Health Organization (WHO) recommendation for regular 
tuberculosis (TB) screening of people living with HIV (PLHIV) using a symptom screen (WHO 
tool), with Xpert MTB/RIF (Xpert) as the initial diagnostic test has major resource 
implications. This thesis examined alternative investigation pathways, including Determine 
TB-LAM (LF-LAM) for TB screening, a clinical score to triage symptomatic individuals for 
Xpert, and repeating Xpert if the initial test was negative. 
  
Design and setting: Prospective cohort of PLHIV, attending four HIV clinics in South Africa. 
 
Methods: A systematic sample of adults attending for routine HIV care were enrolled in 
the XPHACTOR study, which tested a novel algorithm for prioritising investigation with 
Xpert. At enrolment sputum was collected from all and sent for immediate Xpert if any of: 
current cough, fever ≥3 weeks, body mass index (BMI) <18.5kg/m2, CD4 <100 cells/mm3 (or 
<200 if pre-ART) or weight loss ≥10%; otherwise, sputum was stored. Urine was stored if 
CD4 <200 cells/mm3.  
At attendance for immediate Xpert result, further investigations were facilitated per 
national guidelines. For those at highest risk of TB, who had negative initial Xpert result, a 
repeat sputum sample was stored. Participants were reviewed monthly to 3 months, when 
sputum and blood were taken for mycobacterial culture. At study completion stored sputa 
were tested with Xpert, and urine with LF-LAM. 
We defined TB as “confirmed” if Xpert, line probe assay or culture for M. tuberculosis 
within six months of enrolment were positive, and “clinical” if TB treatment was started 
without microbiological confirmation. 
 
Results: 3722 participants enrolled into XPHACTOR, and 167/3678 (4.5%) fulfilled case 
definitions for TB (124 confirmed, 43 clinical); 32.6% reported WHO tool symptoms. 
Amongst 424 participants with LF-LAM results, 56/424 (13%) had TB (40 confirmed, 16 
clinical). Using grade 1 cut-off on pre-2014 reference card, LF-LAM sensitivity for 
confirmed TB (all clinical TB excluded) in CD4<100 vs. CD4 ≥100 was 16.7% (95% CI 4.7%, 
37.4%) vs. 6.3% (95% CI 0.2%, 30.2%).   
1048 participants who were WHO tool positive at enrolment provided data for 
development of a clinical prediction model for TB. The final model comprised ART status; 
BMI; CD4; number of WHO symptoms. When converted to a clinical score, a cut-off score 
of ≥3 identified those with TB with sensitivity and specificity of 91.8% and 34.3% 
respectively. If investigation was prioritised for individuals with score of ≥3, 68% 
(717/1048) symptomatic individuals would be tested, among whom the prevalence of TB 
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would be 14.1% (101/717); 32% (331/1048) of tests would be avoided, but 3% (9/331) with 
TB would be missed amongst those not tested. 
Amongst 227 participants with an initial negative Xpert result, 28 (12%) had TB diagnosed 
during study follow-up (16 confirmed, 12 clinical); stored sputum tested positive on Xpert 
in 5/227 (2%).  
Conclusion: Sensitivity of LF-LAM as a screening test is too low for use. Our clinical score, 
which requires external validation, may help prioritise TB investigation among 
symptomatic individuals. Amongst PLHIV with a negative Xpert result, further investigation 
using appropriate diagnostic modalities is more likely to lead to TB treatment than 
immediately repeating sputum for Xpert. More efficient TB case finding strategies are 
needed for PLHIV established in care, to minimise unnecessary investigation of large 
numbers who do not have TB.     
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1) Introduction    
This chapter provides a background to the human immunodeficiency virus (HIV) -related 
tuberculosis (TB) epidemic in sub-Saharan Africa, and the steps that have been taken to 
address it. It then describes the changing TB diagnostic landscape in 2011 and the 
implications thereof for resource-limited settings, which form the rationale for the 
research undertaken in South Africa for this thesis.   
 
1.1. Background 
1.1.1. Global burden of tuberculosis 
Tuberculosis (TB) has caused illness and death in human beings for thousands of years, and 
in 2016 was the tenth most common cause of death globally,1 responsible for the deaths of 
an estimated 1.3 million HIV-negative and 300,000 HIV-positive individuals.2 It 
disproportionately afflicts people living with HIV (PLHIV), who are at around twenty-fold 
greater risk of TB than HIV-negative individuals,3 and much more likely to die during and 
after treatment.4, 5 Untreated, the 10-year case fatality rate for pulmonary TB in HIV-
negative individuals is estimated at 20% for smear-negative and 70% for smear-positive 
disease.6 However, once infected with M. tuberculosis (MTB), most individuals with a 
competent immune system do not develop clinically manifest active TB,7, 8 but are thought 
to have latent infection, “a state of persistent immune response to stimulation by MTB 
antigens.”9 Globally there is a large reservoir of latent TB infection (LTBI), around one-
quarter of the world’s population in 2014,10 who have a 5-15% lifetime risk of developing 
disease;7 the risk of reactivation is far greater in people living with HIV (PLHIV).11   
Effective drug treatment for TB has been available since the 1940’s, and prior to this TB 
incidence and mortality had been declining in Western Europe alongside improvements in 
living standards.12 However, particularly in sub-Saharan Africa, the global HIV epidemic 
has resulted in a resurgence of TB.11 In 1993 TB was declared a global health emergency by 
the World Health Organization (WHO)13 when identified in the top six contributors to 
global disease by the 1990 Global Burden of Disease Study.14 The burden of TB remains 
vast, mainly affecting South East Asia and Africa, and there were an estimated 10 million 
incident TB cases globally in 2017.2 Around one-third of this estimated total were not 
notified to national TB programmes and deemed “missing”; presumably undiagnosed, 
unreported, or reflecting the uncertainty around the estimates.2 Going forward the WHO 
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goal is to use national TB case notification data directly as a proxy for TB incidence; 
prerequisites for this are accurate reporting and diagnosis of TB, high quality TB 
surveillance systems and good coverage of quality healthcare.15 For 2017, TB incidence 
estimates were derived for most countries from national case notification data adjusted to 
account for gaps in case-detection, and for the 23 countries accounting for 60% of global 
incident cases using data from TB prevalence surveys.16  
 
1.1.2. HIV-associated tuberculosis 
HIV infection is the strongest risk factor for TB, increasing the risk of disease both after 
recent infection and due to reactivation of latent infection;4 recent transmission plays a 
greater role amongst PLHIV in settings of high HIV and TB prevalence.17 
Immunosuppression caused by the destruction of CD4+ T lymphocytes by HIV infection 
greatly increases the risk of developing active TB,4 with risk increasing as CD4 cell counts 
progressively decline.18 Sub-Saharan Africa, home to over half of all PLHIV,19 has borne the 
brunt of the HIV epidemic, which has fuelled the dramatic resurgence of TB in this region. 
In 2017, 9% of global TB cases were attributable to HIV infection, with most (72%) residing 
in Africa.2 TB remains the leading cause of death amongst PLHIV, responsible for about 
one-third of all HIV-related deaths,20 of which again the majority occurred in Africa in 
2017.2  
Early diagnosis with prompt treatment is a key strategy to help reduce HIV-related TB 
morbidity and mortality, yet delay in treatment for pulmonary TB amongst adults in sub-
Saharan Africa is well documented, due to delays in presentation for care and at health 
system level.21-23 Tackling TB in PLHIV is made much harder by limitations in existing 
diagnostic tests, most of which lose accuracy as immunosuppression progresses, and the 
increased frequency of atypical presentations such as extrapulmonary and disseminated 
disease.24 Classical chest radiograph features such as cavitation, known to be associated 
with increased bacillary load in sputum,25 are less likely with advanced 
immunosuppression, 26 and PLHIV are more likely to have smear-negative pulmonary TB.27-
29  
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1.1.3. Ending the tuberculosis epidemic   
The first global response to the resurgence of TB in the early 1990’s was the WHO Directly 
Observed Treatment Short-course (DOTS) strategy.30 DOTS standardised the anti-TB 
treatment regimen, and emphasised diagnosis using quality-ensured sputum microscopy to 
enable treatment of those most infectious, i.e. smear-positive TB, setting targets for 
detecting 70% of estimated TB cases and curing 85%. In addition, sustained political and 
financial commitment, good health-system infrastructure to enable an uninterrupted 
supply of anti-TB medication, and standardised data collection to enable monitoring of 
national TB programmes were prioritised. Subsequent global strategies to reduce the 
burden of TB broadened in scope to address HIV-associated and multidrug-resistant (MDR) 
TB and set targets firstly within the Millennium Development Goals (MDGs) and Stop TB 
strategy. MDG 6C to “halt and reverse TB incidence” was attained globally by 2015,31 and 
the additional Stop TB partnership targets32 to halve TB mortality and prevalence 
compared with 1990 levels by 2015 were almost reached globally at 47% and 42% 
respectively.31   
Post-2015 targets lie within the broader Sustainable Development Goals (SDGs)33 which 
succeeded the MDGs and the WHO End TB strategy.34 SDG 3 focusses on health and 
includes aims to end the epidemics of HIV, TB, malaria and neglected tropical diseases by 
2030, and achieve universal health coverage.33 End TB aims for a 95% reduction in TB 
deaths and a 90% reduction in the TB incidence rate by 2035 compared with 2015, for zero 
TB-affected households to experience catastrophic costs due to TB by 2020, and universal 
drug susceptibility testing (DST).34 Progress needs to be accelerated to reach the End TB 
targets. In order to reach the first End TB milestones by 2020 the decline in TB incidence 
which was 2% per year in 2015 has to reach 4-5%, and TB mortality has to decline from 16% 
of TB cases to 10%.35 This slow decline in TB incidence is likely due to ongoing transmission 
because of delayed diagnosis in individuals with active TB, progression to active TB 
amongst individuals from the large reservoir of those with LTBI,36 and a need to also 
address the social determinants of TB.37 In September 2018, at a high-level United Nations 
(UN) meeting, political leaders reaffirmed their commitment to ending the global TB 
epidemic by 2030. Their pledges included screening all PLHIV regularly for TB, finding the 
missing people with TB, and by 2022 to have treated 40 million people for TB and 30 
million for LTBI (including 6 million PLHIV).38  
 
 
Introduction 
Page | 19  
 
1.2. Addressing the burden of TB in PLHIV   
In response to the huge burden of HIV-related TB, the WHO produced guidance in 200439 
which was updated in 2012, recommending a 12 point package of collaborative TB/HIV 
activities.40 These comprise activities to ensure delivery of integrated TB/HIV services; 
“the Three I’s for HIV/TB” to reduce the burden of TB in PLHIV and initiate early ART; and 
to reduce the burden of HIV in patients with presumptive or diagnosed TB. The Three I’s 
strategy comprises: intensified TB case-finding (ICF); providing isoniazid preventive 
therapy (IPT) for those eligible and early ART; and ensuring TB infection, prevention and 
control (IPC). ICF, treatment for LTBI and early ART are discussed in further detail below. 
 
1.2.1. Intensified TB case-finding 
Intensified TB case-finding, provider-initiated regular screening to identify active TB, aims 
to diagnose TB earlier and therefore help to reduce suffering, mortality and TB 
transmission.36 ICF also enables a healthcare worker (HCW) to rule out active TB in PLHIV 
prior to treatment for LTBI and ART initiation, thus avoiding inadvertent LTBI treatment 
for individuals who need TB treatment and minimising the risk of immune reconstitution 
inflammatory syndrome (IRIS).41  
A screening tool for TB aims to distinguish those individuals likely to have TB from those 
who probably do not have TB. Individuals identified as likely to have TB require 
investigation with a diagnostic test to detect MTB.36 In order to reliably rule out TB the 
tool used for screening requires high sensitivity, i.e. the proportion of individuals with 
disease correctly identified (true positives). The specificity of a screening tool refers to 
the proportion of individuals without disease who are correctly identified (true negatives). 
There is always a trade-off between sensitivity and specificity, hence a screening tool 
designed to maximise sensitivity will lose specificity, but combining it with a diagnostic 
test with high specificity can create an algorithm with high combined sensitivity and 
specificity.36  
A TB screening tool with low specificity will result in a large proportion of those screened, 
many of whom will not have TB, requiring a diagnostic test for TB. This will place a strain 
on scarce resources in low- and middle-income countries (LMIC) and potentially hinder 
scale-up of LTBI treatment. For example, if 1000 HIV-positive individuals are screened for 
TB in a setting where TB prevalence is 5%, using a tool with sensitivity and specificity of 
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80% and 50% respectively (reflecting the performance of the recommended WHO TB 
screening tool in PLHIV), then 475 individuals would undergo unnecessary TB investigation 
(Table 1-1).   
Table 1-1 Relationship between result of screening tool with 50% specificity and 
identification of true negatives 
Result of screening tool TB disease No TB disease Total 
Positive 40 475 515 
Negative 10 475 485 
Total 50 950 1000 
*Assumes prevalence of TB is 5%, and screening tool has sensitivity and specificity of 80% and 50% 
respectively 
 
In the same setting, using a screening tool with sensitivity and specificity of 50% and 70% 
respectively (reflecting the performance of the recommended WHO TB screening tool in 
PLHIV on ART),42 will result in fewer (285) individuals requiring unnecessary investigation 
for TB (Table 1-2).  
 
Table 1-2 Relationship between result of a more specific screening tool and identification of 
true negatives 
Result of screening tool TB disease No TB disease Total 
Positive 25 285 310 
Negative 25 665 690 
Total 50 950 1000 
 
*Assumes prevalence of TB is 5%, and screening tool has sensitivity and specificity of 50% and 70% 
respectively 
 
Health care workers (HCW) may not use a screening tool if they perceive it to be 
inaccurate and thus poor use of their time in already overstretched services. Cross-
sectional surveys from South Africa of consecutive adults leaving primary health clinics, 
which enrolled those with symptoms suggestive of TB when screened at exit by research 
staff, found only 4-50% had been asked about TB symptoms and less than 25% to submit a 
sputum sample by clinic staff.23, 43, 44 Even amongst those specifically attending for TB-
related symptoms, less than 40% reported that clinic staff had requested a sputum sample. 
Introduction 
Page | 21  
 
Limitations of these studies include reliance largely on participant self-report of HCW 
asking about TB symptoms or for sputum, and a large number44 or lack of data23 regarding 
the number of individuals not screened for study eligibility which limits generalisability. 
The aforementioned studies were conducted between 2011 to 2015,23, 43, 44 and the low 
rates of TB screening and investigation are concerning, particularly as the researchers 
identified bacteriologically confirmed TB in 5% of those who were not investigated by 
clinic staff.23, 44 The WHO recommended tool for TB screening and further evaluation of 
those identified as more likely to have TB are discussed in more detail later, as this is 
central to the rationale for the research undertaken in this thesis. 
 
1.2.2. Antiretroviral therapy 
ART reduces the incidence of TB by about 65%, irrespective of baseline CD4 count, with 
the greatest reduction in those with advanced immunosuppression.45 Since 2015 the WHO 
has recommended ART for all PLHIV (“treat-all”),46 based on evidence of marked reduction 
in severe HIV-related (mainly TB and invasive bacterial disease) and non-HIV related illness 
and death,47, 48 improved likelihood of restoration of immune function,47 and reduction in 
HIV transmission.49 This strategy increases ART uptake,50, 51 and modelling using data from 
sub-Saharan Africa suggests that annual HIV testing with immediate ART could avert 40% of 
TB cases between 2015 and 2050.52 Fast-Track targets established to rapidly scale up HIV 
treatment and prevention strategies for SDG 3, set the first milestone to reach “90-90-90” 
targets by 2020.53 These comprise 90% of PLHIV knowing their status, 90% of those HIV-
positive receiving ART, and 90% on ART to be virally suppressed; and thus for 73% of all 
PLHIV to have suppressed viral loads.  
In South Africa, at a time when ART eligibility criteria comprised CD4 count ≤ 200 
cells/mm3 or advanced WHO clinical stage, almost 20% of ART-eligible individuals 
systematically screened for TB had previously undiagnosed bacteriologically-confirmed 
pulmonary TB.54-56 A systematic review of studies published between 2000 and 2012 
estimated a TB incidence rate of 4.17 per 100 person-years (P-Y) in individuals on ART in 
higher TB burden settings, greatest in those with lower CD4 cell counts.57 TB is one of the 
most common causes of mortality within 12 months of starting ART in sub-Saharan Africa.58 
These data highlight the importance of screening for TB prior to and at regular intervals 
following ART initiation. 
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1.2.3. Preventive therapy for treatment of latent TB infection 
Treatment of LTBI in PLHIV reduces the risk of developing active TB by at least one-
third,59, 60 and is of greatest benefit in those with a positive tuberculin skin test (TST) in 
whom the risk of TB is reduced by about two-thirds,59 when compared with placebo. 
Amongst adults attending HIV clinics in Botswana, extending IPT to 36 months was more 
effective, largely amongst those with positive TST, in preventing TB than the standard 6 
month course; ART had an additive beneficial effect.60 In South Africa, amongst individuals 
established or recently initiating ART, 12 months of IPT reduced TB incidence by 37%;61 
and a similar degree of benefit was shown in Ivory Coast when IPT was given for 6 months 
shortly after early ART initiation.47 2018 WHO LTBI guidelines recommend extended IPT 
(36 months rather than 6 months) in TB endemic settings for adults and adolescents with 
positive or unknown TST status.9 TB disease must be excluded prior to preventive therapy, 
and scale up of LTBI treatment therefore requires a reliable TB screening tool. In South 
Africa TST is not required prior to IPT; for those on ART IPT duration is 12 months if TST-
negative or TST–unknown, and at least 36 months if TST-positive.62 Here HCW concerns 
about accurately ruling out TB have been identified as a barrier to IPT implementation.63, 
64  
 
1.2.4. Impact of the Three I’s 
Advanced HIV disease related illness, in particular TB, remained the leading global cause 
of both admission and in-hospital mortality amongst PLHIV in a systematic review covering 
the decade commencing 2007.65 Low CD4 cell counts were associated with admission for 
TB, and less than half of patients were on ART at admission.65 A review of post-mortem 
studies of PLHIV in LMIC published between 1992 and 2012 reported a pooled estimate of 
autopsy prevalence of TB in adults of 40%.66 A study which prospectively enrolled PLHIV 
from primary care clinics in South Africa reported a similar prevalence of TB on autopsy.67 
Almost half of TB cases in the review were only diagnosed at post-mortem, and in most 
cases TB was deemed the primary cause of death and disease was disseminated suggesting 
advanced immunosuppression.66 The studies conducted in sub-Saharan Africa suggested an 
increase, by about 5% each decade between 1992 and 2012, in the autopsy prevalence of 
TB in adults.66 However as autopsy studies are generally undertaken in a highly selected 
group of hospitalised patients, it is not possible to infer that this trend is truly 
representative of deaths amongst HIV-positive individuals during this period.  
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The aforementioned burden of TB in hospitalized PLHIV together with reports of poor 
adherence to TB screening68 and diagnostic23, 43, 64, 69 guidelines by healthcare workers in 
sub-Saharan Africa indicate that much more still needs to be done to tackle HIV-related 
TB. However recent descriptive analyses suggest a possible population level impact of ART 
on TB control in countries where HIV has driven the resurgence of TB.2, 70 In six Southern 
African countries with HIV-related TB epidemics, between 2010 to 2017 (a period of rapid 
increase in HIV care and ART coverage) there has been a sustained decline in TB case 
notifications.2 South Africa is one of these six countries and here TB incidence is estimated 
to have declined rapidly at an average annual rate of 7%.2 An analysis of publicly available 
data from 2010 to 2015 identified a more rapid decline in estimated TB case notification 
rates amongst PLHIV than HIV-negative individuals in sub-Saharan Africa, with greater 
decline in countries with greater ART coverage.70 It is not however possible to assign 
causality from these ecological studies, and factors other than ART rollout may also have 
played a role, e.g. strengthening of health care systems or expansion in IPT provision.2, 70    
  
1.2.5. WHO 4-symptom TB screening algorithm (WHO tool) 
Screening for TB in order to rule out active disease is the entry point to LTBI treatment, 
and is recommended before initiation of ART, and at every clinical encounter in an effort 
to address HIV-related TB.40 The performance characteristics and cost of the selected 
screening tool for ICF and the diagnostic test for TB, as well as the prevalence of TB in the 
population to be screened, are key considerations to ensure both appropriate care and 
efficient allocation of limited resources. Measures of diagnostic accuracy include 
predictive values which relate to sensitivity and specificity through disease prevalence. 
Positive predictive value (PPV) is the proportion of individuals with a positive test result 
who have disease, and negative predictive value (NPV) is the proportion of individuals who 
screen negative who are disease-free. The number needed to be screened (NNS) refers to 
the number of individuals who need to be screened in order to identify one case of TB, is 
dependent on the characteristics of the screening tool and varies with disease prevalence. 
NNS is 1/prevalence if the screening test is perfect (100% sensitivity and 100% specificity), 
and increases as disease prevalence decreases. PPV of a test increases as disease 
prevalence increases, with most of the gain occurring with increases from the lowest rates 
of prevalence,71 and NPV reduces as disease prevalence increases. Another characteristic 
measured, which is not dependant on the prevalence of the disease, is the negative 
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likelihood ratio (LRN) which indicates the change in the odds of having a condition if a 
screening test is negative; the smaller the LRN, the greater the reduction in odds. 
In 2008 absence of a simple, standardised, evidence-based tool to rule out TB amongst 
PLHIV in resource limited settings was identified as contributing to lack of scale up of IPT. 
Many TB screening studies have been published, from different settings and at different 
stages in an individual’s pathway through HIV care, and each identified a different optimal 
combination of symptoms and/or clinical features.55, 72-79 In order to produce a 
standardised tool WHO facilitated an individual participant data meta-analysis of 
observational screening studies published between 2002 and 2010,80 using a gold standard 
of culture-confirmed TB from any specimen with most studies collecting only sputum 
samples. The screening tool developed comprises any one of four symptoms (current 
cough, fever, weight loss or night sweats). It was designed to rule out TB so maximises 
sensitivity (78.9%), and to minimise the LRN for TB, and for ease of use. However, a 
consequence of maximising sensitivity is lack of specificity (49.6%), so half of those 
without TB are incorrectly identified as requiring further evaluation (as illustrated in 
Table 1-1).   
The WHO tool has a very high NPV, 97.7% at a TB prevalence of 5% in PLHIV, so absence of 
all symptoms effectively rules out TB; and in the meta-analysis a NNS of 12 (amongst all 
participants) was reported at 5% TB prevalence.80 However its PPV is only 8% (at a TB 
prevalence of 5%), so the vast majority of those who screen positive will not have TB 
(475/515 [92%] as illustrated in Table 1-1), yet will require further evaluation for TB. This 
simple screening tool, primarily designed to rule out TB prior to preventive therapy for 
LTBI in PLHIV, is the recommended tool for ICF in PLHIV at every clinical encounter.40, 81 
Since 2010 WHO has recommended Xpert MTB/RIF (Cepheid, Sunnyvale, CA; henceforth 
Xpert) as the initial diagnostic test for TB in PLHIV.82 The combination of a screening tool 
that lacks specificity with an expensive diagnostic test for TB poses a huge challenge in 
resource-constrained settings, as discussed further below.  
The original WHO meta-analysis and a systematic review undertaken for the 2018 WHO 
LTBI guidelines to determine the accuracy of the WHO tool to rule out TB in individuals on 
ART are discussed in further detail in the literature review (Chapter 2).9, 42, 80 
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1.2.6. Diagnostic tests for active TB   
In 2017, only 64% (6.4 million), 51% (464,633), and 29% (160,684) of the global estimated 
number of people with an incident TB episode, HIV-related TB, and drug-resistant TB 
respectively were actually notified to national programmes and then reported to WHO.2 
14% of notified incident TB diagnoses were extrapulmonary, and amongst pulmonary TB 
diagnoses only 56% were bacteriologically confirmed. Individuals with coincident 
pulmonary and extrapulmonary TB are notified as pulmonary TB, hence the actual 
proportion with extrapulmonary TB is likely to be greater.83 Access to a rapid, accurate 
diagnostic test for TB is one key element to addressing the gaps between estimated and 
notified TB diagnoses, and the three main tests currently used (microscopy, culture and 
nucleic acid amplification assays), as well as testing for lipoarabinomannan (LAM) which is 
not recommended for general use are discussed below.  
In 2014 WHO identified four high priority areas for new TB diagnostics.84 These comprised 
three point-of-care (POC) tests, one non-sputum-based test to detect all forms of TB, one 
to triage patients for confirmatory testing, and one sputum-based test for pulmonary TB to 
replace smear microscopy. The fourth product identified was a rapid drug-susceptibility 
test (DST) for use in lower tiers of laboratory service closer to primary health care. As 
highlighted by this report, there is a great need in resource-constrained settings for a 
simple triage test for use at lower levels of care after screening for TB. A triage test 
would identify amongst symptomatic individuals those at greatest risk of TB who should 
have confirmatory testing, so that the volume of individuals requiring an expensive 
diagnostic test (Xpert) can be reduced. Minimum sensitivity (>90%) and specificity (>70%) 
requirements were agreed by consensus for this test.84 
 
Smear microscopy 
First developed in the 1880s, smear microscopy of sputum or other specimens using the 
Ziehl-Neelsen (ZN) bacteriological stain to identify acid-fast bacilli (AFB) is still widely 
used in resource-limited settings to identify mycobacteria. It is simple, inexpensive, rapid, 
and requires little infrastructure, thus making it suitable for use at peripheral laboratory 
level. However it is insensitive against a gold standard of culture-confirmed MTB, requiring 
an estimated 5,000 bacilli per milliliter of sputum for a positive result, and cannot 
distinguish MTB from non-tuberculous mycobacteria (NTM).85, 86 The reported sensitivity of 
smear microscopy is highly variable, from 20% to 80%.85 Sensitivity is further reduced 
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amongst PLHIV who are more likely to have paucibacillary and extrapulmonary disease.54, 
75, 87 Replacement of conventional microscopy by light-emitting diode (LED) fluorescence 
microscopy which is 10% more sensitive, inexpensive, and faster, is now recommended by 
WHO.86 
 
Mycobacterial culture 
Mycobacterial culture is the current gold standard test for identifying MTB, requiring only 
10 to 100 bacilli per millilitre of sputum. However, culture takes time, ranging from 7-14 
days (longer if bacillary load is lower) for automated systems using liquid media which are 
more prone to contamination, to four weeks for a positive result using traditional solid 
media. Mycobacterial culture is also expensive, requiring infrastructure which may not be 
feasible at peripheral laboratories, and thus access is limited in resource-constrained 
settings.85 
 
Cepheid® Xpert® MTB/RIF assay 
In 2010 WHO recommended Xpert as the initial diagnostic test for PLHIV, replacing sputum 
microscopy.82 Xpert is an automated polymerase chain reaction (PCR) based test that 
provides rapid (turnaround time 2 hours) and simultaneous detection of both TB and 
rifampicin resistance, and requires only 131 bacilli per millilitre of sputum for detection. 
Sample processing and PCR take place within the GeneXpert cartridge, so that after the 
sputum sample is inserted all further processes are fully automated, enabling near patient 
testing with minimal operator requirements.  
A 2014 Cochrane review reported pooled sensitivity and specificity of Xpert for culture-
positive pulmonary TB in PLHIV of 79% (95% credible intervals [CrI] 70-86%) and 98% (95% 
CrI 96-99%) respectively, which is far superior to the performance of sputum smear 
microscopy.88 Xpert performs less well for smear-negative, culture-positive pulmonary TB 
in PLHIV;56, 89 with pooled sensitivity of 61% (95% CrI 40-81%) vs. 97% (95% CrI 90-99%) 
respectively for smear-negative vs. smear-positive, culture-positive TB.88 There does 
appear to be an incremental yield from additional samples which is discussed further in 
the literature review (Chapter 2).  
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In order to further improve the diagnosis of HIV-related and paucibacillary TB, Cepheid 
have developed Xpert Ultra (henceforth Ultra), which is more sensitive than Xpert (90% vs. 
77%) for sputum culture-positive TB in PLHIV. Overall, Ultra is also more sensitive than 
Xpert for sputum smear-negative and culture-positive TB (63% vs. 46%), however 
specificity is reduced (96% vs. 98%) and this is speculated to be due to detection of DNA 
from non-viable MTB, which may result in inappropriate TB treatment in individuals 
without TB.90 Ultra uses the same GeneXpert platform as Xpert, and WHO has endorsed its 
use as an alternative to Xpert. A truly POC, battery-operated device, GeneXpert Omni, 
which is suitable for use in health care facilities is currently in development.85 Cepheid 
have, in the interim, launched GeneXpert Edge, a portable, battery-powered, single 
module system compatible with both Xpert and Ultra cartridges.91  
In 2013 the recommendations for Xpert were updated to include use in children, for 
extrapulmonary samples such as cerebrospinal fluid or lymph nodes, and if resource 
allowed for consideration as the initial diagnostic test in all adults.92 Although designed to 
be used near-patient, rollout of Xpert to peripheral health centres has been limited by 
cost, requirements for an uninterrupted power supply, and a maximum recommended 
operating temperature of the GeneXpert platform of 30°C. The cost per Xpert cartridge, 
even with preferentially negotiated pricing which is available only to the public sector in 
LMIC, is US$9.98.93 Laboratory cost analysis in South Africa indicates a cost per test 
conducted (including consumables, equipment, labour and overheads) of US$14.93 for 
Xpert vs. US$2.25 for ZN smear microscopy (US$3.40 for fluorescence smear microscopy). 
The cost for liquid culture (Mycobacterial Growth Indicator 960 automated liquid culture 
system [MGIT]) was US$12.16 in this analysis, so comparable to Xpert.94 In spite of WHO 
recommendations, a 2017 Médecins Sans Frontières (MSF) survey of national TB policies 
and practices undertaken in 29 countries (all but three featuring in at least one WHO high 
burden category for TB), reported that only 15/28 (54%) had implemented on a wide scale 
Xpert as the initial diagnostic test for PLHIV and other high risk groups.95 
In 2011, South Africa made a policy decision, to replace sputum microscopy with Xpert as 
the initial diagnostic test for TB. From 2010 to 2016, South Africa purchased both the most 
Xpert cartridges under concessional pricing (11 million) and the most GeneXpert Xpert 
MTB/RIF modules (four thousand), globally; and in 2016 alone purchased almost 2.5 million 
cartridges.96 In spite of the cost implications of replacing microscopy with a much more 
expensive test, mathematical modelling predicted cost-effectiveness of this strategy in 
sub-Saharan Africa because of reduction in early mortality on ART97 and increased TB case 
finding.98 Subsequent modelling, using data collected during the rollout of Xpert in South 
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Africa, found that this strategy had little impact on either cost or cost-effectiveness of TB 
evaluation and treatment (within 6 months of the initial diagnostic test).99 From 2017 
South Africa commenced a phased rollout of Ultra to replace Xpert. 
Two randomized trials in Southern Africa in “real-world” settings, which compared testing 
sputum with Xpert vs. microscopy in symptomatic patients attending primary health 
facilities, did not find differences in morbidity, mortality, or the overall proportion of 
adults starting TB treatment.100, 101 TB-NEAT was a pragmatic multicenter trial, in which 
patients were randomly assigned to either on-site Xpert (performed by a nurse) or 
microscopy (performed by a technician at an attached or nearby laboratory) with provision 
of same-day test result.101 Patients who could provide two spot sputum samples were 
enrolled. One sample underwent mycobacterial culture and the other either same day 
Xpert or microscopy; patients were asked to wait for the test results, during which time 
they underwent chest radiography. More patients in the Xpert vs. microscopy arm started 
same day TB treatment (17% vs. 9%), mainly based on positive Xpert. TB-NEAT reported a 
high level of empiric TB treatment, largely based on chest radiograph. This ease of access 
to chest radiography and point-of-care Xpert is not generalizable to most clinics in sub-
Saharan Africa and does not reflect routine clinical care in these settings. Although about 
15% of culture-confirmed cases were missed in the microscopy group, the proportions of 
culture-negative patients who received TB treatment did not vary between Xpert and 
microscopy arms.101 XTEND was a pragmatic cluster-randomised trial, embedded within 
the national roll out of Xpert in South Africa, with clusters (laboratories) allocated to 
either Xpert or microscopy for adults investigated for TB by clinic staff. Investigators 
found between the two groups no difference in 6-month mortality, the proportion who had 
started TB treatment, or time to treatment in those with a positive test result. Although 
mycobacterial culture was not routinely done due to the pragmatic nature of XTEND, in 
accordance with TB-NEAT these findings also suggested that Xpert had replaced empirical 
treatment rather than improving TB case-finding.100  
Analysis of programme data from Cape Town, over a period (2010 to 2014) spanning the 
national Xpert rollout (2011-2013), found amongst HIV-positive individuals a reduction in 
TB notification rates of 19% and halving of empiric TB treatment rates, with a slight 
increase of 3% in the rate of bacteriologically confirmed TB.102 A similar pattern was seen 
in notification rates amongst HIV-negative individuals. At the end of the period, however, 
more than a quarter of HIV-positive TB patients were still treated empirically. The authors 
postulate that rates of empiric treatment and/or TB case notification rates may have 
declined during this period, but firm conclusions could not be drawn using this 
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observational data. The high levels of empiric TB treatment, also reported globally,2 
indicate a great need for accessible, low cost, non-sputum based diagnostic tests capable 
of detecting both pulmonary and extrapulmonary TB.84 
 
Testing for urine lipoarabinomannan 
LAM, a cell wall lipopolysaccharide specific to mycobacteria that is detectable in urine, 
can be tested for using a POC lateral flow LAM assay (LF-LAM) (Determine TB-LAM; Alere, 
USA). LF-LAM has many attractive attributes, including relatively low cost (around US$ 
3.50 per test), rapid results (within 25 minutes), low biosafety risk, and ease of sample 
collection; but it has poor sensitivity (45% in symptomatic PLHIV for bacteriologically-
confirmed TB).103 LF-LAM sensitivity, against a gold standard of bacteriologically-
confirmed TB, is inadequate for use as a screening tool for TB either prior to ART 
initiation,104, 105 or on receiving a new HIV-positive diagnosis;106, 107 studies evaluating its 
utility as a screening test are discussed in the literature review.  
LF-LAM sensitivity increased when evaluated in hospitalised HIV-positive patients with TB 
symptoms in Uganda and South Africa, particularly amongst those with advanced 
immunosuppression for whom very high specificity (99%)108 suggests possible utility as a 
rule-in test for TB in this population.109-111 Even in symptomatic, hospitalised PLHIV with 
advanced immunosuppression, LF-LAM sensitivity is suboptimal; therefore 2015 WHO 
guidance supports its use only to assist TB diagnosis in symptomatic PLHIV with CD4 counts 
≤100 cells/mm3, or those who are seriously ill irrespective of CD4 count.112 This 
recommendation is supported by the recently published STAMP trial.113 STAMP evaluated 
the impact on 56-day mortality of screening HIV-positive inpatients with urine LF-LAM, 
within 48 hours of admission.113 Participants were randomly assigned to standard-of-care 
evaluation by the attending clinician, or additional urine LF-LAM test. At enrolment 
sputum was requested from all participants and tested with Xpert. The results of all TB 
screening tests were reported to the responsible clinical teams only as positive or negative 
so that the study groupings were not revealed. There was no difference in overall 2-month 
mortality between groups, but in three pre-specified high-risk groups (CD4 <100 
cells/mm3, severe anaemia, clinically suspected TB) mortality was lower in the group who 
underwent LF-LAM testing. A more sensitive LAM test, Fujifilm SILVAMP TB LAM, developed 
by the Foundation for Innovative New Diagnostics (FIND) is undergoing clinical 
evaluation.114 
Introduction 
Page | 30  
 
  
1.3. Context of the work conducted for this thesis     
1.3.1. Country setting: South Africa   
South Africa is classified by the World Bank as an upper middle-income country, but has 
high levels of poverty disproportionately affecting black South Africans. It is one of the 
most unequal countries in the world, and levels of inequality have increased since the end 
of apartheid in 1994.115 South Africa is home to the world’s largest HIV epidemic, 19% of 
the world’s HIV-positive individuals; and has the world’s largest HIV treatment 
programme.116 2017 data estimate between seven117 to eight118 million PLHIV in a country 
with a population of just 56 million in 2016. Major strides have been made in the fight 
against HIV, and the country is in the process of ensuring universal health coverage 
through implementation of national health insurance.119 In 2015 South Africa rolled out 
immediate lifelong ART for all PLHIV irrespective of CD4 cell count, and recommended 
viral load as the preferred option for monitoring treatment success.120 The following year 
pre-exposure prophylaxis (PrEP) for key populations was approved.121 
The Fifth South African national HIV prevalence survey, a cross-sectional household survey 
undertaken in 2017, reported adult (ages 15 to 49 years) HIV prevalence of 20.6% (26.3% 
vs. 14.8% in females vs. males), disproportionately affecting black Africans, adolescent 
girls, and young women; and with a marked geographical variation from 12.6% in Western 
Cape to 27% in KwaZulu-Natal.118 In this survey 82% of households approached completed 
an interview, and amongst eligible adults (ages 15 to 64 years) 68% vs. 58% of women vs. 
men provided blood for HIV testing. Lower participation rates might explain the low 
reported HIV prevalence in males as it is not clear if the prevalence estimates reported 
were adjusted for non-response. The estimated annual HIV incidence in adults (ages 15-49 
years) was 0.79%, a reduction compared with 1.79% in the previous 2012 survey.122   
UNAIDS 2017 data estimate adult (ages 15-49) HIV prevalence of 18.8% and indicate South 
Africa has reached the first of the 90-90-90 targets, with 90% of all estimated PLHIV aware 
of their status, 61% of whom are accessing ART, and 47% of those on ART with suppressed 
viral load.117 2017 national survey data report attaining 85%-71%-86% with respect to the 
90-90-90 targets.118 Between 2010 and 2017, the annual number of new HIV infections 
reduced by 31%, and AIDS-related deaths reduced by 43%, to 270,000 and 110,000 
respectively in all age groups.117  
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South Africa has one of the world’s worst TB epidemics, driven by its HIV epidemic. In 
2017 it ranked second in the world in terms of the percentage of TB patients who were 
HIV-positive (60%), TB mortality amongst PLHIV (99/100,000 population), and the overall 
per capita TB incidence (567 per 100,000 population); as well as accounting for 3% of the 
global total of incident TB cases.2 89% of TB cases notified (new and relapse) were 
reported to have pulmonary disease, and amongst those 65% were reported to be 
bacteriologically confirmed (largely by Xpert). South Africa appears in all three of the 
WHO high-burden country lists for TB, TB/HIV, and multidrug resistant (MDR) TB, and 
ranks ninth amongst the top ten countries with the largest gaps between notification of 
incident TB cases and best estimate of TB incidence.2 WHO TB incidence estimates for 
South Africa are derived from case-notification data adjusted using expert opinion to 
estimate case-detection gaps. TB incidence estimates have recently been revised in light 
of the consistent downward trend in TB case notifications; a national TB prevalence survey 
is currently underway and will better inform incidence estimates. The overall prevalence 
of drug resistance was found to be high in the 2012-2014 South African TB drug resistance 
survey.123 It was 2.8%, 4.6% and 9.3% respectively for MDR TB, any rifampicin and any 
isoniazid resistance respectively.123 Compared with the previous 2001-2002 survey the 
overall MDR TB prevalence was similar, but the prevalence of rifampicin resistance in new 
cases was much greater; overall prevalence of both MDR and rifampicin-resistant TB was 
much greater in HIV-positive vs. HIV-negative individuals with TB (3.1% vs. 2.0% for MDR 
TB, and 4.9% vs. 3.2% for rifampicin resistant TB respectively).  
South Africa performs well in terms of some, but not all, TB/HIV collaborative activity 
statistics. In 2017, 94% of TB cases had known HIV status, with 89% of those who were HIV-
positive on ART, and 53% of PLHIV newly enrolled in care were on TB preventive therapy.2 
As in previous years South Africa accounted for the largest proportion of those newly 
enrolled in HIV care on IPT (39%) globally. 2015 National Department of Health (NDOH) 
ART120 and 2014 TB124 guidelines recommend regular symptom screening for TB in PLHIV 
based on the WHO tool, comprising any of: “current cough of any duration, persistent 
fever >2 weeks, unexplained weight loss of >1.5kg in a month, or drenching night sweats.” 
Subsequent 2017 South African HIV clinicians society guidelines encourage ART initiation 
on the day of receiving an HIV diagnosis or CD4 count result, and recommend the WHO 
tool for TB screening prior to ART and IPT initiation.62 These guidelines advise, prior to 
ART initiation, further investigation of those with any WHO tool symptom using both Xpert 
and mycobacterial culture on sputum, plus urine LAM if the CD4 count is <100 cells/mm3. 
In addition they recommend, if feasible, sputum mycobacterial culture for all individuals 
with CD4 count <200 cells/mm3 as part of TB screening prior to IPT initiation. 
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1.3.2. TB investigation pathways and HIV care in South Africa 
The research undertaken for this PhD was part of the XPHACTOR study (“Xpert MTB/RIF for 
people attending HIV care: an interventional cohort study to guide rational 
implementation”). XPHACTOR methodology and how this thesis links in are described in 
Chapter three.  
XPHACTOR was conceptualized in 2011 at a time when the diagnostic landscape for TB was 
changing, and South Africa had decided to replace sputum microscopy with Xpert as the 
initial diagnostic test for TB across its entire laboratory service. Prior to this the only 
available diagnostic tests for TB were microscopy which is insensitive in PLHIV; and 
mycobacterial culture which is not available at lower tiers of laboratory, is slow and 
relatively expensive. The role of testing for LAM had yet to be defined for screening or 
diagnosis of TB in PLHIV, but it had become available as the POC LF-LAM.   
The replacement of microscopy with the far more expensive Xpert test, in the context of a 
highly symptomatic population of people attending for HIV care, was foreseen to have 
major resource implications. Resource constraints in LMIC were likely to limit use of this 
rapid diagnostic test, anticipated at the time to be “game-changing”, in the very regions 
with HIV-related TB epidemics which stood to gain the most. Anecdotal experience from 
South Africa at the time was that in many clinics ICF guidelines for PLHIV were not 
followed, possibly because they were considered impractical, and therefore little 
screening or testing for TB was carried out.  
XPHACTOR enrolment and follow-up were conducted between 2012 and 2014, during the 
national Xpert rollout in South Africa. At this time ART eligibility comprised CD4 ≤350 
cells/mm3 or WHO clinical stage ≥3. There was also a clear division between pre-ART care 
for PLHIV not yet eligible for ART, which was generally only provided in primary care 
clinics, and care for those on ART which was provided at all levels of care. Historically ART 
care had been provided at hospital-based clinics with doctor-led ART initiation, but since 
2010 nurse-initiated management of antiretroviral treatment (NIMART) has been rolled 
out, enabling decentralisation of and expanded access to ART. 
2014 NDOH guidance, which was also standard-of-care during the XPHACTOR study, 
recommends further evaluation of ambulatory PLHIV with a negative initial sputum Xpert 
result aligned with the 2007 WHO algorithm for smear-negative TB.124 This comprises 
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clinical reassessment, chest radiograph if available, sputum for mycobacterial culture, and 
treatment with an antibiotic if clinically indicated (Figure 1-1).124 Mathematical modelling 
using a decision model from South Africa125 suggested that replacing sputum culture with a 
second Xpert (estimated to be cheaper than culture) would reduce loss to follow-up so 1% 
more patients would start TB treatment,126 and save an estimated US$17.4 million per 
year.126 This model assumed, based on limited data, the same sensitivity for the second 
Xpert test as for the first, guidelines would be correctly followed, and only 1% of those 
with TB symptoms would start TB treatment based on a clinical diagnosis.125, 126 The 
strategy of sending a repeat Xpert for HIV-positive individuals whose initial Xpert result 
was negative had not been evaluated empirically at the time of the XPHACTOR study. 
However of note, current (2016) WHO ART guidelines, post-dating the XPHACTOR study, 
recommend that further evaluation in those with negative initial Xpert who are not 
seriously ill should include chest radiograph, clinical assessment and a repeat Xpert on a 
fresh sputum sample, with mycobacterial culture where feasible.127  
 
Figure 1-1. 2012 South African Department of Health algorithm for Xpert124 
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1.4. Rationale   
The rationale for the XPHACTOR study was that the combination of regular TB screening of 
PLHIV with the WHO tool, which would generate large numbers of patients requiring 
further investigation (of whom only a small proportion would have TB), and Xpert (the 
recommended initial diagnostic test), which is more expensive than smear microscopy, 
would pose a huge challenge in resource constrained settings. Targeting testing to those at 
greatest risk of TB in these settings was envisaged as a strategy to prioritise resources. 
XPHACTOR was a prospective cohort study that evaluated an algorithm (described in 
Chapter 3) which aimed to identify, among HIV-positive clinic attendees, those deemed 
"high priority" for immediate investigation with Xpert, and allowed watchful waiting for 
those assessed as lower priority.  
XPHACTOR provided an opportunity to attempt to answer key questions arising from WHO 
ICF recommendations, as detailed in the thesis objectives below. Firstly, amongst those 
reporting WHO tool symptoms, could individuals at greatest risk of TB be identified to 
enable prioritisation of testing with Xpert? Secondly, amongst those for whom TB had been 
excluded but who continued to report symptoms, what were the causes for and “natural 
history” or evolution of these symptoms? Finally, LF-LAM had recently become available, 
affording an opportunity to evaluate its potential as a screening test for individuals 
attending for routine HIV care. 
 
1.5. Aims and objectives of this thesis   
The aim of this thesis is to explore, within the context of regular TB screening for 
individuals attending for routine HIV care, alternative screening and investigation 
pathways (to standard of care) at different stages of an individual’s journey through 
evaluation for TB (Figure 1-2). 
This thesis comprises four studies which address each of the following objectives. 
 
Objective 1 (Chapter 5 - Research Paper 1, “TB Screening with LAM in an HIV Clinic”) 
Firstly, starting with TB screening itself, to evaluate the role of LF-LAM for screening 
individuals with advanced immunosuppression. 
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• To evaluate the diagnostic accuracy of LF-LAM among adults with advanced 
immunosuppression (CD4 cell count <200 cells/mm3) established in HIV care, i.e. 
not those newly diagnosed HIV-positive.   
 
Objective 2 (Chapter 6 - Research Paper 2, “Clinical Score for TB in HIV-positive adults 
in South Africa”) 
Secondly, to identify a simple “second step” algorithm (triage tool) to prioritise 
investigation amongst those identified by the WHO symptom tool as requiring further 
evaluation. This tool would help HCW decide whom to prioritise for immediate sputum 
test with Xpert. Again the focus was on individuals established in HIV care. 
• To develop a clinical prediction model using data from the XPHACTOR study, 
comprising elements readily available in primary care, to predict the probability of 
TB in adults attending for routine HIV care screened for TB and found to be WHO 
tool positive.    
 
Objective 3 (Chapter 7 - Research Paper 3, “Investigating TB if initial Xpert is 
negative”) 
Thirdly, amongst those who have been investigated for TB, but have a negative Xpert 
result, to evaluate the strategy of sending a second sputum sample for Xpert. 
• To describe the diagnostic yield from two different strategies for investigating 
adults with HIV who are suspected of having TB, but whose first Xpert test is 
negative. These were immediate repeat sputum tested with Xpert, compared to 
sequential further investigation guided by NDOH recommendations (sputum for 
mycobacterial culture, chest radiograph, trial of antibiotics if clinically indicated).  
 
Objective 4 (Chapter 8 - Research Paper 4, “Causes of TB symptoms in HIV-positive 
adults”) 
Finally, amongst those who have been investigated for and found not to have TB, to 
attempt to identify the cause for persistent symptoms suggestive of TB. 
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• To determine causes for persistent or recurrent symptoms suggestive of TB 
amongst ambulatory adults attending for HIV care who have negative initial TB 
investigations. 
 
Figure 1-2. Aims of this thesis 
  
1 TB treatment commenced if positive Xpert 
2 TB treatment commenced if positive mycobacteriology or indicated by CXR (chest radiograph) or 
clinical evaluation 
CXR, chest radiograph 
 
 
Individual attends for routine 
HIV care 
Screened for TB with WHO tool 
Reports WHO tool symptoms(s) 
Sputum sent for Xpert1 
Xpert result is negative 
Further evaluation2 (CXR, 
sputum TB culture, antibiotics) 
Further evaluation rules out 
TB, but symptoms persist 
1.Screen with LF-LAM if CD4 ≤200 
Research paper 1 
2. Triage to prioritise whether 
Xpert requested 
Research paper 2 
3. Repeat Xpert on second sample 
Research paper 3 
4. What is causing symptoms? 
Research paper 4 
Standard of care Examined in thesis 
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1.6. Structure of the thesis   
This thesis is structured in research paper style format.  
Chapter 2 presents the literature review which addresses each thesis objective, focusing 
on existing evidence relevant to PLHIV in LMIC settings, and highlighting gaps in the 
knowledge. Firstly, evidence pertaining to the role of urine LAM as a screening test for TB 
in individuals attending for routine HIV care. Secondly, an overview of recommended 
strategies for developing clinical prediction rules to inform further investigation of 
patients, and then a review of current prediction rules for TB in PLHIV. Thirdly, the 
evidence pertaining to the utility of repeating Xpert on sputum in PLHIV who have an 
initial negative sputum Xpert result; and fourthly the causes identified for persistent 
symptoms suggestive of TB from studies amongst PLHIV in Sub-Saharan Africa.   
Chapters 3 to 4 provide an overview of the XPHACTOR study methods and present key 
results. Chapter 3 describes the study design, and how the objectives addressed in this 
thesis flow from XPHACTOR. The frequency of symptoms suggestive of TB in XPHACTOR 
study participants, both at enrolment and monthly follow up visits is reported in chapter 
4. These data provide an indication of the potential volume of testing using Xpert required 
following screening with the WHO tool, and the extent to which repeat testing may be 
needed.  
Chapters 5 to 8 provide, in the form of papers which are either published or in press, the 
methods, results and discussions for each study. Chapter 5 (Paper 1) provides the 
evaluation of LF-LAM to screen ambulatory PLHIV for TB, and has been published in PLoS 
One.128 Chapter 6 (Paper 2) presents the clinical score for TB as published in PLoS One.129 
Chapter 7 (Paper 3) reports the diagnostic yield from repeat Xpert on sputum amongst 
HIV-positive individuals at high risk of TB, but with initial negative result. This paper has 
been published by Gates Open Research, but requires revision (which I am currently 
undertaking) before passing peer review. This chapter, therefore, presents the paper prior 
to revision.  Chapter 8 (Paper 4) presents the causes for persistent or recurrent symptoms 
suggestive of TB, as published in the International Journal of Tuberculosis and Lung 
Disease.130   
Chapter 9 summarizes the main findings of this research, the implications of these results 
for clinical practice and wider policy, limitations and generalizability, conclusions and 
recommendations for future research. 
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The appendices provide the ethical approval documents, consent form, XPHACTOR study 
enrolment questionnaire, standard operating procedures (SOPs) for Paper 4, and research 
posters describing the evaluation of the WHO tool for ruling out TB undertaken using 
XPHACTOR study data131 and the frequency and seasonal variation of TB symptoms 
amongst participants on ART.132 
  
1.7. Role of the candidate   
I was the research manager for XPHACTOR, based in South Africa from 2012 to 2014, 
where I ran the study. The study was conceived and funding acquired by Prof Alison Grant 
and Dr. Katherine Fielding from the London School of Hygiene & Tropical Medicine 
(LSHTM), and colleagues at the Aurum Institute and the University of Cape Town in South 
Africa. 
I contributed to protocol development, study design, and obtaining all required regulatory 
approvals and permissions. I consulted with stakeholders in South Africa at proposed study 
sites (community health clinics and hospitals), laboratories, and provincial and district 
level regulatory bodies. In collaboration with colleagues at the Aurum Institute and 
supervised by Prof Grant, I set up and managed the XPHACTOR study on a day-to-day 
basis. This included recruiting and training all research staff; monitoring study sites; 
developing all standard operating procedures (SOPs) and case report forms; assisting with 
database development, data entry and data cleaning. 
I conceptualized and designed the standard set of investigations for participants with 
persistent symptoms suggestive of TB, assisted by Dr. Sandra Toro Silva from LSHTM, and 
we personally undertook clinical evaluation of participants together with two clinicians 
from the Aurum Institute. We also extracted relevant data from participants’ medical 
records. 
I conducted all the statistical analyses and interpretation reported in this thesis. I wrote 
the original drafts of all manuscripts for the research papers presented, incorporated 
feedback from co-authors, finalized and submitted them for publication.   
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1.8. Ethical clearance 
Ethical approval for the XPHACTOR study was provided by ethics committees at the 
London School of Hygiene & Tropical Medicine (approval # 6165), University of the 
Witwatersrand in South Africa (approval # M120343), and University of Cape Town in South 
Africa (approval # 106/2012).   
  
1.9. Funding 
The research for this thesis was undertaken while I was a staff member at LSHTM. My 
salary support was provided through the funding awarded for the XPHACTOR study by the 
Bill and Melinda Gates Foundation (Grant number OPP1034523). 
  
Literature review 
Page | 40  
 
2) Literature review 
2.1. Introduction 
This thesis explored alternative pathways for finding TB in HIV-positive individuals 
established in care. The literature review, therefore, commences by examining the 
recommended tool for TB screening at each clinical encounter, the WHO symptom screen. 
The studies in the original systematic review which developed the WHO tool, in the update 
which investigated its performance in PLHIV on ART, and studies which report the 
frequency of WHO tool symptoms amongst those on ART are discussed. These studies 
provide comparison, with respect to the extent to which diagnostic testing for TB may be 
needed in the context of routine screening, for XPHACTOR which enrolled a population 
established in HIV care.   
Subsequent sections of the review examine the published literature relating to alternative 
screening and diagnostic pathways for PLHIV in outpatient settings, starting with the 
utility of LF-LAM as an alternative to TB screening using the WHO tool. Published clinical 
prediction models are reviewed, both as alternative TB screening tools and also in a triage 
role, i.e. to prioritise diagnostic testing for individuals who have reported WHO tool 
symptoms during screening. The review then moves down the Xpert algorithm (Figure 1-1) 
to discuss the literature pertaining to the investigation of individuals with an initial 
negative Xpert result, specifically looking at the likely diagnostic yield from a repeat Xpert 
test and the factors that might improve this yield. Finally, in order to guide the 
investigation of patients who persistently report WHO tool symptoms on screening, the 
aetiology of these symptoms are summarised from studies investigating PLHIV in 
outpatient settings. The findings from the review put into context those from this thesis, 
and also helped to identify gaps in the literature which inform the objectives of this 
research. 
 
2.2. WHO 4-symptom TB screening tool  
2.2.1. Studies in the original meta-analysis 
The original WHO meta-analysis used data from twelve studies which, irrespective of the 
presence of symptoms suggestive of TB, undertook mycobacterial culture (mainly on 
sputum) for all participants.80 Amongst almost 10,000 PLHIV, mostly from sub-Saharan 
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Africa, median CD4 count was 248 cells/mm3 (available for 36% of participants), and 
overall TB prevalence was 5.8% (39% smear-positive pulmonary TB, 52% smear-negative 
pulmonary TB, 5% extrapulmonary TB only). The final tool comprised presence of any of 
current cough, fever, night sweats or unintentional weight loss. It had sensitivity and 
specificity for culture-confirmed TB of 78.9% (95% CI  58.3, 90.9) and 49.6% (95% CI 29.2, 
70.1) respectively, and was more sensitive in a clinical setting. 
The primary analysis was undertaken in just over 8,000 individuals with complete data 
from nine of these studies (Table 2-1), and investigated the performance of 23 
combinations of five candidate symptoms, which were asked about in all studies and 
deemed easy to assess at all levels of healthcare (current cough, haemoptysis, fever, night 
sweats and weight loss). Participants in these nine studies were screened for TB in a wide 
range of settings including HIV testing and counselling (HTC) services;73, 79 prior to ART 
initiation;72, 133 and prior to the widespread availability of ART within the public sector, 
namely home-based pre-ART care,76 community-based HIV-TB prevalence surveys,74, 134, 135 
and occupational health services for gold miners.136 Most of the participants (60%) were 
contributed by three studies, two household prevalence surveys74, 134 and one workplace 
survey.135 These community-based studies unsurprisingly reported low prevalences of TB 
(0.4-1.9%), which might also relate to their more stringent criteria for defining culture-
confirmed TB. In these studies, if the initial sputum was culture-positive for MTB, then 
further sputum samples were collected for microbiology and chest radiography was 
performed; and more than one sputum culture-positive for MTB was required to fulfil the 
case definition for confirmed TB.  
The phrasing of the symptom screen naturally varied between studies, in particular with 
respect to the duration of symptoms, and the time frame for reporting presence of 
symptoms.80 Cough > 21 days rather than current cough was stipulated by two studies.73, 76 
The timeframe for reported weight loss varied from presence of symptom within the last 
1,72, 134 279 or 6135, 136 months; and for night sweats and fever within the last 1,72 or 279 
months. These differences might have impacted on the overall diagnostic accuracy of the 
WHO tool which requires “current” presence of symptom(s). When utilised in a screening 
tool, stipulating a duration for a symptom will reduce sensitivity but improve specificity; 
increasing the period during which a symptom can be present will increase sensitivity at 
the expense of specificity. 
Cain et al, whose data were included in the meta-analysis, evaluated more than eighty 
million combinations of between one to five variables (easily obtainable symptoms or 
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signs) to rule out culture-confirmed TB in clinic attendees prior to ART initiation.72 Their 
best performing combinations of three or four predictors (sensitivity 93%, specificities 35-
37%, NPV 97%), using data from 1748 participants of whom 15% had TB, all included cough, 
fever, and night sweats. The findings of their “exhaustive” search support the utility of 
these symptoms within the WHO tool, and suggest that even though the meta-analysis 
evaluated only five candidate symptoms, potentially little would have been gained if 
additional predictors had been included.  
A strength of the meta-analysis was the use of individual participant data, but the studies 
included were largely conducted prior to the widespread availability of ART,74, 76, 134-136 or 
if available in individuals who had not yet started ART,72, 73, 79, 133 and only one study72 
collected non-sputum samples, limiting the ability to identify extrapulmonary TB. The 
WHO tool, therefore, cannot be assumed to perform similarly in a population on ART; and 
hence the rationale for undertaking a subsequent review, discussed later in this chapter, 
to determine its accuracy amongst individuals on ART.42 Fifteen percent (1478/9629) of 
participants were excluded due to missing data, rather than using statistical methods such 
as imputation, which might have resulted in biased estimates of sensitivity and specificity.  
The WHO tool has higher sensitivity (90.1%) in clinical settings and amongst individuals 
who have not been previously screened for TB (88%) (Table 2-2).80 Sensitivity of a 
screening tool may decline if applied at regular intervals to the same population, and this 
may have implications when the WHO tool is used, as recommended, at every clinical 
encounter for PLHIV.136 This decline in sensitivity can be explained in part by the 
successful detection of TB by the screening tool (followed by TB treatment) in prior rounds 
of screening.137 This changes the characteristics of those remaining, who are less likely to 
have TB and are also likely to be less symptomatic. The proportion of individuals with 
active TB will be reduced and this will reduce the PPV of the WHO tool.74, 136 The three 
studies which contributed to the assessment of the performance of the WHO tool in a 
previously screened populations were a household survey,74 a workplace survey,135 and one 
that enrolled gold miners at annual occupational health screening;136 overall 52/3191 
(1.7%) had culture-confirmed TB (Table 2-1). It seems unlikely that the sensitivity 
estimate for the WHO tool in previously screened populations of 40.5% (95% CI: 16.6, 69.9) 
can be generalised to active TB case finding in HIV clinics. The uncertainty around the 
sensitivity estimate is wide due to the small number of TB diagnoses. In these studies solid 
culture media, which is less sensitive than liquid media, was used and may have missed 
some TB diagnoses, impacting upon the estimation of the sensitvity of the WHO tool for TB 
in previously screened populations.    
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Table 2-1 Characteristics of studies contributing data to the WHO meta-analysis80  
Author 
Country 
Year 
Design 
Study population 
Procedures 
Exclusions from analysis 
TB Case definition Number of PLHIV 
contributed to meta-
analysis80 
Median CD4 cells/mm3 
C+ TB prevalence in PLHIV80 
n/N (%) 
Comments 
Getahun80 
2011 
Metanalysis 
• 12 studies (N=9626) including PLHIV  
• Had to collect sputum & symptoms/sign 
from ALL, & ≥1 sample for MTB culture  
• Identified 5 symptoms common to all 
studies (C,F,S,H,W) 
C+ 
 
Meta-analysis included 9 
studies (N=8148) 
evaluable on C,F,S,H,W 
 
CD4 248 (N=3489) 
557/9626 (5.8%) 
• 288/557 (52%) SM-ve PTB 
• 218/557 (39%) SM+ve PTB 
• 28/557 (5%) EPTB only 
• 23/557 (4%) site unknown 
• 1478/9626 (15%) excluded as 
incomplete symptom data 
• Sensitivity: 78.9% (58.3, 90.9) 
• Specificity: 49.6 (29.2, 70.1) 
Ayles134 
2009 
Zambia 
X-sectional 
Community TB/HIV prevalence survey; 
2005 
Randomly sampled households 
Adults > 15y 
ALL at enrolment: Symptom screen, 1 
sputum (culture), HIV test on oral fluid 
• Further evaluation if C+ MTB: 2 sputa 
(SM, culture) + CXR 
 
>90% consented + had culture result 
N=8044 in analysis 
HIV prevalence 2297/8044 (28.6%) 
• Confirmed: 2 C+; or 1 
C+ & 1 SM+ve 3+ 
 
• Unconfirmed: 1 C+ & 
TB Rx (based on CXR / 
symptoms) 
 
• Subclinical: 1 C+, & no 
symptoms & CXR 
normal, & no other 
positive microbiology 
N=2145 41/2145 (1.9%) ART data not collected, but low 
availability reported 
Cain72 
2010 
Cambodia 
Thailand 
Vietnam 
X-sectional 
HIV clinic attendees; 2006-2008 
Consecutive sample 
Age > 6y (median age 31y) 
ALL at enrolment: Symptom screen + 
exam; CXR; SM and culture on sputa (x3), 
urine, blood, stool, LNA if appropriate; 
FBC + CD4 
C+ on any sample 
 
“Not TB”: at least 1 
sputum C-ve & 1 non-
sputum C-ve  
 
 
N=1721 
 
CD4 242  
267/1721 (15.5%) Excluded those on ART  
Chheng73 
2008 
Cambodia 
X-sectional 
HCT attendees 
Consecutive sample, aged ≥ 19y 
ALL at enrolment: Symptom screen, 3 
sputa (SM, culture) 
C+ or ≥2 SM+ve N=123 20/123 (16.3%) L-J media only   
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Author 
Country 
Year 
Design 
Study population 
Procedures 
Exclusions from analysis 
TB Case definition Number of PLHIV 
contributed to meta-
analysis80 
Median CD4 cells/mm3 
C+ TB prevalence in PLHIV80 
n/N (%) 
Comments 
Corbett135  
2007 
Zimbabwe 
Cohort 
Employees; 2001-2002 
ALL approached:  
• HIV test at enrolment 
• Access to OHS (TB Ix, HTC, HIV care 
[CPT, IPT, no regular TB screening])  
• After 2 years - prevalence survey 
(>90% consented): symptom screen & 
sputum culture & HIV test.  
o Further evaluation if TB symptoms 
or C+: CXR & sputum SM & culture 
 
HIV prevalence 19%: 
• Baseline 1233/6440  
• After 2 years 874/4668  
o 13/874 HIV-Pos fulfilled TB case 
definitions, of whom 5 C+ 
Prevalent TB: 
• Definite: 2 C+, or 1 C+ & 
CXR TB 
 
• Probable: CXR TB & 
response to TB Rx 
within 2m 
N=797 3/797 (0.4%) Contributed to “previously 
screened” population in 
metanalysis 
18/1233 (1.5%) on ART at 
enrolment 
6% of PLHIV received IPT   
If asymptomatic: pooled sputum 
cultured & SM read only if C+ 
L-J media only   
Corbett74  
2010 
Zimbabwe 
X-sectional 
Community TB/HIV prevalence survey; 
2005-2006 
Randomly sampled households 
Adults > 15y 
ALL at enrolment: Symptom screen, 2 
sputa (culture), HIV test   
• Further evaluation if C+ or TB symptom: 
Sputum (SM, culture) + CXR 
>90% consented and submitted sputum 
 
HIV prevalence 1858/8979 (21%) 
• 48/1858 fulfilled TB case definition 
• Definite: 2 C+,  
• Probable: 1 C+ & 
compatible symptoms / 
CXR, & response to TB 
Rx within 1m 
• Probable C-ve MTB: C-
ve MTB, & compatible 
symptoms / CXR, & 
response to TB Rx 
within 1m 
N=1834  31/1834 (1.7%) Contributed to “previously 
screened” population in 
metanalysis 
If asymptomatic: pooled sputum 
cultured & SM read only if C+ 
L-J media only   
Kimerling76 
2002 
Cambodia 
X-sectional 
Home based HIV care service; 2000 
Adults ≥ 15y 
ALL at enrolment: Symptom screen, 1 
sputum (culture)  
• 40/427 (9.4%) previously undiagnosed 
C+ MTB, & 14/441 already on TB Rx 
C+ N=393 36/393 (9.2%) Unable to verify HIV status for all 
participants. 
Only 441/787 (56%) registered 
with service were surveyed 
L-J media only   
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Author 
Country 
Year 
Design 
Study population 
Procedures 
Exclusions from analysis 
TB Case definition Number of PLHIV 
contributed to meta-
analysis80 
Median CD4 cells/mm3 
C+ TB prevalence in PLHIV80 
n/N (%) 
Comments 
Lawn133 
2009 
SA 
X-sectional 
HIV clinic attendees prior to ART start 
Adults ≥ 18y 
ALL at enrolment: Symptom screen, CXR, 
2 sputa (culture), urine stored (LAM)   
58/235 (25%) fulfilled TB case definition 
C+ N=218 
 
CD4 125 
57/218 (26.1%)  
Lewis136 
2009 
SA 
X-sectional 
Gold miners at annual OHS screen (mini 
CXR + urine); 2000-2001 
Alternate attendees sampled 
ALL at enrolment: Symptom screen, mini 
CXR, 2 sputa (culture), urine HIV 
• Further evaluation if C+, SM+, TB 
symptoms, CXR changes: sputa x3 
(SM, culture) + CXR 
HIV prevalence 567/1995 (29%) 
• 20/567 (4%) fulfilled TB case definition 
• Definite: 1 C+ & 
compatible symptoms / 
CXR; or 2 C+ 
• Probable: Compatible 
symptoms & response to 
TB Rx within 2 m & 
SM+/ new CXR 
abnormalities 
N=560 18/560 (3.2%) Contributed to “previously 
screened” population in 
metanalysis 
ART not available  
L-J media only   
 
Shah79 
2009 
Ethiopia 
X-sectional 
New HIV-pos from HTC 2005-2006 
Consecutive sample; Adults ≥ 18y 
ALL at enrolment: Symptom screen + 
exam, CXR, sputa x3 (SM + culture); 
Blood (CD4) 
32/438 (7%) fulfilled TB case definition (5 
SM+ C-ve) 
• SM+ TB: SM+ or C+ 
• SM- TB: 3 SM -ve & C+ 
• “Not TB”: none of the 
above 
N=427 
 
CD4 181 
27/427 (6.3%)  L-J media only  
 
ART, antiretroviral therapy; C,F,S,H,W = current cough, fever, night sweats, haemoptysis, weight loss, C+, culture-positive MTB; CI, confidence interval; CPT, cotrimoxazole preventive therapy;  
CXR, chest radiograph; FBC, full blood count, HIV-pos, HIV-positive; HTC, HIV testing & counselling services; IPT, isoniazid preventive therapy; LNA, lymph node aspirate; OHS, occupational 
health service; SA, South Africa; SM, TB microscopy; SM+, smear-positive; SM-, smear-negative; TB Rx, TB treatment; L-J, Löwenstein-Jensen media 
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Table 2-2 Performance of the WHO tool in different populations42, 80  
 
Population screened TB prevalence 
% 
WHO tool 
positive1 %   
Sensitivity  
(95% CI) 
Specificity 
(95% CI) 
Original meta-analysis80     
Overall (N=8148) 5.8% (557/9626) 
(range: 0.4-25.7) 
49.8% 
(3981/8148) 
78.9% (58.3,90.9) 49.6% (29.2, 70.1) 
Screened in clinical setting   90.1% (76.3, 96.2)  
Not previously screened for TB   88.0% (76.1, 94.4)  
Screened in community setting    67.1% (41.7, 85.3)  
Previously screened for TB   40.5% (16.6, 69.9)  
Any WHO tool symptom or 
abnormal CXR2 (N=2805) 
  90.6% (66.7, 97.9) 38.9% (12.8, 73.3) 
Update from systematic review42     
On ART (N=4640) 1.5%3 
(IQR: 0.6, 3.5%) 
29.7%3 
(IQR: 14.3, 45.7) 
51.0% (28.4, 73.2) 70.7% (47.8, 86.4) 
Not on ART (N=8664)  71.2%3 
(IQR: 46.7, 87.1) 
89.4% (83.0, 93.5) 28.1% (18.6, 40.1) 
Any WHO tool symptom or 
abnormal CXR2 (N=646) 
  84.6% (69.7, 92.9) 29.8% (26.3, 33.6) 
ART, antiretroviral therapy; CI, confidence interval; CXR, chest radiograph; IQR, interquartile range 
1 Any of: cough, fever, night sweats or weight loss  
2 Any of: abnormal chest radiograph or any WHO tool symptom 
3 Median 
 
2.2.2. Performance of WHO tool in individuals on ART 
A systematic review and meta-analysis were undertaken for the 2018 WHO LTBI guidelines, 
to determine the accuracy of the WHO tool to rule out TB in individuals on ART, and to 
further assess the impact of addition of abnormal chest radiograph to the WHO tool which 
had been reported to increase sensitivity in the original meta-analysis.9, 42 Table 2-2 
summarises the findings from the original meta-analysis and the systematic review. The 
prevalence of TB amongst those on ART was much lower (1.5%) compared to the 
prevalence in the pre-ART population from the original meta-analysis (5.8%). The 
systematic review reported a lower pooled sensitivity of the WHO tool (51.0% vs. 89.4%) 
and greater pooled specificity (70.7% vs. 28.1%) for those on ART vs. those not on ART; 
estimates did not vary by CD4 count in meta-regression. The estimated NPV in those on 
ART vs. those not on ART was 99.3% vs. 99.6% at 1% TB prevalence, and 96.5% vs. 98.0% at 
5% TB prevalence, enabling TB to be ruled out prior to preventive therapy. Addition of any 
abnormal chest radiograph findings to the WHO tool increased sensitivity to 84.6% for 
those on ART. 
Seven studies provided data for individuals on ART for the systematic review and these are 
summarised in Table 2-3.131, 138-143 These studies enrolled participants prospectively, and 
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evaluated all for TB irrespective of the presence of TB symptoms, against a reference 
standard of bacteriologically confirmed TB (smear, culture and/or Xpert). The study 
reporting the highest sensitivity for the WHO tool (49/50 [98%]) enrolled a convenience 
sample and findings will be biased. It is likely to have overestimated the sensitivity of the 
WHO tool.140 Five studies excluded enrolled individuals for whom a final TB outcome could 
not be assigned, usually because sputum samples were not submitted at enrolment or 
results were contaminated or not available.131, 138, 141-143 Three of these studies excluded 
almost 10% or more of enrolees from their analyses because of lack of sputum 
mycobacteriology and additional reasons including either data integrity concerns,138 or 
failure to complete other study procedures (chest radiograph / TST), or missing data.143 
This will have introduced selection bias, perhaps improving sensitivity estimates, and 
impacts on the generalisability of findings of these studies. Individuals who cannot 
produce sputum are less likely to have reported current cough; which may also explain 
why cough is often the most commonly reported of the WHO tool symptoms in these 
studies (Table 2-4). Exclusion of individuals unable to produce sputum is likely to have 
impacted on the studies in the original meta-analysis, but it is not possible to assess this 
due to lack of clear reporting of whether these exclusions occurred. 
Rangaka et al undertook a secondary analysis of data from their clinical trial which 
investigated the impact of IPT in individuals on ART, in order to evaluate the effect of ART 
on the performance of the WHO tool.143 In the trial a consecutive sample of HIV clinic 
attendees underwent TB symptom screening and had sputum collected for mycobacterial 
culture. The WHO tool was retrospectively applied to data collected from these 
individuals, and all analyses in this study were performed on a dataset with complete 
data. 661/2090 (32%) of individuals without data for predetermined predictors, or unable 
to produce sputum, or without culture results were excluded from their analysis.143 
Patients were enrolled from a clinic where TB screening at every visit was already 
standard of care. Visit were undertaken at 2-4 weekly intervals for individuals preparing 
for ART, and 4-8 weekly for those on ART. Therefore, those enrolled to this trial had 
probably been repeatedly pre-screened for TB, and it is unlikely that symptomatic 
patients were considered for screening for the trial. These factors probably explain the 
very low proportion (6.6%) of participants who reported WHO tool symptoms, and thus the 
lack of sensitivity of the tool (23.8%), which as already discussed is less sensitive amongst 
individuals previously screened for TB.80 In spite of this, the prevalence of culture-
confirmed TB was high and was 5.4%, amongst those on ART. One might speculate that 
having experienced repeated rounds of screening, participants were more reluctant to 
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report symptoms or self-identify as symptomatic, or this might have arisen from the 
retrospective application of the WHO tool.  
Two of the studies in the systematic review were conducted amongst pregnant and 
lactating women.139, 141 Data for one study undertaken in Swaziland, which appeared to 
require duration of symptoms for fever or night sweats of two weeks to qualify as a 
positive symptom screen, were only available as a conference presentation.139, 144 The 
WHO tool lacks sensitivity for culture-confirmed TB in pregnancy, which may reflect the 
impact of ART and previous TB screening. Furthermore, pregnancy itself may influence the 
presence of TB symptoms, in particular reported weight loss, and other measures of 
weight loss such as mid-upper arm circumference require evaluation. In this population, 
the addition of presence of TB symptoms in household members141 or reported exposure to 
a TB case145 is reported to improve the performance of the WHO tool.   
Data from XPHACTOR, of which the research undertaken for this thesis forms part, are also 
included in the updated systematic review.131 One hundred and forty-three individuals  
were excluded from the XPHACTOR analysis because of unclassifiable TB outcome (did not 
satisfy “TB” or “not TB” case definitions), but we did not exclude participants unable to 
produce sputum at enrolment, therefore our results are less likely to be biased. Strengths 
of the study include follow up of participants for 3 months, and collection of samples for 
mycobacteriology at both enrolment and 3-month visit, irrespective of presence of TB 
symptoms. All other studies presented in Table 2-3 were cross-sectional with samples 
collected only at enrolment.  
In summary, the findings of the updated systematic review indicate that the WHO tool is 
less sensitive but more specific amongst PLHIV on ART, compared with those pre-ART.42 At 
a median reported TB prevalence amongst those on ART of 1.5% the NPV of the tool was 
high, enabling TB to be ruled out prior to the provision of IPT. Limitations of the studies in 
the updated review include exclusions of large numbers of participants who did not 
produce sputum samples and the inclusion of ANC attendees who might not be 
representative of PLHIV attending for routine care. A reference standard of culture-
confirmed pulmonary TB was used, hence limiting applicability to diagnosing 
extrapulmonary TB. 
  
Literature review 
Page | 49  
 
Table 2-3 Sensitivity and specificity of the WHO tool for TB in adults on ART  
Author 
Country 
Year 
Design 
Study population 
Procedures 
Exclusions from analysis 
TB Case definition Number in 
analysis 
Median CD4 
cells/mm3 
TB prevalence 
n/N (%) 
WHO-
Positive 
 n/N (%) 
Sensitivity  
(95% CI) 
Specificity  
(95% CI) 
Comments 
Ahmad 
Khan138 
SA 
2014 
X-sectional 
HIV clinic attendees 
Consecutive sample 
ALL at enrolment: Symptom 
screen, 3 sputa (2 smears & 
1 culture), CXR 
SM+ or C+ 737 in analysis 
• 522 on ART 
(70.8%)  
CD4 = 365 
On ART: 
31/522 (5.9%) 
On ART:  
233/522 
(45%)   
On ART:  
51.6% 
(33.1,69.9) 
On ART:  
55.8% 
(51.3,60.3) 
Excluded from analysis if: 
no sputum / submitted >14 
days after enrolment (15), 
or data integrity concern 
(73) 
Hanifa131 
SA 
2015 
Cohort 
HIV clinic attendees1 
Systematic sample  
ALL at enrolment: Symptom 
screen, 1 sputum (GXP) 
All at 3 months: Blood & 1 
sputum for culture   
 
Confirmed = GXP+ / C+ 
Clinical = TB Rx without 
+ve MTB microbiology 
Not TB: No +ve MTB 
microbiology (≥ 1 
specimen) & alive ≥3m 
after enrolled. 
3229 in analysis 
• 2439 on ART 
(75.5%)   
CD4 = 439 
 
On ART: 
Confirmed: 
61/2421 (2.5%) 
All TB: 79/2439 
(3.2%) 
 
On ART:  
736/2439 
(30%)  
 
 
On ART:  
60.7% 
(47.3,72.9) 
(confirmed 
TB) 
On ART:  
71.1%  
(69.2,72.9) 
Excluded from analysis if: 
unclassifiable TB outcome 
(143) or clinical TB (18) 
Kufa140 
SA 
2012 
X-sectional 
HIV clinic attendees  
Convenience sample   
ALL at enrolment: Symptom 
screen, 1 sputum & blood 
(culture), CD4, urine LAM 
Confirmed = C+ 
Probable = SM+, 
compatible histology or 
CXR 
 
422 in analysis 
• 196 on ART 
(68.1%) 
CD4 = 264 
On ART: 
Confirmed:  
8/196 (4.1%) 
All TB: 20/196 
(10.2%) 
On ART: 
162/196 
(82.7%) 
 
On ART:  
98.0%2 
(89.4,>99.9) 
(confirmed 
TB) 
Not reported Convenience sample   
 
Calnan139 
Swaziland 
2016 
X-sectional 
Ante- & postnatal MCH clinic 
attendees 
Consecutive sample 
ALL at enrolment: Symptom 
screen, sputum (GXP & 
culture), urine LAM, TST, 
IGRA, CXR, CD4 if HIV-pos 
Confirmed = C+ 990 in analysis 
• 470 HIV-pos 
3.4% amongst 
HIV-pos 
Not reported 14.3% 
overall 
82.2% overall Conference presentation 
TB screening tool specifies 
duration of 2 w for fever & 
night sweats 
Exclusions not reported 
Sensitivity & specificity did 
not vary by HIV / 
pregnancy status 
ART use not reported; but 
90% PMTCT coverage 
nationally  
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Author 
Country 
Year 
Design 
Study population 
Procedures 
Exclusions from analysis 
TB Case definition Number in 
analysis 
Median CD4 
cells/mm3 
TB prevalence 
n/N (%) 
WHO-
Positive 
 n/N (%) 
Sensitivity  
(95% CI) 
Specificity  
(95% CI) 
Comments 
LaCourse141 
Kenya  
2016 
X-sectional 
ANC attendees 
Consecutive sample 
ALL at enrolment: Symptom 
screen, 2 sputa (1GXP & 1 
culture), Urine LAM, TST 
C+ 
 
288 in analysis 
(CD4 = 437) 
• 165 on ART 
(57.3%) 
• 62 PMTCT 
Overall: 7/288 
(2.4%)3 
 
Overall: 
56/288 
(19%) 
Overall: 
42.9% 
(9.9, 81.6) 
On ART: 
1/4 (25%) 
Overall: 
81.1% 
(76.1,85.5) 
Excluded from analysis if: 
unable to produce sputum 
or contaminated culture 
(18) 
Nguyen142, 
146 
Viet Nam 
2011 
X-sectional 
HIV clinic enrollees 
Consecutive sample   
ALL at enrolment: Symptom 
screen, 2 sputa (smear & 
culture), TST, CXR 
C+ 397 in analysis4 
(CD4 = 336) 
• 230 on ART 
(57.9%) 
Overall: 28/397 
(7.1%) 
Overall: 
147/397 
(37.0%) 
Overall: 
50% 
Overall: 64% Excluded from analysis if: 
Did not complete all 
procedures or NTM / 
contaminated culture (39) 
Rangaka143 
SA 
2012 
X-sectional 
HIV clinic attendees, on / 
about to start ART, 
undergoing screening for 
clinical trial  
Consecutive sample 
ALL at enrolment: Symptom 
screen, 1 sputum (smear & 
culture) 
C+ 1429 
• 775 on ART 
(54.2%) 
CD4=289 
On ART: 
42/775 (5.4%) 
On ART5: 
51/775 
(6.6%) 
On ART:  
23.8% 
(12.1,39.5) 
 
On ART:  
94.4% 
(92.5,96) 
Excluded from analysis if: 
unable to produce sputum 
within 1 m of enrolment or 
missing results; or missing 
symptoms or 
predetermined predictors 
(357 on ART; 304 pre-
ART) 
ANC, antenatal clinic; ART, antiretroviral therapy; C+, culture-positive MTB; CI, confidence interval; CXR, chest radiograph; GXP+, Xpert-positive; HIV-pos, HIV-positive; IGRA, interferon 
gamma release assay; m, month; MCH, maternal child health clinic; NTM, nontuberculous mycobacteria; PMTCT, ART for prevention of mother-to-child transmission; SA, South Africa; SM+, 
smear-positive; TB Rx, TB treatment; TST, tuberculin skin test; w, week 
1 Analysis of data collected for the XPHACTOR study 
2 49/50 of all participants who fulfilled case definition for either confirmed or probable TB were WHO tool positive 
3 One additional participant with positive Xpert result was classified as not TB 
4 Data stratified by ART status not reported 
5 WHO tool retrospectively applied  
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2.2.3. Frequency of WHO tool symptoms amongst PLHIV attending for routine 
care 
The frequency of WHO tool symptoms amongst HIV clinic attendees provides an indication 
of the volume of testing with Xpert that might be required when it is used for TB 
screening. Table 2-4 summarises the frequency of WHO tool symptoms in seven published 
studies (four of which are already described in Table 2-3)138, 141-143 which systematically 
enrolled and screened PLHIV established in care, as opposed to studies screening 
individuals at new HIV diagnosis or before initiation of ART. The proportion reporting any 
WHO tool symptom varies from 37%-45% in studies including those on ART from HIV 
clinics,138, 142, 146, 147 16-19% in ANC attendees,141, 145 33% in those postpartum,148 and 71% in 
an exclusively pre-ART group.138 The most common symptom reported was cough, except 
by those exclusively pre-ART who most often reported weight loss. The exclusion of 
individuals unable to produce sputum samples from four of these studies may have 
introduced selection bias and resulted in a greater proportion reporting cough than would 
otherwise be found in the context of routine HIV care.138, 141-143 Adelman147 et al 
investigated only those who were symptomatic, and Cranmer148 et al did not report on TB 
diagnoses or investigations; hence it is not possible to estimate TB prevalence in these 
studies. However, these two studies which enrolled a representative sample of PLHIV, are 
likely to provide an accurate reflection of the proportion of individuals established in care 
who have WHO tool symptoms. The data presented in Table 2-4 suggest that screening for 
TB using the WHO tool could identify one-third to almost half of individuals on ART, who 
are attending for routine HIV care, as requiring a diagnostic test for TB.  
 
2.2.4. Summary 
The WHO tool was designed to rule out TB prior to IPT using individual level participant 
data from PLHIV who were pre-ART, and from a disparate range of studies, from 
community-based TB/HIV prevalence surveys (who supply most of the participants but few 
TB diagnoses), to HIV clinic attendees. The performance of the WHO tool amongst 
individuals previously screened for TB utilised data in the original meta-analysis from 
settings far removed from routine HIV care, i.e. community-based surveys and an 
occupational health service for gold miners. A subsequent systematic review suggests that 
it is less sensitive and more specific amongst those on ART.42 The studies included in the 
aforementioned review are at risk of bias, having excluded participants unable to provide 
sputum at enrolment (possibly because they did not have cough) from analyses, limiting 
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generalisability and an accurate reflection of the impact of previous screening on the 
performance of the WHO tool. These studies indicate, however, that a minimum of one-
third of those on ART report WHO tool symptoms (mainly cough and weight loss) and 
therefore require a diagnostic test.     
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Table 2-4 Prevalence of WHO tool symptoms amongst HIV-positive adults attending for routine care  
 
Author 
Country 
Year 
Design 
Study population 
Procedures 
Exclusions from analysis 
TB Case 
definition 
Number  
Median CD4 cells/mm3 
TB prevalence 
n/N (%) 
Prevalence of TB symptoms % Comments 
WHO+ C W F N 
Ahmad 
Khan138 
SA 
2014 
X-sectional 
HIV clinic attendees 
Consecutive sample 
ALL at enrolment: Symptom 
screen, 3 sputa (2 smears & 
1 culture), CXR 
SM+ or C+ 737 in analysis 
• 522 on ART (70.8%)  
CD4 = 365 
• 215 pre-ART (29%) 
CD4 = 200 
On ART: 31/522 
(5.9%) 
45%1 
N=522 
30% 17% 7% 19% Excluded if: no sputum / 
submitted >14 days after 
enrolment (15), or data 
integrity concern (73) 
Pre-ART: 34/215 
(15.8%) 
71% 
N=215 
46% 50% 15% 30% 
Nguyen142, 
146 
Viet Nam 
2011 
X-sectional 
HIV clinic enrollees 
Consecutive sample   
ALL at enrolment: Symptom 
screen, 2 sputa (smear & 
culture), TST, CXR 
C+ 397 in analysis (CD4 = 
336) 
• 230 on ART (57.9%) 
Overall: 28/397 
(7.1%) 
37%1 
N=397 
27% 20% 7% 3% Excluded from analysis if: 
did not complete all 
procedures or NTM / 
contaminated culture (39) 
Rangaka143 
SA 
2012 
X-sectional 
HIV clinic attendees, on / 
about to start ART, 
undergoing screening for 
clinical trial  
Consecutive sample 
ALL at enrolment: Symptom 
screen, 1 sputum (smear & 
culture) 
C+ 1429 
• 775 on ART (54.2%) 
CD4=289 
On ART: 
42/775 (5.4%) 
On 
ART1,2: 
51/775 
(6.6%) 
5% 2%3 NR 1% Excluded from analysis if: 
unable to produce sputum 
or missing results, or 
missing symptoms or 
predetermined predictors 
(661) 
Adelman147 
Ethiopia 
2015 
X-sectional 
HIV clinic attendees 
Consecutive sample 
At enrolment: Symptom 
screen & IF symptomatic 3 
sputa (smear, Xpert & 
culture)  
GXP+ or C+ 828 in analysis (CD4 = 
420 [mean]) 
• 730 on ART (89%) 
13/217 (6.0%) who 
provided sputum 
had TB 
39% 
N=828 
34% 13% 19% 21% First 5 symptomatic 
patients enrolled per day. 
Investigated only if 
symptomatic (n=321), of 
whom 35% did not provide 
sputum. 
Hoffman145 
SA 
2013 
X-sectional 
 
ANC attendees 
Consecutive sample 
ALL at enrolment: Symptom 
screen, sputa (smear & 
culture) 
C+ 1403 not on TB Rx at 
enrolment + 12 on Rx 
• Amongst all 1415 
(CD4 = 394)  
• Median gest 24 wks  
• 39% no ART agent 
35/1403 (2.5%) 16% 
N=1403 
8% 7% 4% 3% WHO tool sensitivity 28%, 
specificity 84% for 
previously undiagnosed 
TB 
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Author 
Country 
Year 
Design 
Study population 
Procedures 
Exclusions from analysis 
TB Case 
definition 
Number  
Median CD4 cells/mm3 
TB prevalence 
n/N (%) 
Prevalence of TB symptoms % Comments 
WHO+ C W F N 
LaCourse141 
Kenya  
2016 
X-sectional 
ANC attendees 
Consecutive sample 
ALL at enrolment: Symptom 
screen, 2 sputa (1GXP & 1 
culture), Urine LAM, TST 
C+ 
 
288 in analysis (CD4 = 
437) 
• Median gest 26 wks 
• 26% no ART agent 
7/288 (2.4%) 
 
19%1 
N=288 
15% 1% 5% 7% Excluded from analysis if: 
unable to produce sputum 
or contaminated culture 
(18) 
Cranmer148 
Kenya 
2017 
X-sectional 
Postpartum MCH attendees 
for 6-wk or 9-month infant 
immunisation 
Systematic sample 
ALL at enrolment: Symptom 
screen + if symptomatic 
further evaluation arranged 
by clinic. 
N/A N=498 (6 wks n=260, 9 
months n=238) 
• 313 on ART (63%) 
• CD4 483 
Not known 33% 
N=498 
19% 11% 15% 9% Analysis of data from HIV-
positive mothers from 
national PMTCT-MCH 
survey. 
No data re TB 
investigations / results. 
15% reported IPT 
 
ANC, antenatal clinic; ART, antiretroviral therapy; C+, culture-positive MTB; CXR, chest radiograph; GXP+,  Xpert-positive; MCH, maternal child health clinic; PMTCT, ART for prevention of 
mother-to-child transmission; SA, South Africa; SM+, smear-positive; TB Rx, TB treatment; TST,  tuberculin skin test; WHO +, WHO tool positive 
C W F N, cough, unintentional weight loss, fever, night sweats 
1 Sensitivity and specificity of WHO tool in this population presented in Table 2-2; 2 WHO tool retrospectively applied; 3 Self-report or documented 
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2.3. Urine lipoarabinomannan as an alternative TB screening tool for PLHIV      
2.3.1. Introduction 
Testing for LAM is unique within the array of available TB diagnostics, as firstly it has 
greater sensitivity for TB in HIV-positive compared with HIV-negative individuals,149, 150 and 
secondly amongst HIV-positive individuals sensitivity is greater in those with more 
advanced immunosuppression.103 The test itself has gone through a number of iterations, 
with a commercially available laboratory-based urine LAM Enzyme-Linked Immunosorbent 
Assay (ELISA) (Clearview TB-ELISA; Alere, USA) preceding the current LF-LAM formulation; 
as has the reference card for LF-LAM. Prior to 2014, the manufacturer’s reference card for 
LF-LAM comprised five grades of colour intensity. The least intense band was assigned 
grade 1, absence of a band graded negative, and absence of a control band deemed a 
failed test. In order to improve the specificity of the test, in January 2014 the reference 
card was revised to include only four bands, with band intensity grade 1 on the new card 
corresponding to grade 2 on the previous card. Therefore, evaluations of the diagnostic 
accuracy of LF-LAM have used varying cut-offs to define a positive LF-LAM test, which 
needs to be considered when comparing the performance of LF-LAM between studies. 
A 2016 Cochrane review of LF-LAM for diagnosing TB in PLHIV reported its utility, against a 
reference standard of microbiologically-confirmed TB, firstly as a diagnostic test for 
individuals who were unwell (largely from inpatient studies) and secondly when used as a 
screening test in outpatient settings.103 In the review a grade 2 cut-off on the pre-2014 
reference card was deemed a positive LF-LAM result. For diagnosing bacteriologically-
confirmed TB amongst symptomatic PLHIV the median pooled sensitivity and specificity 
were 45% (95% CrI 29%, 63%) and 92% (95% CrI 80%, 97%) respectively. Sensitivity was 
greater amongst those with CD4 ≤100 vs. >100 cells/mm3, 56% (95% CrI 41%, 70%) vs. 26% 
(95% CrI 16%, 46%); although specificity was slightly less at 90% (95% CrI 81%, 95%) vs. 92% 
(95% CrI 78%, 97%) respectively.    
Performance of LF-LAM for TB screening was reported from three studies in the Cochrane 
review, and sensitivity and specificity ranged from 0-44% and 94-95% respectively in these 
studies.103 2015 WHO guidance112 and the Cochrane review103 therefore advise against the 
use of LF-LAM as a screening test for TB because of its poor sensitivity in this context. 
However, because its sensitivity is better in symptomatic PLHIV, particularly amongst 
those with very low CD4 cell counts and its specificity is consistently high, it is suggested 
as an ancillary test to assist TB diagnosis in symptomatic PLHIV with CD4 counts ≤100 
cells/mm3, or those who are seriously ill (presence of any of respiratory rate > 30/minute, 
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temperature >39°C, heart rate > 120/minute, or unable to walk unaided) irrespective of 
CD4 count.112 2017 South African HIV clinicians society guidelines, in keeping with this 
guidance, recommend that all who have WHO tool symptoms when screened prior to ART 
initiation should be investigated with both Xpert and mycobacterial culture on sputum, 
and LF-LAM if CD4 count <100 cells/mm3.62  
At the time the research was commenced for this thesis, LF-LAM had recently become 
available, and the opportunity was taken to investigate how it performed as a TB 
screening test for individuals established in HIV care. Published studies reporting the 
diagnostic accuracy of LF-LAM as a screening test for PLHIV in outpatient settings, but not 
those undertaken in inpatient settings are discussed below. 
 
2.3.2. Performance of LF-LAM as a screening test for TB in outpatient settings 
Eight published studies report LF-LAM performance for screening ambulatory PLHIV for TB. 
These can be divided into those screening PLHIV at first HIV-positive diagnosis (3),106, 107, 151 
prior to ART initiation (3),104, 105, 152 and those established in care (2).141, 153 Two of these 
studies are not discussed further, because LF-LAM performance data is not reported 
separately for inpatient vs. outpatients,152 or because the data report the same population 
of participants from a subsequent study.107 The remaining six studies are summarised in 
Table 2-5, four104-106, 141 of which were included in the 2016 Cochrane review. 
Two studies screened clinic attendees established in care, both using the current 
recommended cut-off to define positive LF-LAM result. Thit et al enrolled patients from a 
tertiary level hospital in Myanmar, a country where levels of HIV-TB coinfection are lower 
than in sub-Saharan Africa where most other LF-LAM studies have been performed.153  
Participants were followed for six months to confirm TB diagnoses, and 70% were on ART. 
Against a reference standard of bacteriologically-confirmed TB (Xpert or culture) they 
report an unusually high sensitivity of 63% and an unusually low specificity of 69%, using 
the current recommended cut-off for positive LF-LAM. The investigators do not report data 
regarding study exclusions or those who declined to take part, so selection bias is possible. 
All LF-LAM testing was undertaken by research doctors who were blinded to clinical 
details, and the investigators question whether the poor specificity arose from the 
particular batch of tests used, or the study doctors’ reading of the test result. LaCourse et 
al screened ANC attendees, of whom around 80% were either established on ART or had 
commenced it as part of prevention of mother to child transmission (PMTCT). 141 In this 
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cross-sectional study, 20% of those screened declined to participate, and there were only 
seven culture-confirmed TB diagnoses, none of which were LF-LAM positive.  
Drain et al screened individuals at new HIV-positive diagnosis, using LF-LAM performed by 
study nurses on fresh urine samples, and reported sensitivity of 30.9% and specificity of 
92% for culture-confirmed TB, using the pre-2014 grade 1 cut-off to define a positive LAM 
result.151 Using the same more sensitive cut-off, two other studies which screened 
participants prior to ART initiation, reported sensitivities and specificities for 
bacteriologically confirmed TB of 25.8-28.2% and 92.9-98.6% respectively.104, 105 The 
aforementioned studies froze urine samples, for later laboratory-based testing with LF-
LAM.104, 105 
Only one study undertook prospective follow up to confirm TB diagnoses and collected 
extrapulmonary samples for TB culture (if clinically indicated), however submission of at 
least one sputum sample was one of the study inclusion criteria, introducing bias.154 Lawn 
et al screened all participants at enrolment (unless pregnant) with chest radiograph.105  
Underdiagnosis, in particular of extrapulmonary TB is likely in these studies, because of 
limited investigation for extrapulmonary TB, and this might have resulted in 
underestimation of LF-LAM sensitivity. Very few participants enrolled to these studies are 
reported (where data are available) to have been unable to provide a urine sample, 
suggesting ease of sample collection. However it is likely that those unable to produce 
urine declined to participate, so urine sample collection might not be as straightforward 
as suggested.
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Table 2-5 Performance of LF-LAM for TB screening amongst PLHIV in outpatient settings  
Author 
Country 
Year 
Design 
Study population 
Procedures 
 
TB Case definition 
 
LF-LAM cut-off 
 
 
Number in 
analysis 
Median CD4 
cells/mm3 
TB prevalence 
n/N (%) 
LAM-
Positive 
 n/N (%) 
Sensitivity  
n/N, % 
(95% CI) 
Specificity  
n/N, % 
Comments 
Screened at new HIV-positive diagnosis 
       
Drain151 
2016 
SA 
X-sectional 
Newly diagnosed HIV-pos 
(outpatients) 
ALL at enrolment: Symptom 
screen, 1 sputum induced if 
necessary (solid & liquid culture), 
urine LF-LAM, CXR if indicated. 
Definite TB: C+ 
 
Positive LF-LAM = Gd 
1 pre-2014 card 
726/757 (95.9%) 
produced urine 
 
675 in analysis 
CD4 = 213 
Definite: 
123/675 (18.2%) 
 
89/675 
(13.2%) 
Definite TB: 
38/123, 30.9% 
Definite TB: 
508/552, 92.0% 
Excluded from analysis if: 
• No culture result (51) 
• No urine (31) 
 
LF-LAM by study nurse   
Includes same study 
population as below106 
Drain106 
2015 
SA 
X-sectional 
Newly diagnosed HIV-pos 
(outpatients) 
ALL at enrolment: Symptom 
screen, 1 sputum induced if 
necessary (solid & liquid culture), 
urine LF-LAM, CXR if indicated. 
Definite TB: C+ 
Clinical TB: Started TB 
Rx within 9 m without 
+ve MTB microbiology  
 
Positive LF-LAM = Gd 
1 pre-2014 card or Gd 
2 
351 enrolled 
 
320 in analysis 
CD4=248 
(n=288) 
Definite: 54/320 
(16.9%) 
 
Clinical: 14/320 
(4.4%) 
Either test 
Gd 1: 43/320 
(13.4%)   
Gd 2: 32/320 
(10.0%) 
Definite TB: 
Gd 1 either test: 
22/54, 40.7% 
• CD4<100: 
55.6% (35-75) 
 
Gd 2 either test: 
15/54, 27.8% 
• CD4<100: 
37.0% (19-58) 
Definite TB: 
Gd 1 either test: 
242/266, 91.0% 
 
Gd 2 either test:  
249/266, 93.6% 
Excluded from analysis 
• No LAM or TB culture result 
(31) 
 
2 LF-LAM tests per sample by 
study nurse. Similar sensitivity 
/ specificity to 1 test per 
sample 
 
Screened prior to ART initiation  
       
Balcha104 
2014 
Ethiopia 
Prospective 
HIV clinic attendees 
ART-eligible 
Consecutive sample 
ALL at enrolment: Symptom 
screen, ≥1 sputum (liquid culture, 
GXP), blood (FBC, CD4), 50 ml 
urine 
LNA (culture & GXP) if indicated 
Outcomes reviewed after 6m 
Definite TB: GXP+ / C+ 
Clinical TB: TB Rx 
without +ve MTB 
microbiology 
Not TB: None of the 
above 
 
Positive LF-LAM = Gd 
1 pre-2014 card 
757/812 (93.2%) 
produced urine 
 
757 in analysis: 
 
CD4 = 211 
Definite: 
128/757 
(16.9%); 126 
PTB 
 
Clinical: 20/757 
(2.6%); 15 PTB 
78/757 
(10.3%)   
Definite TB1: 
33/128, 25.8% 
• CD4<100: 
52.8% (35.7–
69.3) 
Definite TB1: 
566/609, 92.9% 
Study exclusion criteria: 
• Unable to produce sputum 
Excluded from analysis if: 
• No urine (55) 
 
Urine frozen & tested when all 
enrolment completed 
LF-LAM by lab technician 
blinded to clinical details 
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Author 
Country 
Year 
Design 
Study population 
Procedures 
 
TB Case definition 
 
LF-LAM cut-off 
 
 
Number in 
analysis 
Median CD4 
cells/mm3 
TB prevalence 
n/N (%) 
LAM-
Positive 
 n/N (%) 
Sensitivity  
n/N, % 
(95% CI) 
Specificity  
n/N, % 
Comments 
Lawn105 
2012 
SA 
X-sectional 
HIV clinic attendees prior to ART 
start 
Consecutive sample 
ALL at enrolment: Symptom 
screen, CXR, 2 sputa (liquid 
culture, GXP induced if 
necessary), urine for LF-LAM 
Definite TB: C+ 
 
Positive LF-LAM = Gd 
1 pre-2014 card 
595/602 (98.8%) 
produced urine 
 
516 in analysis 
CD4 = 170 
 
 
Definite: 85/516 
(16.5%) 
30/516 
(5.8%) 
Definite TB: 
24/85, 28.2% 
 
CD4<100: 51.7% 
(95% CI, 32·5–
70·6) 
Definite TB: 
425/431, 98.6% 
Excluded from analysis if: 
• Unable to produce sputum 
(60) 
• Culture contaminated or no 
GXP result (19) 
• No urine (7) 
 
Urine frozen prior to testing in 
laboratory 
Screening PLHIV established in care  
       
Thit153 
2017 
Myanmar 
Prospective 
Hospital attendees (in & 
outpatients) – tertiary level 
Consecutive sample 
ALL at enrolment: Symptom 
screen + exam, 1 sputum induced 
if necessary (L-J culture, GXP), 
CXR, urine LF-LAM 
Outcomes reviewed after 6m 
Definite TB: GXP+ / C+ 
Clinical TB: TB Rx 
without +ve MTB 
microbiology 
Not TB: None of the 
above 
 
Positive LF-LAM = Gd 
1 post-2014 card 
517 in analysis 
• 463 
outpatients 
• 54 inpatients  
 
CD4 = 270 
On ART = 
360/517 (70%) 
 
Outpatients: 
Definite: 46/463 
(9.9%) 
 
Clinical: 103/463 
(22.2%) 
 
Outpatients: 
166/463 
(35.9%) 
Outpatients: 
Definite TB1: 
29/46, 63.0% 
 
Outpatients: 
Definite TB1: 
217/314, 69.1% 
Exclusions / number declining 
not reported, possible selection 
bias 
 
LF-LAM by research doctor 
blinded to clinical details. 
Clinical team unaware of LF-
LAM result. 
LaCourse141 
2016 
Kenya 
X-sectional 
ANC attendees 
Consecutive sample 
ALL at enrolment: Symptom 
screen, 2 sputa (1GXP & 1 liquid 
culture), Urine LAM within 8 hours 
of collection, TST 
Definite TB: C+ 
 
Positive LF-LAM = Gd 
1 post-2014 card 
288 in analysis  
 
CD4 = 437 
On ART = 
165/288 (57.3%) 
PMTCT = 
62/288 (20.3%) 
Overall: 7/288 
(2.4%)3 
 
13/266 
(4.9%) 
Definite TB: 
0/7 
Definite TB: 
95.1% 
76/388 (19.6%) screened, 
declined to participate 
Excluded from analysis if: 
• Unable to produce sputum 
(14) 
Contaminated sputum (4) 
 
ANC, antenatal clinic; ART, antiretroviral therapy; C+, culture-positive MTB; CI, confidence interval; CXR, chest radiograph; GXP+,  Xpert-positive; HIV-pos, HIV-positive;; PMTCT, ART for 
prevention of mother-to-child transmission; SA, South Africa; SM+, smear-positive; TB Rx, TB treatment 
1 Excluded clinical TB 
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2.3.3. Summary 
In spite of its relatively low cost and ease of sample collection, LF-LAM evaluations 
undertaken in outpatient settings demonstrate inadequate sensitivity (even if CD4 <100 
cells/mm3) to replace the WHO symptom screen for TB screening. Limitations of these 
studies include lack of prospective follow-up, and reliance on an imperfect reference 
standard of culture-positive pulmonary samples which will not identify TB in those who 
have solely extrapulmonary disease.  
LF-LAM’s high specificity has been suggested as indicating a role as a rule in test for TB. 
However a retrospective record review of a small number of HIV-positive inpatients with 
disseminated nontuberculous mycobacterial (NTM) disease identified false-positive LF-LAM 
result in 19/21 who had negative TB microbiology.155 These patients had advanced HIV 
disease, with median CD4 count of 5 cells/mm3, and represented only a tiny fraction of 
the 1687 inpatients evaluated by the infectious disease consultation service in the tertiary 
level hospital in South Africa over a one-year period. However the authors highlight that 
caution is required to ensure that a positive LF-LAM result in a seriously unwell PLHIV, in 
whom TB treatment may well be clinically highly appropriate, does not preclude 
investigation and treatment for other likely diagnoses.    
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2.4. Clinical prediction models as alternative TB screening tools or as triage 
tools for symptomatic PLHIV   
2.4.1. Introduction 
In order to reduce the volume of Xpert testing undertaken, the WHO has highlighted the 
need for a low-cost triage test, to identify amongst symptomatic individuals, those 
requiring confirmatory testing for TB.84 A suitable triage test has not yet been identified 
and possible candidate tests are discussed in Chapter 9. A clinical prediction model, used 
as a “second step algorithm” in symptomatic individuals could fulfil this role. Clinical 
prediction models (also known as clinical prediction rules, prognostic models or risk 
scores) combine the characteristics of an individual and/or a particular disease 
(predictors), to predict a particular outcome. Diagnostic prediction models predict the 
likelihood that an outcome, e.g. TB disease is present, whereas prognostic models predict 
the probability that a particular event might occur in the future.156, 157  
Clinical prediction models are increasingly abundant in the literature, with variable 
quality of construction as well as reporting, as highlighted by the TRIPOD statement which 
presents a recommended reporting framework,157, 158 and the CHARMS checklist for 
systematic reviews of prediction modelling studies.159 Developing a clinical prediction 
model is not a straightforward process, with consensus yet to be reached on key steps 
such as selection of candidate predictors and model building. 
In this section I will present an overview of recommended strategies for developing a 
clinical prediction model,159, 160 and subsequently using these assess published prediction 
models for active TB in PLHIV undertaken in outpatient settings in LMIC. 
 
2.4.2. Recommended strategies for developing prediction models 
Choice of model 
Regression models are the most widely used statistical models for clinical prediction, and 
multivariable logistic regression the most commonly used technique for developing 
diagnostic prediction models. Alternative statistical models include classification and 
regression tree modelling (CART) and artificial neural networks, both of which require 
large datasets.156 The CART method is based on splitting patients into pairs of groups 
based on cut-off levels of predictors which maximally separate (discriminate between) the 
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two subgroups in terms of the outcome, but within the subgroups there is minimal 
variability.156 The predictor which causes the largest separation is placed at the top of the 
tree, and splitting continues until a minimum size is reached or groups become 
homogenous. However, although these models provide a simple graphical display which is 
easy to understand, they must always categorise continuous variables thereby losing 
information, and have limited power as they quickly run out of “cases” within branches. 
In neural networks the relationship between the outcome and the input variables is 
determined entirely by the data, with errors from initial predictions fed back into the 
network, so the network learns by example.156 Candidate predictors based on clinical 
knowledge or literature review cannot be a priori included in the final model developed 
using a neural network. This type of model is less likely to be used in a clinical setting, 
where the structure of the model and the predictions need to be clinically credible to a 
healthcare worker, who holds responsibility for the consequences of all decision making.161 
 
Candidate predictors 
Candidate predictors are all the variables that are considered for possible inclusion in the 
model, and not just those in the final selected multivariable model.160 There is no 
consensus on the best method for selecting candidate variables, but suggested approaches 
include using literature review, clinical knowledge and studying the distribution of 
predictors in the study data.156, 157, 160 Dichotomising continuous predictors is discouraged, 
as this results in both loss of information and statistical power.162 Continuous predictors 
cannot be assumed to have a linear relationship with the outcome, and non-linearity 
should always be explored using appropriate statistical techniques.160 
 
Sample size 
The sample size requirements for prediction studies are determined by the number of 
outcome events.156, 159 In order to reduce the risk of overfitting, i.e. fitting a model that 
describes well the features of the data studied (including any quirks of the data), but does 
not predict reliably in new individuals the number of outcomes in the data relative to the 
number of predictive variables (events-per-variable [EPV]) is a key consideration.156, 159 
These predictive variables include not only all candidate predictors, but also the indicator 
variables for categorical predictors and transformations for continuous predictors. EPV of 
at least ten is recommended to ensure predictive accuracy.163   
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Handling of missing data 
The recommended strategy for handling missing data in prediction studies is to use the 
multiple imputation method, which replaces missing observations with values estimated 
from the available data. Omitting all data from participants who have missing values 
(complete-case analysis) risks developing a prediction model in a subset of individuals who 
are not representative of the original sample, 159 but might be considered if less than 5% of 
observations are missing.160 
 
Model building 
A common method of selecting predictors for inclusion in the multivariable modelling 
(predictor pre-selection) is based on the strength of their univariable association with the 
outcome. This method risks predictor selection bias, i.e. predictors with large but spurious 
associations with the outcome are selected, and important predictors which may become 
associated with the outcome after adjustment for other variables are rejected.159, 160 
There is no consensus on how best to select variables during multivariable modelling, but 
backward elimination and the full model approach are considered to reduce the risk of 
overfitting. In the full model approach, all candidate predictors are included in the model. 
In backward elimination the model starts with all candidate predictors, then a sequence of 
statistical tests is run to select predictors. The least significant candidate predictor at 
each step is sequentially eliminated according to a pre-specified criterion, e.g. Wald p-
value >0.05 if logistic regression is used. Backward elimination risks predictor selection 
bias, but the full model approach is not straightforward as it may not be possible to define 
the full model, or practical to include all candidate predictors.157, 159, 160 
 
Assessing the performance of a prediction model 
The performance of a clinical prediction model is commonly described using two statistical 
measures, discrimination and calibration. Discrimination refers to the ability of a model to 
differentiate individuals with from those without disease. Calibration refers to the 
accuracy of the model in predicting the outcome, i.e. the agreement between model-
predicted outcomes and the actual observed outcomes. The concordance (C) statistic or 
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index is often used to quantify discrimination, and in logistic regression models 
corresponds to the area under the receiver operating characteristics (ROC) curve or 
AUROC. An AUROC of 0.5 indicates that the model cannot discriminate between those with 
and without disease. AUROC values of  0.7-0.79, 0.8-0.89, and ≥0.9, are respectively 
considered acceptable, excellent and outstanding discrimination.164 Calibration is assessed 
visually using calibration plots which plot the predicted outcome probabilities against the 
observed outcome frequencies within quantiles of predicted risk. Calibration can also be 
assessed statistically using the Hosmer-Lemeshow test, and a p-value of <0.05 indicates 
lack of model fit (poor calibration), but this test has limited statistical power to detect 
poor calibration unless the sample size is large and the outcome frequent.160 
 
Evaluation of a prediction model 
A prediction model is designed to optimally fit the data from which it was developed, so 
there is a potential that a model will be overfitted, and therefore the assessment of its 
predictive performance (C index) is likely to be “optimistic”; this is particularly so if the 
number of outcomes is small and the EPV is small.165 Internal validation, using the data in 
which the model was developed, is recommended to estimate overfitting and optimism in 
model performance. Strategies for internal validation include the commonly used method 
of splitting the sample (randomly, non-randomly, or temporally), with model development 
in one portion (development sample), followed by assessment of predictive performance 
in the second portion (validation sample). 
The split sample method is considered statistically inefficient as not all available data is 
used to develop the prediction model, and the development and validation samples tend 
to be similar. The preferred method for internal validation is to use a resampling 
procedure called the bootstrap.159 Bootstrapping draws with replacement (to introduce a 
random element) a study sample of the same size as the original dataset from the entire 
dataset; thereby mimicking the process of sampling from the underlying population. 
Firstly, a prediction model is constructed using the entire dataset, and its performance 
assessed. Then, several hundred bootstrap samples are drawn, and each step of model 
development is repeated in every sample. Different models may be yielded in each 
bootstrap sample, and the performance of each of these models is evaluated in the 
original dataset. This enables estimation of the optimism in performance of the model 
developed in the original sample, and adjustment for this to the C index and the 
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estimated regressions coefficients in the final model.156, 165 This adjusted performance 
therefore corrects for optimism and helps to “fine-tune” the model to the data. 
In order to be clinically useful a prediction model needs to accurately predict the outcome 
in individuals outside of the development data. External validation, the process of 
evaluating the performance of the model in new data, is strongly recommended for all 
prediction models. This enables the updating or adjustment of the model if it performs 
poorly in the new data, thereby improving its generalisability.166 
 
 
2.4.3. Prediction models for prevalent active TB amongst PLHIV 
The aim of this section is to describe and assess the quality of clinical prediction models 
for previously undiagnosed prevalent active TB in HIV-positive adults. The review focusses 
on models designed to identify prevalent active TB when screening PLHIV in LMIC 
outpatient settings.  
 
Search strategy 
The Medline database was searched for publications in the English language up to 1st May 
2019. The Cochrane Library, and abstracts of world conferences of the International Union 
Against Tuberculosis and Lung Disease from 2013 to 2018 were also searched. In addition a 
systematic review of prediction models for pulmonary TB in adults published in 2017 was 
checked for further references.167 This review identified six studies in total, only two of 
which reported models developed for screening PLHIV in outpatient settings.143, 146 and 
which are discussed below. The authors concluded that the level of reporting on model 
development and evaluation of the studies in the review was poor, and that those 
reported were not useful for TB screening.    
Recommended search terms for diagnostic prediction studies were used in Medline, 
including the Ingui search filter168 updated with an additional search string as 
recommended by Geersing et al.169 The search strategy is detailed in Table 2-6.     
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Table 2-6 Search terms used in MEDLINE to identify clinical prediction studies 
Ingui Filter168 #1 validat* OR predict*[Title] OR rule* 
#2 predict* AND (outcome* OR risk* OR model*) 
#3 (history OR variable* OR criteria OR scor* OR characteristic* OR 
finding* OR factor*) AND (predict* OR model* OR decision* OR 
identif* OR prognos*) 
#4 decision* AND (model* OR clinical* OR logistic models[MeSH 
Terms]) 
#5 prognostic AND (history OR variable* OR criteria OR scor* OR 
characteristic* OR finding* OR factor* OR model*) 
Geersing updated 
search string169 
#6 Stratification OR ROC Curve [MeSH Terms] OR discrimination OR 
discriminate OR c-statistic OR c statistic OR area under the 
curve OR AUC OR calibration OR indices OR algorithm OR 
multivariable 
Additional string 
for clinical score 
#7 clinical scor* 
Tuberculosis 
search string 
#8 “Tuberculosis” [Mesh Terms] OR tuberculosis OR TB 
HIV search string #9 "HIV"[MeSH Terms] OR acquired immune deficiency 
syndrome[MeSH Terms] OR HIV OR human immunodef* OR AIDS 
OR acquired immune def* OR acquired immunodef*  
Final search (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7) AND (#8 AND #9) 
Filters applied Humans; English; Adult: 19+ years; Adolescent: 13-18 years 
MeSH: Medical subject headings 
 
Inclusion and exclusion criteria 
Studies were included if they developed or validated a clinical prediction model for 
prevalent active tuberculosis in an outpatient setting and included HIV-positive 
individuals. Those which excluded or did not report enrolment of PLHIV, were conducted 
in high income countries or inpatient settings, or used tests which were unlikely either to 
be routinely available or used for tuberculosis investigation (e.g. biomarkers undergoing 
evaluation or computed tomography [CT] imaging) were excluded.  
 
Results 
3809 publications were identified, and studies were excluded based on title or abstract. 
Four studies which developed prediction models for smear-negative TB in PLHIV,170-173 and 
one which developed a model for incident TB in PLHIV were excluded,174 as the focus of 
this thesis was screening individuals for prevalent TB as part of routine HIV care. Only 
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three studies were identified that fulfilled the eligibility criteria for this review, and these 
are described in Table 2-7.146, 175 Two of these studies developed prediction models to 
identify prevalent active TB in PLHIV, the majority of whom were on ART, who were 
screened for TB in outpatient settings.146, 175 The other study developed a model to triage 
individuals for further investigation, amongst those who had WHO tool symptoms when 
screened prior to ART initiation.176 The final models and their performance are detailed in 
Table 2-8, and the studies themselves are discussed below. 
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Table 2-7 Studies developing clinical prediction models for prevalent TB in the context of TB screening for PLHIV 
 
Author 
Country 
Year 
Design 
Aim of model  
Setting / population 
Enrolment procedures 
Exclusions 
Type Participants  
TB case definitions 
Outcome  
In analysis  
Candidate 
predictor 
selection  
N 
Events 
per 
variable 
Model development  Validation Comments 
Balcha176 
Ethiopia 
2014 
Cohort 
To triage WHO+ve PLHIV 
identified by screening for 
TB investigation   
ART-eligible clinic 
attendees (N=812), CD4 
212 
 
Consecutive sample 
Not eligible: if had ART, TB 
Rx within 2w 
 
ALL screened at enrolment: 
symptom,  2 sputa (C, 
GXP), FBC, CD4. 
If indicated: LNA (C & GXP)  
Outcomes reviewed after 
6m 
D N=625 WHO+ve 
 
• Definite: C+ / GXP+ 
• Clinical: TB Rx without 
+ve bacteriology  
• Not TB: Negative 
bacteriology & no TB Rx 
within 3m 
Definite TB 
N=116 
 
Total in analysis 
= 569 
Preselected by 
univariate analysis 
 
N=15 
<10 Multivariable logistic 
regression + 
backwards 
elimination 
 
Complete case 
analysis 
 
Continuous variables 
categorized  
 
 
Not done Enrolled only if able to produce 
paired sputa – not 
generalisable 
 
• Excluded from analysis: 
Missing values 56/625 (9%) 
• Clinical TB 21 
 
Predictor selection bias 
 
Transformation to score: 1 
point assigned to each item 
Nanta175 
Thailand 
2011 
Cohort 
To predict TB in PLHIV 
screened for TB 
 
PLHIV attending OPD, ART 
& TB clinics, and IP  
Not eligible: if had IPT or TB 
Rx within 1y 
 
ALL screened at enrolment: 
symptom, CD4, FBC 
• TB investigations 
arranged as part of 
routine care 
Followed for 2m 
D N=257 
 
• TB = any of: SM+, C+, 
compatible histology, 
clinical or radiological 
response to TB Rx. 
 
TB N=66 
 
Total in analysis 
= 257 
171 (66.5%) on 
ART 
Preselected by 
univariate analysis 
 
N not reported 
 
<10 Multivariable logistic 
regression + 
backwards 
elimination 
 
Complete case 
analysis 
 
Continuous variables 
categorized  
 
 
Not done Sampling unclear, exclusions 
and missing data not reported. 
Likely selection bias + 
enrolment from TB clinics 
 
Verification bias. Reference 
standard relied on routine 
investigation 
 
Proportion IP not reported 
 
Transformation to score: 
Weighted by coefficient from 
logistic regression model 
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Author 
Country 
Year 
Design 
Aim of model  
Setting / population 
Enrolment procedures 
Exclusions 
Type Participants  
TB case definitions 
Outcome  
In analysis  
Candidate 
predictor 
selection  
N 
Events 
per 
variable 
Model development  Validation Comments 
Nguyen146 
Viet Nam 
2011 
X-sect 
To predict C+ PTB in PLHIV 
screened for TB 
 
HIV clinic attendees 
(N=436), CD4 336 
 
Consecutive sample 
Not eligible: if screened for 
TB within 3m, TB Rx within 
1y 
   
ALL at enrolment: Symptom 
screen, 2 sputa (smear & 
culture), TST, CXR 
D N=436 
• TB: C+ 
TB N= 28 (6 
AFB+) 
 
Total in analysis 
= 397 
230 (57.9%)  on 
ART 
Clinically important 
predictors & 
additional 
preselected by 
univariate analysis  
 
N not reported 
<10 Multivariable logistic 
regression 
 
Complete case 
analysis 
Not done Excluded from analysis: 
• Did not complete all 
procedures (36)  
• NTM / contaminated culture 
(3) 
 
Symptom screen positive if 
present ≥2w in previous 4w 
 
Final model includes diagnostic 
tests (CXR, sputum smear), 
not feasible for screening 
 
C, mycobacterial culture; C+, Culture positive; CXR, chest radiograph; D, development; FBC, full blood count; GXP, Xpert;  HIV-P, HIV-positive; IP, inpatient; OP, outpatient; SA, South Africa; 
SM, smear microscopy; SM-Neg, smear-negative; TB Rx, TB treatment; TST, tuberculin skin test; WHO+ve, WHO-tool positive;  X-sect, Cross-sectional 
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Table 2-8 Performance of clinical prediction models for prevalent TB in the context of TB 
screening for PLHIV 
Author 
Country 
Year 
Outcome predicted  
Population 
n/N (% with outcome) 
Final model / score Performance of score 
Balcha176 
Ethiopia 
2014 
Cohort 
C+ or GXP+ve TB  
 
WHO+ve ART-eligible 
individuals, screened in 
primary care 
 
137/791 (17.3%) 
1 point each: 
• Cough 
• Karnofsky ≤80  
• MUAC <20 cm 
• Lymphadenopathy  
• HB <10 g/dL 
Amongst WHO+ve (N=569) 
≤1: PPV 20/255 (7.8%, 95% CI 4.9, 11.9)  
2-3: PPV 77/280 (27.5%, 95% CI 22.4, 33.1) 
≥4: PPV 19/34 (55.9%, 95% CI 37.9, 72.8) 
 
Amongst N=791: WHO tool followed by 
investigation if score ≥4 AUC 0.75 vs. 0.70 
using WHO tool alone  
Nguyen146 
Viet Nam 
2011 
X-sect 
C+ TB 
 
HIV clinic attendees, 
screened for TB 
 
28/397 (7.1%) 
Any of: 
• CD4 <200 
• Sputum AFB+ve 
• CXR compatible with TB 
Amongst WHO+ve (N=147) 
• Sensitivity 100%, Specificity 59% 
• PPV 20%, NPV 100% 
 
AUC 0.83 (N=397) 
Nanta 
Thailand 
2011 
Cohort 
TB (confirmed or clinical) 
 
PLHIV attending hospital 
OP, ART or TB clinics, or 
inpatients; who were 
screened for TB 
 
66/257 (25.7%) 
Points assigned 
• BMI <19 = 2 
• Cough > 2w = 3  
• Shaking chills ≥1w = 3 
• On ART = 3 
• CD4 ≤200 = 2 
• Previous TB = 3 
≤2: PPV 1/126 (0.8%, 95% CI 0.02, 4.3) 
3-7: PPV 21/57 (36.8%, 95% CI 24.4, 50.7) 
>7: PPV 16/22 (72.7%, 95% CI 49.8, 89.2) 
 
AUC 0.92 (N=257) 
 
 
AUC, area under ROC curve; C+, Culture positive; CXR, chest radiograph; GXP, Xpert; HB, haemoglobin; HIV-P, HIV-
positive; IP, inpatient; OP, outpatient; WHO+ve, WHO-tool positive;  X-sect, Cross-sectional 
 
 
Prediction models for prevalent active TB in PLHIV undergoing TB screening 
Nanta et al enrolled PLHIV from two hospitals in Thailand who were attending outpatient 
clinics or had been admitted, between 2009 and 2010.175 All participants underwent 
symptom screen and had blood collected for CD4 and full blood counts, but investigation 
for TB was only undertaken as part of routine care; all were followed for two months. A 
very high proportion, 66/257 (26%) of those enrolled, fulfilled study case definitions for TB 
(bacteriologically confirmed or clinical), and over half were on ART. The final prediction 
model for TB, developed using multivariable logistic regression, comprised six items (BMI, 
cough, shaking chills, ART status, CD4 count, previous TB) which are easily obtainable at 
primary care level in LMIC. After transformation to a clinical score, the authors report AUC 
of 92%. ROC AUC is not the best measure for assessing utility of screening tests, as it 
assigns equal importance to sensitivity and specificity; whereas better screening tests 
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need to increase sensitivity at high specificity in order to reduce the number of false-
positives requiring further evaluation.177 The aforementioned study has many limitations, 
in particular the sampling strategy is unclear, participants were enrolled from TB clinics, 
the proportion enrolled from inpatient departments and study exclusions were not 
reported, and no information was provided regarding handling of missing data. The 
reference standard was poor, relying solely on investigation undertaken as part of routine 
care, although the authors did follow participants for two months in order not to miss TB 
diagnoses. The proportion diagnosed with TB was very high due to selection bias as 
participants were enrolled from TB clinics and inpatient departments, but the number of 
candidate predictors was too large (EPV < 10) and the model is likely to have been 
overfitted. The study is likely to be extremely biased in terms of participant selection and 
assignment of reference standard, the findings may not be generalisable to individuals 
attending clinics for routine HIV care, and validation was not undertaken. However, the 
final model is simple and the predictors are clinically logical, although “shaking chills” 
may not translate well in all settings. 
Nguyen et al developed a clinical prediction model for use as a TB screening tool in PLHIV 
attending for routine HIV care in Viet Nam.146 The investigators enrolled consecutive HIV 
clinic attendees and at enrolment, all underwent symptom screen, TST, chest radiography 
and had two sputa collected for mycobacterial culture. Over half of participants were on 
ART and 28/397 (7%) fulfilled their reference standard of culture-confirmed TB. However, 
around 10% of those enrolled were excluded from model development because of missing 
data. This will have introduced bias, if for example those who did not return for TST 
reading were unable to do so because they were too unwell because they had TB, and 
alternative statistical methods for dealing with missing data should have been considered. 
The final selected model comprised three items (CD4 count, sputum microscopy result and 
chest radiograph compatible with TB), hence including indicator variables the EPV was less 
than 10. Two of the three variables in Nguyen’s final model were the results of diagnostic 
tests, sputum microscopy (which would have contributed to the reference standard) and 
chest radiograph; so the model’s reported sensitivity of 100% amongst individuals with 
WHO tool symptoms is unsurprising. A model that requires chest radiograph or sputum 
investigation is not suitable for use as a screening tool for PLHIV at every clinical 
encounter for TB. Individuals who had been screened for TB in the preceding three months 
were excluded from this study, limiting applicability to routine HIV care settings at the 
time the study was conducted, when PLHIV are likely to have attended on a monthly basis 
for ART pick up. No form of validation was undertaken by the authors. 
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Triage tool for prevalent active TB for use after WHO symptom screen 
Balcha et al performed a secondary analysis of data collected for a study undertaken in 
Ethiopa, which compared the diagnostic yield of Xpert on sputum with microscopy and 
culture, amongst adults screened for TB prior to ART initiation.176 The authors developed a 
prediction model for triaging those who reported WHO tool symptoms for TB investigation. 
116/569 (20%) of those who reported WHO tool symptoms fulfilled their case definition for 
bacteriologically-confirmed TB. The authors selected candidate predictors using univariate 
analysis and excluded 9% of those eligible for the analysis because of missing data. EPV 
was less than ten, suggesting an overfitted model, and validation was not undertaken. A 
major limitation of this analysis, is that the original study appears to have excluded 
individuals who could not produce a paired sputa sample, introducing bias. This also limits 
generalisability of the study to routine clinic settings, where not everyone is able to 
produce even one sputum sample.  
The authors’ final model comprised five predictors (cough, Karnofsky score, mid-upper 
arm circumference [MUAC], peripheral lymphadenopathy and haemoglobin), but did not 
perform much better than using the WHO tool alone when assessed using the receiver-
operating characteristic curve (AUROC). In busy routine clinic settings, where HIV care is 
often delivered by nursing staff, and adherence to TB screening algorithms is poor,43 it is 
unlikely that a second step triage tool which incorporates Karnofsky score, recent 
haemoglobin level and examination for peripheral lymphadenopathy will be utilised. ROC 
AUC is not the best measure for assessing utility of screening tests as it is an average 
across all possible cut-offs for a test, including those that might not be clinically relevant; 
and is not an intuitive concept to understand. Furthermore it assigns equal weighting to 
sensitivity and specificity, but a better screening test is one that increases sensitivity at 
high specificity, so that the number of false-positives requiring further evaluation is 
reduced.177  
  
Other screening tools developed using statistical modelling 
An additional two studies, which are relevant to TB screening in PLHIV, but do not strictly 
fulfil the eligibility criteria for this review are discussed below.72, 143 These comprise Cain 
et al’s algorithm,72 which was included in the original WHO meta-analysis (Table 2-1), 
because it uses CART modelling to guide investigation; and Rangaka et al who evaluated 
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whether additional predictors might improve the discriminatory ability of the WHO tool.143 
The latter study has already been described in detail as it was included in the systematic 
review to determine the accuracy of the WHO tool to rule out TB in individuals on ART 
(Table 2-3). 
Cain et al developed a TB screening algorithm for PLHIV prior to ART initiation which has 
been implemented and evaluated in a number of HIV clinics in Cambodia, Viet Nam and 
Thailand.72 The improving diagnosis of TB among people living with HIV (ID-TB/HIV) 
algorithm, comprises cough of any duration, fever of any duration, or night sweats lasting 
≥3 weeks in the preceding 4 weeks. The presence of any of the aforementioned symptoms 
triggers investigation for TB. Derivation of this tool has already been discussed, and it has 
higher sensitivity (93%) but lower specificity (36%) than the WHO tool. The investigators 
used CART analysis to develop a simple prediction model to guide further investigation of 
those who had a positive symptom screen, and in particular to prioritise mycobacterial 
culture. The diagnostic algorithm provides an alternative to the smear-negative pathway 
and started with collection of two sputum samples for microscopy, followed by chest 
radiography if both sputa were negative. If the radiograph was abnormal then empiric TB 
treatment could be commenced whilst awaiting confirmatory mycobacterial culture result, 
as 33% in this group had confirmed TB. If the radiograph was normal, but TB was still 
suspected, then the risk of TB was further stratified by CD4 cell count. If CD4 count was 
<350 cells/mm3 empirical TB treatment (as 10% had TB in this group) with confirmatory 
mycobacterial culture could be considered. In those with CD4 count ≥ 350 cells/mm3, as 
only 5% in this group had culture-confirmed TB, then a strategy of monitoring instead of 
mycobacterial culture could be considered. The symptom screen has been evaluated in 
Kenya in individuals aged > 7 years who were newly diagnosed HIV-positive and performs 
similarly in terms of sensitivity and specificity to the WHO tool.178 The yield from the 
entire screening and diagnostic algorithm has been investigated in clinics in Thailand, Viet 
Nam and Cambodia, amongst ART-naive adults attending for routine HIV care; but culture 
was not undertaken systematically for all participants, limiting ability to compare 
sensitivity and specificity of this algorithm with the WHO tool.179 
Rangaka et al undertook a secondary analysis of data collected for an IPT trial, and 
limitations of this analysis, in particular selection bias, have already been discussed (Table 
2-3). The authors investigated whether additional predictors might improve on the 
performance of the WHO tool amongst individuals on ART. Six predetermined predictors 
(all categorised) were added in multivariable logistic regression to a model which 
comprised only the WHO tool. The authors undertook backwards elimination, starting with 
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the full model, retaining variables deemed statistically significant, and compared the final 
model with the WHO tool using AUC. In multivariable analysis, BMI, CD4 count, and ART 
duration of less than three months were independent predictors of TB amongst those on 
ART. Addition of these variables to the WHO tool improved the discrimination of the tool, 
as measured by the AUC, from 59% (95% CI, 53%–66%) to an acceptable 70% (95% CI, 60%–
79%) amongst those on ART. ROC AUC is not the best measure for assessing utility of 
screening tests, as already discussed above. The authors’ findings are however pertinent 
when choosing predictors for prevalent TB in clinical prediction model development, and 
this is relevant to Research Paper 2.   
 
2.4.4. Summary   
There is a paucity of published clinical prediction models developed for use either as a 
screening tool for TB in PLHIV attending for routine care, or as a second step triage tool to 
prioritise investigation for those who report symptoms when screened using the WHO tool. 
Published models suffer from methodological flaws, in particular inadequate sample size, 
selection bias, failure to deal adequately with large volumes of missing data, and lack of 
validation.  
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2.5. Investigation pathways for PLHIV following a negative Xpert result 
2.5.1. Introduction 
In 2012, at the time the research for this thesis commenced, the algorithm devised for 
investigating PLHIV with a negative Xpert result124 (Figure 1-1) was identical to the 2007 
WHO algorithm for diagnosing smear-negative TB in ambulatory adults which commenced 
with sputum microscopy for all with chronic cough.180 The aim of the 2007 algorithm was 
to expedite treatment of smear-negative TB in PLHIV, within a maximum of four visits, 
and thereby reduce the high mortality previously arising from protracted evaluations for 
TB in this population. Additionally, the use of mycobacterial culture and chest radiograph 
early in the pathway aimed to improve the accuracy of diagnosis. The case definition for 
smear-negative pulmonary TB was revised for HIV-prevalent settings, requiring either one 
positive mycobacterial culture and compatible symptoms; or two sputa negative on TB 
microscopy, with compatible chest radiograph and a decision to commence TB treatment. 
If the initial sputum microscopy was negative, then at the second visit which was 
envisaged to occur the following day, all of chest radiography, a second sputum sample 
(for microscopy and mycobacterial culture), and a clinical assessment regarding empiric 
TB treatment were required. The third visit was for review of the chest radiograph and 
second microscopy result; and if TB was deemed unlikely then to provide antibiotics to 
treat, as appropriate, either bacterial or Pneumocystis jirovecii pneumonia. The purpose 
of the fourth visit was to assess the response to the antibiotic trial and to re-evaluate for 
TB those patients whose symptoms had not resolved. The antibiotic trial was not intended 
as a diagnostic aid, but rather to treat any commonly co-existing bacterial infection in 
PLHIV, with advice to reattend if symptoms that responded to treatment recurred. 
The Xpert-negative algorithm for PLHIV, compared with the smear-negative pathway, 
reduced the number of attendances required for evaluation from four to three, by 
providing the antibiotic trial at the second visit (Figure 1-1). This pathway is still onerous, 
and still requires good access to chest radiography and a lengthy wait for the result of 
mycobacterial culture. Innovative ways of getting around this include upfront collection of 
two sputum samples from all who are symptomatic, with testing of the second sample 
determined by the result of the initial Xpert (e.g. mycobacterial culture if the initial Xpert 
result is negative), as is policy in Cape Town, South Africa.181, 182 If resources permit, then 
access to on-site chest radiography or laboratory would be the ideal solution, but this is 
rarely feasible outside of a clinical research setting in most LMICs.101, 181     
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Schnippel et al modeled the costs and impact, for symptomatic PLHIV investigated for TB 
who had a negative initial Xpert, of replacing the entire pathway with a second Xpert 
test.126 The authors concluded that this strategy could save an estimated US$17.4 million 
per year at national programme level in South Africa. The assumptions made in their 
model included sensitivity estimates for Xpert based on Boehme et al’s implementation 
study,183 i.e. 100% and 79% for smear-positive and smear-negative culture-confirmed TB, 
respectively; 1% of symptomatic individuals started empiric TB treatment based on 
antibiotic trial and/or chest radiograph;125 loss to follow-up of 13% and 26% following the 
first and second visits respectively; and it did not consider extrapulmonary TB. It is 
unclear if the model assumed that everyone with a negative Xpert result was able to 
produce a further sputum sample, but this would have equally impacted either pathway, 
as both require a second sputum sample. Repeating the Xpert test is very attractive 
compared to the Xpert-negative algorithm, as it is far simpler and could markedly reduce 
diagnostic delay. However, in the aforementioned model all further evaluation stopped if 
the repeat Xpert result was negative, risking missing TB diagnoses, which the authors 
estimated at 2% fewer diagnoses made compared with the culture-based pathway. 
Interestingly, 2016 WHO ART guidelines do recommend a repeat Xpert test on a fresh 
sample, but this is in addition to chest radiograph and clinical assessment, and if feasible 
submission of sputum for mycobacterial culture.127 
The rationale for a repeat Xpert in the 2016 WHO ART guidelines appears likely to be the 
evidence of an improved diagnostic yield from repeating Xpert, which is described in 
diagnostic accuracy or TB screening studies that have tested multiple sputum samples 
collected at study enrolment using Xpert. These studies are discussed below, together 
with factors likely to improve yield. At the time the research for this thesis was 
undertaken, the strategy of repeating the Xpert test had not been empirically evaluated in 
the context of investigating PLHIV established in HIV care, who had been identified as 
needing confirmatory testing by TB screening. It is likely that the sensitivity of any 
diagnostic pathway will be lower in PLHIV identified through TB screening, a scenario 
where the prevalence of TB will be lower and individuals will be less symptomatic, 
compared with patients attending because of TB symptoms, or those preparing for ART 
who are at greater risk of TB and likely to have higher sputum bacillary load.   
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2.5.2. Studies performing Xpert on multiple samples obtained at enrolment 
Data regarding the yield from a second sputum sample tested with Xpert are derived from 
two main sources, firstly the original multicenter evaluation of Xpert amongst HIV-positive 
and -negative individuals attending for care because they were unwell, and secondly 
studies screening PLHIV for TB, which investigated all using Xpert irrespective of the 
presence of symptoms. In general, in both scenarios, multiple sputum samples were 
collected either at a single visit or for the initial diagnostic process, which does not reflect 
how the Xpert-negative pathway is followed in real life. Studies were generally cross-
sectional in design, with no prospective follow-up. 
Boehme et al undertook a large, multi-country evaluation in individuals with symptoms 
suggestive of TB, collecting three sputum samples (two spot and one morning sample) 
which appear to have been spontaneously produced.184 Two samples were first 
decontaminated, followed by centrifugation, then sputum deposits underwent microscopy 
after resuspension in phosphate buffer; following this, each sample underwent both Xpert 
test (after further processing) and mycobacterial culture (on both liquid and solid media, 
therefore four cultures in total). The third sample underwent direct microscopy and Xpert 
testing. Overall, 50.6% (741/1462) of participants had culture-confirmed TB, and 40% of 
participants were HIV-positive. The sensitivity of testing one (untreated sample) vs. two 
vs. all three samples using Xpert was 92.2% (675/732) vs. 96.0% (1423/1482) vs. 97.6% 
(732/741) for all culture-confirmed TB; and 72.5% (124/171) vs. 85.1% (296/348) vs. 90.2% 
(157/174) for smear-negative, culture-positive TB. The denominator for testing on two 
samples included two observations per participant, the first observation combined the 
first and third samples, and the second observation combined the second and third 
samples. The sensitivity data for repeat testing was not reported stratified by HIV status. 
However, the investigators did report that amongst HIV-positive participants, there was no 
difference between the sensitivity of Xpert on decontaminated vs. untreated sputum, 
which is of relevance for research studies which store decontaminated pellets for later 
testing with Xpert.  
6% of those fulfilling study eligibility criteria were not enrolled to the aforementioned 
study, mainly because they could not produce three sputum samples, so the authors are 
likely to have overestimated the sensitivity of Xpert.184 Almost half of all participants had 
previously been treated for TB. False-positive Xpert results can arise from detection of 
dead bacilli, thus potentially reducing test specificity, but specificity was high in this 
evaluation (99.2% vs. 98.6% vs. 98.1% for one vs. two vs. three samples) .185, 186 The study 
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was undertaken only in reference facilities, limiting generalizability to other settings, and 
in routine care settings patients are unlikely to be able to produce this many sputum 
samples. 
Lawn et al investigated the diagnostic accuracy of Xpert in a different context in South 
Africa, namely for screening PLHIV for TB prior to ART initiation.56 Median CD4 count in 
participants was 171 cells/mm3. Two sputum samples were collected from all participants; 
the first was a spot sample (induced if necessary), and the second was induced for all 
participants. The findings from studies which induce sputum samples are not generalizable 
to routine HIV care settings. Both sputum samples were decontaminated and processed as 
detailed above,184 prior to undergoing microscopy, testing with Xpert, and mycobacterial 
culture using liquid media. About 15% of those enrolled did not contribute to the analysis 
as they could not produce two sputum samples, and about one-quarter of those enrolled 
had previously been treated for TB. This exclusion potentially results in an overestimation 
of the sensitivity of Xpert and underestimation of its specificity. In this study the 
prevalence of culture-confirmed TB was 17.3% (81/468; 5.3% smear-positive, and 12% 
smear-negative), and the reported sensitivities of Xpert for one vs. two samples were 
58.3% (42/72) vs. 72.2% (52/72) for all culture-positive TB, and 43.4% (23/53) vs. 62.3% 
(33/53) for smear-negative, culture-positive TB.   
Cavanaugh et al, screened consecutive individuals at enrolment to HIV care in 24 Kenyan 
facilities, specifically excluding those who had received TB treatment within the 
preceding one year to reduce the risk of false-positive Xpert results.187 Three sputum 
samples (one morning, and two spot specimens) were requested, lymph node aspiration 
(LNA) undertaken if appropriate, and stool samples were collected at three facilities. 
Xpert was undertaken on one spot sputum (unprocessed), and on the morning sample 
(processed as detailed above to enable mycobacterial culture)184 only if the sample was of 
sufficient volume. Mycobacterial culture using liquid media was undertaken on two sputum 
samples (one morning and one spot), LNA, and stool. Median CD4 count in participants was 
343 cells/mm3, and the case definition for TB of positive mycobacteriology on culture or 
Xpert was fulfilled by 11.3% (88/778) of participants, of whom 8% (7/88) were diagnosed 
by Xpert alone. Amongst 74 TB diagnoses made in participants with two sputa tested with 
Xpert, 57% (42/74) vs. 66% (49/74) respectively were identified by the spot vs. morning 
samples. The morning sample identified 20% (14) TB diagnoses undetected by the spot 
sample, suggesting that a morning sample might improve yield compared with a spot 
specimen; and therefore, sensitivity of Xpert for one vs. two samples of 42/74 (57%) vs. 
56/74 (76%). Amongst 69 participants with TB diagnosed and CD4 cell count results, two 
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Xpert tests were reported to identify more TB diagnoses in those with CD4 counts <100 vs. 
≥100 cells/mm3 (22/24 [92%] vs. 30/45 [67%]). However, the numbers in this analysis were 
small, and not all participants had a repeat Xpert test on the morning sample, potentially 
introducing bias. Limitations of this study include a case definition which included Xpert 
results and limits comparability with the aforementioned studies. The yield of a repeat 
Xpert could not be accurately estimated from this study because not all participants 
submitted the morning sputum sample on which the repeat Xpert was performed. 
 
2.5.3. Studies undertaking repeat Xpert following an initial negative result 
There is only one published study reporting the yield of repeat Xpert testing following an 
initial negative test result.188 This was undertaken in the context of screening PLHIV for TB 
prior to ART initiation in Mozambique. All participants underwent TB screening using the 
WHO tool, urine LF-LAM and Xpert on sputum. If the initial Xpert was negative then a 
second sample was collected after two to three days for a repeat Xpert test; this was 
undertaken irrespective of the presence of WHO tool symptoms. TB was diagnosed based 
on either a positive Xpert or LF-LAM result. Amongst 972 participants included in the 
analysis, representing 96% of those eligible, median CD4 count was 278 cells/mm3; and 
10.1% (98/972) were diagnosed with TB (positive Xpert, 90; positive LF-LAM, 34). The first 
Xpert was positive in 74/972 (7.6%) of participants. Repeat Xpert was undertaken in all 
898 participants with a negative initial Xpert, and identified an additional 16 TB 
diagnoses. The sensitivity of Xpert testing of one vs. two samples was therefore 74/98 
(76%) vs. 90/98 (92%). Limitations of this study include the inclusion of the Xpert result 
itself (and LF-LAM) in the reference standard and the absence of mycobacterial culture.   
 
2.5.4. Factors improving the yield of Xpert from sputum 
Acuna-Villaorduna et al undertook a secondary analysis of data collected for a study 
evaluating a new TB microscopy method.186  The authors enrolled adults attending 
outpatient clinics in Uganda who had symptoms of TB, defined as cough ≥ 2 weeks plus one 
other of the WHO tool symptoms, and reported convenience sampling to include more HIV-
positive participants. Three sputa were collected (two spot and one morning), of which all 
underwent microscopy and TB culture on liquid media, and one spot sample was tested 
with Xpert. Amongst 860 participants in the analysis, 205 (24%) fulfilled the TB case 
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definition of positive mycobacterial culture on any sample; and 69% were HIV-positive.The 
authors reported lower Xpert sensitivity and greater specificity in mucosalivary vs. 
mucopurulent samples (sensitivity 82.5% [52/63]) vs. 95.8% [136/142]; specificity 95.6% 
[282/295] vs. 97.5% [350/359]).186 Multivariate analysis was undertaken to investigate 
factors associated with discordant Xpert and culture results (both Xpert and culture 
positive [n=188] vs. Xpert-positive, culture-negative [n=22]). The final model was adjusted 
for age, sex, weight loss, fever, previous TB treatment, HIV infection, and sputum quality 
(salivary vs. purulent). Salivary sputum (adjusted odds ratio [aOR], 95% CI 4.1, 1.1-14.6), 
previous TB treatment (aOR 8.3, 2.1-32.0), and fever (aOR 0.23, 0.1-0.7) were 
independently associated with discordant results. The confidence intervals are wide, 
reflecting the small number with discordant results, and approach 1 for sputum quality. 
Limitations of this study include potential bias due to convenience sampling, and the strict 
definition of TB symptoms which is in contrast to the usual criteria of the presence of any 
WHO tool symptom in PLHIV and thus limits generalisability. The authors did not 
undertake any prospective follow up to confirm TB diagnoses in those with discordant 
results so may have missed TB diagnoses. In addition, the number of discordant results 
reported by the authors was small, reflected in the broad confidence intervals which 
almost approach unity for sputum quality. The findings suggest that Xpert might perform 
less well in salivary samples, but the authors also postulate that the discordant results 
might reflect worse yield of TB culture compared with Xpert from salivary samples.  
Griesel et al report from their study which developed a clinical prediction model for TB in 
seriously ill HIV-positive inpatients in South Africa, a significantly greater yield of Xpert 
with sputum induction compared with spontaneous sputum samples (51.9% [162/312] vs. 
41.7% [68/163]).189 This may not be generalisable to PLHIV in outpatient settings attending 
for routine care.   
 
2.5.5. Summary 
An increased yield of TB diagnoses from performing Xpert on multiple samples has been 
reported from studies where multiple samples have been taken at study enrolment for 
screening prior to ART initiation,56 or investigation of HIV-positive and HIV-negative 
symptomatic individuals.184 Increased yield was also reported from one further study 
screening PLHIV prior to ART initiation, in which Xpert was repeated on a further sputum 
sample collected after a few days if the initial sample was negative, irrespective of 
whether symptoms were reported. 188 Induction of sputum rather than spontaneous 
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expectoration, morning rather than spot specimens, and possibly also mucopurulent rather 
than salivary samples may improve the yield from Xpert testing. However, prior to the 
research undertaken in this thesis, the strategy of repeating Xpert testing on a fresh 
sputum sample had not been undertaken in the context of the Xpert-negative pathway 
after screening individuals established in HIV care for TB. 
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2.6. Causes of symptoms suggestive of TB amongst PLHIV    
The aim of this section is to describe the findings from published studies which report the 
aetiology of symptoms suggestive of TB among PLHIV in LMIC settings, focussing on those 
conducted in outpatient settings, and in particular on chronic cough.    
The Medline database was searched for publications in the English language up to 1st May 
2019 using the search strategy detailed in Table 2-9. 
 
Table 2-9 Search terms used in MEDLINE to identify studies reporting causes of symptoms 
suggestive of TB   
#1 Cough OR fever OR sweats OR weight loss OR cachexia 
#2 chronic airflow obstruction OR post-TB OR tuberculosis-associated OR post-
tuberculous OR post tuberculous 
#3 Lung Diseases, Obstructive[MeSH Major Topic]) OR Airway Obstruction [MeSH Major 
Topic]) OR Airways Obstruction OR Obstructive Airway Disease OR Obstructive 
Airways Disease OR Pulmonary Emphysema OR Emphysema OR asthma 
#4 “Africa South of the Sahara” [Mesh Terms] 
#5 "HIV"[MeSH Terms] OR acquired immune deficiency syndrome[MeSH Terms] OR HIV 
OR human immunodef* OR AIDS OR acquired immune def* OR acquired immunodef*  
Final 
search 
(#1 OR #2 OR #3) AND (#4 AND #5) 
Filters 
applied 
Humans; English; Adult: 19+ years; Adolescent: 13-18 years 
MeSH: Medical subject headings 
 
957 publications were identified, and studies were excluded based on title or abstract. 
Seven relevant studies evaluating mainly ambulatory PLHIV with persistent cough or 
reporting diagnoses amongst individuals attending for routine HIV care are summarized in 
Table 2.10.  
Four studies focussed on extensively investigating patients with chronic symptoms who 
were sputum smear negative or febrile, aiming to identify serious infectious causes for 
symptoms.190-193 Amongst smear-negative patients with chronic cough, tuberculosis, 
bacterial pneumonia, lower respiratory tract infections, Pneumocystis pneumonia and 
pulmonary Kaposi’s sarcoma were the most frequent diagnoses, with most participants 
having multiple aetiologies.190, 192-194 Hargreaves et al, who performed bronchoscopy on 
patients with chronic cough reported that over half of TB cases were diagnosed on repeat 
sputum microscopy taken prior to bronchoscopy, although the proportion of these who 
were HIV-infected is not reported.192 In this study no causative organism was identified in 
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7% of participants who made a full recovery and they were categorized as having a non-TB 
chest infection. Okwera et al also identified no causative organism in induced sputum 
samples from more than half of their study participants, who were smear-negative PLHIV 
with a previous history of tuberculosis undergoing investigation for chronic cough.193 
Serious blood stream infections, in particular, non-typhoidal Salmonellae and 
cryptococcosis were also identified as responsible for chronic symptoms suggestive of 
tuberculosis and acute fever amongst PLHIV.190 One further study in which ART clinic 
attendees underwent limited (and not systematic) evaluation as part of routine care, with 
no access to mycobacterial culture, also reported tuberculosis as the most common 
diagnosis.191 Limitations of these studies include the focus on investigating only for an 
infectious cause, selection bias,190 and findings from studies which included only smear-
negative individuals may not be generalisable to a population attending for routine HIV 
care. 
Two studies investigated populations including PLHIV for non-communicable diseases 
(NCD) as causes of chronic cough.194, 195 Munyati et al evaluated primary care attendees in 
Zimbabwe with chronic cough and unsuprisingly amongst 454 newly-diagnosed HIV-positive 
patients, the majority of diagnoses were infectious (TB 46%, lower respiratory tract 
infection 31%).194 Munyati also identified a high proportion of NCD diagnoses, in particular 
post-tuberculous disease, asthma and heart failure.194 Calligaro found that one-third of a 
cohort of patients on ART in South Africa, who had no features of acute respiratory 
disease, reported respiratory symptoms and that this was associated with current smoking. 
195 In this cohort one-third of patients reported a smoking history and 7% had chronic 
airflow obstruction on lung function testing. If these findings are generalisable it is likely 
that smoking may contribute to respiratory symptoms amongst PLHIV,195 although smoking 
itself is a recognised risk factor for TB disease.196 One further study in which electronic 
and paper records of a consecutive sample of adults on ART were reviewed for NCD 
diagnoses, reported that 4% of study participants had a diagnosis of asthma and 2% of 
heart failure.197 Both diagnoses can cause chronic cough, but a limitation of this study is 
reliance on documentation of diagnoses, rather than confirming the criteria used to assign 
diagnoses. 
Post-tuberculous lung disease is increasingly recognised amongst PLHIV in LMIC settings. 
Allwood et al in a systematic review, largely comprising an HIV-negative population, 
reported an association between a past history of tuberculosis and the presence of 
spirometrically-confirmed chronic airflow obstruction (forced expiratory volume in 1 
second [FEV1] / forced vital capacity [FVC] <0.70 or less than lower limit of normal [LLN]), 
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which was independent of cigarette smoking.198 A systematic review of studies undertaken 
in South Africa, in community and occupational health settings, found an increased 
prevalence of respiratory symptoms amongst individuals who had previously been treated 
for TB.199 In a prospective cohort of PLHIV in South Africa who underwent annual 
spirometry over a period of three years, at study enrolment prevalent spirometrically-
confirmed obstructive lung disease (FEV1/FVC<0.70) was found to be associated with older 
age, current smoking, and higher C-reactive protein (CRP) levels. 25% of this cohort were 
on ART at enrolment. Amongst individuals with a previous history of tuberculosis, the 
authors reported a greater decline in lung function (FEV1 and FVC reductions of 35 
ml/year and 57 ml/year respectively) compared to those with no previous tuberculosis. In 
multivariable analysis (adjusted for time-updated CD4 cell counts, viral load, ART use at 
enrolment) the authors reported that only ever having smoked and previous tuberculosis 
were independently associated with excess loss in FEV1.200 Smoking and a previous history 
of TB are common among PLHIV, so it is likely that both contribute to the aetiology of 
chronic or recurrent cough in this population. However, it is also possible that asthma and 
chronic obstructive pulmonary disease (COPD) are underdiagnosed in busy primary health 
care settings in LMIC. 
 
2.6.1. Summary  
Published studies focus mainly on identifying infectious aetiology for symptoms suggestive 
of tuberculosis, although a few report non-communicable diseases such as asthma and 
cardiac causes for respiratory symptoms. Some studies report multiple aetiologies in 
patients for these symptoms. In all studies where infectious aetiologies are sought, the 
most frequent diagnosis, where a cause is found, is active tuberculosis. Post-tuberculous 
lung disease is increasingly recognised in PLHIV in LMIC settings. Large-scale 
epidemiological studies are needed to describe this phenomenon better, and to provide 
better evidence to guide criteria to distinguish this from active TB and guide optimal 
management.      
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Table 2-10 Diagnoses amongst PLHIV with symptoms suggestive of TB in LMIC or Sub-Saharan Africa 
Author 
Country 
Design 
Study population 
Median CD4 count cells/mm3 
(N) 
Inclusion criteria Study procedures 
 
Key findings & comments 
Magoro 2016197 
Zimbabwe 
Cross-section 
Adults attending HIV clinic 
All on ART 
Median CD4 191  
(N=1033) 
Consecutive sample 
Adults on ART 
Excluded if not already registered at 
clinic 
Systematic review of all paper 
and electronic records for NCD 
diagnoses after patient had 
attended clinic 
NCD identified from record review: 
• Hypertension 106 (10%) 
• Asthma 45 (4%) 
• Type 2 diabetes mellitus 22 (2%)  
• Cancer 19 (1.8%) 
• Congestive cardiac failure 16 (2%) 
• Stroke 10 (1%) 
• Other 39 (4%) 
Retrospective record review with no validation of 
diagnoses 
Okwere 2013193 
Uganda 
Cross-sectional 
Smear negative HIV-positive 
adults undergoing evaluation 
for recurrent PTB at TB clinic 
47% on ART 
Median CD4 261  
(N=178) 
Consecutive sample 
Sputum smear negative & previous 
history of TB & cough > 2w 
Excluded if other severe illness 
(cardiac disease or asthma) 
Sputum (induced and spot) for 
TB culture + bacterial 
pathogens + Pneumocystis 
jirovecii PCR 
FBC, CD4 
Pathogens identified in sputa: 
• 95 (53%) no bacteria 
• 33 (19%) bacteriologically confirmed TB 
• 48 (27%) other bacteria (most commonly S. 
pneumoniae [10), M. catarrhalis [8]), H. influenzae 
[8]) 
• 12 (6.7%) Pneumocystis jirovecii 
Not generalisable to routine HIV care settings 
Authors looked only for infectious causes 
Damtie 2013191 
Ethiopia 
Cross-sectional 
Adults attending ART clinic 
78% on ART 
52% had CD4 >350 (median 
not reported)  
(N=360) 
Random sample 
Adults on ART 
Exclusion criteria not reported 
Routine clinical investigation by 
clinician in accordance with 
clinic protocol, mainly clinical 
diagnoses 
If cough>2w: sputum smear, + 
CXR if smear-negative 
FNA if indicated for TB 
microscopy 
Diarrhoea: stool microscopy 
Diagnoses: 
• 35 (10%) TB of which 30 PTB (22 smear-negative), 
5 EPTB 
• 18 (5%) Oral candidiasis 
• 12 (3%) Diarrheal disease (strongyloides [2], 
Schistosoma [1]) 
• 6 (2%) Pneumonia 
• 5 (1%) Skin fungal infection 
• 12 (3%) Other 
No systematic investigation of participants. Diagnoses 
were made during routine clinical care 
Literature review 
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Author 
Country 
Design 
Study population 
Median CD4 count cells/mm3 
(N) 
Inclusion criteria Study procedures 
 
Key findings & comments 
Bedell 2012190 
Malawi 
Prospective cohort 
 
Ambulatory adults prior to 
ART initiation   
Median CD4 129  
(N=469) 
Potential participants referred 
by clinicians undertaking 
routine clinical care  
3 negative sputum smears & 
unexplained weight loss and/or 
chronic fever / diarrhoea / unable to 
cough  
 
Excluded if TB treatment in past 
month or pregnant 
Blood culture (MTB + other 
pathogens) 
CrAg  
Sputum (induced): TB culture 
FBC, CD4  
CXR 
Diagnoses: 
52 (11%) bacteriologically confirmed TB 
50 (11%) positive (non-TB) blood culture +/or CrAg-pos.  
Non typhoidal Salmonellae most common blood culture 
pathogens (6% of participants and 52% bloodstream 
isolates). 
Selection bias likely as referred to study by clinicians 
Calligaro 2011195 
South Africa 
Cross-sectional  
Cohort of patients on ART 
Median CD4 380 
On ART median 2.1 years 
(N=152) 
No features of acute respiratory 
disease 
Stable on ART for at least 3 months 
Respiratory questionnaire 
Pulmonary function tests pre- 
and post- bronchodilator 
32.9% - history of smoking  
31% - respiratory symptoms  
Any respiratory symptom (cough, phlegm, wheeze or 
dyspnoea) associated with current smoking (OR 2.6, 
95% CI 1.05-6.2) 
CAO in 7% & associated with ever smoking (OR 6.4, 
95% CI 1.6-25.9) 
Munyati 2005194 
Zimbabwe 
Prospective cohort 
 
Ambulatory adults with 
chronic cough 
CD4 not reported 
(N=544) 
Systematically sampled 
Cough ≥ 3 weeks 
 
Excluded if danger signs requiring 
admission / on TB treatment 
HIV test 
Evaluation using standardised 
set of investigations including 
CXR, sputum (TB culture + 
bacterial pathogens) 
 
454/544 (83%) HIV-pos, (13% >1 diagnosis) 
• >90% reported fever, NS and UWL 
• 46% (207) TB diagnosed 
o microbiologically-confirmed (n=162) 
o smear and culture negative TB (n=45) 
• 17% bacterial pneumonia 
• 31% LRTI 
• 7% fibrotic lung disease 
• 3% heart failure 
• 3% asthma 
• 2% Pneumocystis pneumonia  
• 1% Cryptococcosis 
Hargreaves 2001192 
Malawi 
Prospective cohort 
Ambulatory patients about to 
start treatment for smear-
negative TB 
N=352 
Consecutive sample 
Cough ≥ 3 weeks 
Fulfilled national TB control 
programme criteria for diagnosis of 
smear-negative TB 
 
HIV test 
Clinical assessment 
Sputum + blood for TB culture 
Bronchoscopy and BAL 
examined for TB, Pneumocystis 
jirovecii and other fungi. 
278/313 (89%) of those tested HIV-pos (81% met the 
WHO case definition for AIDS) 
Diagnoses: 
• 137 (39%) microbiologically confirmed TB  
•  17 (5%) Pneumocystis pneumonia   
• 27 (7%) no organism identified but full recovery  
• 10 (3%) pulmonary Kaposi’s sarcoma 
CAO, chronic airflow obstruction; CrAg, Cryptococcal antigen test; CXR, chest radiograph; EPTB, extrapulmonary TB; FNA, fine needle aspiration; FBC, full blood count; LRTI, lower respiratory 
tract infection; NCD, non-communicable disease; NS, night sweats; UWL, unintentional weight loss; PTB, pulmonary TB 
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3) XPHACTOR study methods       
The research undertaken for this PhD forms part of the XPHACTOR study. This chapter 
details the methods for XPHACTOR and how the research papers presented in this thesis 
flow from XPHACTOR (Figure 3-1).  
XPHACTOR evaluated an algorithm which was designed to identify, among HIV-positive 
clinic attendees, those deemed "high priority" for immediate investigation with Xpert 
MTB/RIF, and allowed watchful waiting for those assessed as lower priority. The study 
hypothesis was that an algorithm which prioritised immediate testing for the high priority 
group while allowing deferral of investigation for those assigned lower priority would 
reduce health service costs with minimal risk to patients. Investigation was prioritised for 
individuals at highest risk of death due to TB, and/or those at highest risk of transmitting 
TB to others, using markers readily available in primary care clinics in South Africa. The 
markers selected were body mass index (BMI) and CD4 count, which are known to be risk 
factors for TB and mortality,140, 201-204 and cough as a clinical marker of smear positivity (as 
the best indicator of infectiousness).27, 205, 206 The study algorithm is presented in Figure 3-
2. 
 
3.1. XPHACTOR study aims and objectives 
The aims of the XPHACTOR study were: 
• Aim 1: to determine the sensitivity and specificity of the study algorithm and to 
compare the outcomes (sensitivity of the algorithm, time to TB diagnosis) and costs of 
the strategy with modelled outcomes and costs assuming immediate testing with Xpert 
MTB/RIF for all symptomatic individuals, as defined by the WHO tool. 
• Aim 2: to describe the diagnostic yield from two different strategies for investigating 
adults with HIV who are suspected of having TB, but whose first Xpert test is negative. 
(Chapter 7 - Research Paper 3).   
• Aim 3: to determine causes for persistent or recurrent symptoms suggestive of TB 
amongst ambulatory adults attending for HIV care who have negative initial TB 
investigations. (Chapter 8 - Research Paper 4) 
• Aim 4: to determine the natural history of TB symptoms among individuals without a 
final diagnosis of TB, in order to estimate the likely demand for repeat Xpert testing 
among patients attending for HIV care. (Chapter 4). 
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Figure 3-1. XPHACTOR study flow and entry points for research papers in this thesis 
 
XPHACTOR enrolment (N=3722) 
High priority OR newly diagnosed HIV 
OR pre-ART with CD4<200: 
Sputum for immediate Xpert 
Medium / low priority 
Sputum stored 
Xpert positive: start TB treatment Xpert negative 
Further evaluation in accordance with national guidelines  
CD4<200 / newly diagnosed HIV: eligible for Repeat Xpert study (Paper 3) (n=227)  
Sputum stored 
XPHACTOR assessment at 1 and 2 months 
High priority: Sputum for immediate Xpert 
Xpert negative Xpert positive: start TB treatment 
Further evaluation in accordance with national guidelines  
CD4<200: eligible for Repeat Xpert study - Sputum stored (Paper 3) 
XPHACTOR assessment at 3 months 
ALL - Sputum and blood for mycobacterial culture  
Consecutive sample: screened + enrolled to Causes of TB symptoms study (Paper 4) (n=103) 
High priority: Sputum for immediate Xpert 
Xpert negative Xpert positive: start TB treatment 
Further evaluation in accordance with national guidelines  
CD4<200: eligible for Repeat Xpert study (Paper 3) - Sputum stored 
XPHACTOR assessment at 4, 5, and 6 months for Causes of TB symptoms study  
as per 1- and 2- month assessments 
Data for clinical prediction model (Paper 2) 
(n=1048) 
CD4<200: 
Urine stored 
for LF-LAM 
study (Paper 1) 
(n=424) 
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In addition, the opportunity was taken to evaluate the diagnostic accuracy of LF-LAM for 
TB at enrolment to XPHACTOR amongst participants with CD4 count <200 cells/mm3 
(Chapter 5 – Research Paper 1). 
A secondary analysis of data collected for XPHACTOR was used to develop the clinical score 
for TB (Chapter 6 – Research Paper 2).    
 
Figure 3-2. XPHACTOR algorithm at enrolment 
 
 
BMI = Body mass index 
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3.2. XPHACTOR study setting 
XPHACTOR was conducted in Gauteng province in South Africa, at two hospital-based and 
two community health centre (CHC) clinics. The two hospital-based clinics were at Chris 
Hani Baragwanath hospital, south of Johannesburg in Soweto, and Mamelodi hospital which 
is nearer Pretoria. The two community health clinics (CHC) were Ramokonopi and 
Jabulane Dumane CHCs, in Ekurhuleni district (Figure 3-3).  
At the time the study was conducted, ART eligibility comprised CD4 ≤350 cells/mm3 or 
WHO clinical stage ≥3. National guidelines for TB investigation during this time have 
already been described in section 1.3 (Figure 1-1). 
 
3.3. XPHACTOR study population and recruitment 
We enrolled a systematic sample of adults (aged ≥18 years) attending for HIV care, 
irrespective of the presence of symptoms suggestive of TB. Patients taking anti-
tuberculosis treatment within the previous 3 months and those who were acutely unwell 
requiring urgent referral to higher level care were excluded. Patients were enrolled into 
three groups: “on antiretroviral therapy (ART)” (currently taking or ART-experienced) 
group; “pre-ART” (in HIV care but not yet taking ART) group; and “HIV Testing and 
Counselling (HTC)” (newly-diagnosed HIV-positive).  We recruited to the on ART group 
from hospital clinics because their patient population solely comprised those ART-
experienced; and pre-ART and HTC groups were recruited from CHCs.   
The sampling strategy varied between study sites due to differences in clinic flow and 
numbers of patients. At the hospital-based clinics the numbers of patients attending were 
too large to invite consecutive patients to participate in our study. One of these sites had 
a clinic register which we used to systematically invite patients, at a predetermined 
frequency, to hear further information about the study. The other site had no register so 
we used simple random sampling; all patients in the waiting area were invited to select a 
stick or sweet hidden in a bag, and those who pulled a predetermined colour were invited 
to participate. The CHCs were smaller, and therefore consecutive patients attending the 
clinic were invited to participate. 
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Figure 3-3. XPHACTOR study sites 
 
HTC = HIV Testing and Counselling  
 
3.4. XPHACTOR procedures  
3.4.1. Enrolment 
At enrolment, research staff administered a standardised questionnaire which 
incorporated the WHO tool, collected details of TB and HIV treatment, and basic 
demographic and socioeconomic information. Staff measured height and weight, MUAC, 
and recorded most recent clinic CD4 cell count. Further investigation was prioritised 
according to the XPHACTOR algorithm (Figure 3-2) with an immediate spot sputum sample 
sent for Xpert for individuals at a priori highest risk of active TB: (i) all assigned high 
priority; (ii) those in the pre-ART group with CD4 <200 cells/mm3 at enrolment (iii) all in 
the HTC group (whose CD4 count was unknown) at enrolment. For all other participants, a 
spot sputum sample was collected at enrolment and frozen at -80 ºC within 24 hours, for 
smear microscopy and testing with Xpert at the end of the study. Testing of this sample 
enabled comparison of the sensitivity and specificity of the XPHACTOR study algorithm 
(Aim 1) to detect TB cases against the sensitivity and specificity if Xpert had been 
performed immediately for all with any WHO tool symptom; and to determine whether any 
smear-positive patients had been missed. 
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Individuals in the HTC group and those in the pre-ART group with CD4 <200 cells/mm3 did 
not contribute to XPHACTOR aim 1 (evaluation of the study algorithm). This was because 
of a priori high risk of active TB, hence these participants underwent immediate testing 
with Xpert at enrolment and were not prioritised for testing using the study algorithm. 
These individuals contributed to XPHACTOR aim 2 (Chapter 7 - Research Paper 3, 
“Investigating TB if initial Xpert is negative”), if the immediate Xpert was negative. 
 
3.4.2. Follow-up 
Participants were reviewed monthly to three months, with repeat WHO symptom screen 
and a spot sputum sample was requested for Xpert if high priority by the study algorithm 
at that visit (Figure 3-4), with the exception of those in the on ART group who were 
asymptomatic at enrolment, who were telephoned at 1 and 2 months to update locator 
information but were not asked about TB symptoms. The protocol was modified for these 
individuals, because we identified after enrolling around 1000 participants to the on ART 
group, that almost no TB diagnoses had been made at 1- and 2-month follow up in those 
assigned low priority at enrolment.   
 
The study algorithm at follow up visits varied very slightly to ensure that participants who 
had persistent night sweats ≥4 weeks were investigated for TB, as night sweats of any 
duration were assigned medium priority at enrolment (Figure 3-4). At the 3-month visit 
sputum (induced if necessary) and blood were collected for mycobacterial culture on 
liquid media (Bactec MGIT 960 and 9240 systems, BD Diagnostics) from all study 
participants, regardless of symptoms. We allowed a broad window period around the 
scheduled 3-month visit, until around six months, in order to maximise study follow-up.  
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Figure 3-4. XPHACTOR algorithm at monthly follow up 
 
BMI = Body mass index 
 
Participants who submitted an Xpert sample were reviewed within one week. If Xpert-
positive, TB treatment was initiated; if negative, research staff repeated the WHO 
symptom screen and facilitated the Xpert-negative algorithm which comprised chest 
radiograph, spot sputum for TB culture, and antibiotic trial if clinically appropriate.  The 
Xpert-negative algorithm was also facilitated, because of a priori high risk of active TB, 
for all pre-ART participants with CD4 count <200 cells/mm3 who had submitted sputum for 
immediate Xpert at enrolment to XPHACTOR. 
Chest radiographs were reported by a single reader (consultant radiologist or physician), 
and data extracted onto a standardised form. Investigation results were returned to clinic 
staff, who were responsible for management decisions. Clinic records were reviewed at 
the end of the study to ascertain any additional relevant investigations and/or TB 
diagnoses. Deaths were identified through reports from participant-nominated contacts, 
clinic staff, and by accessing the Department of Home Affairs vital statistics database 
using participants’ South African identification (ID) numbers if they were South African 
citizens. 
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Methods relevant to specific research aims are detailed in the relevant papers (chapters 5 
to 8). 
 
3.5. Laboratory methods 
3.5.1. Xpert MTB/RIF 
Xpert testing was undertaken at the routine National Health Laboratory Services (NHLS) 
for sputum samples for immediate Xpert requested at Chris Hani Baragwanath hospital. 
For all other sites (due to their resource limitations) and for all stored samples Xpert 
testing was undertaken at the research laboratory (Centre for Tuberculosis, which is a 
national reference laboratory) by experienced research laboratory technologists. 
 
3.5.2. Mycobacterial culture 
Sputum for mycobacterial culture requested as part of the Xpert-negative algorithm was 
generally undertaken at the routine NHLS laboratories. Sputum samples collected for the 
XPHACTOR 3-month visit were processed at the research laboratory, by fluorochrome 
staining for acid-fast bacilli and fluorescence microscopy, and cultured using BACTECTM 
Mycobacteria Growth Indicator Tube (MGIT) 960 (BD, Sparks, MD, USA). Line probe assay 
(LPA) was performed on smear-positive or cultured isolates (GenoType MTBDRplus, Hain 
Lifesciences) to identify MTB complex and resistance to isoniazid or rifampicin. If 
resistance was identified, then further drug susceptibility testing was undertaken. 
Mycobacterial culture on 3-month visit blood samples was performed using the BD BactecTM 
9240 system. 
 
3.5.3. LF-LAM 
At the end of the study urine samples were thawed to ambient temperature and tested 
with LF-LAM by the research laboratory technologists in accordance with training provided 
by Alere representatives. The technologists did not have access to other bacteriological 
results when performing the LF-LAM tests. Each test was graded once, using the pre-
January 2014 manufacturer’s reference card comprising five grades of colour intensity 
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with the least intense band assigned grade 1, absence of a band graded negative, and 
absence of a control band deemed a failed test.207    
 
3.6. Case Definitions 
A 2005 community-based HIV and TB prevalence survey in South Africa reported a large 
burden of previously undiagnosed bacteriologically-confirmed pulmonary TB, mainly 
amongst those HIV-positive, of which two-thirds of cases were asymptomatic.208 This study 
estimated mean time before initiation of TB treatment of around 1 year irrespective of 
smear or HIV status. Mathematical modelling estimates a nine month period of subclinical 
disease prior to a diagnosis of TB being made.209 Studies amongst PLHIV with LTBI which 
have used highly sensitive imaging modalities,210, 211 and the discovery of a blood 
biomarker which predicts the risk of active TB within 12 months,212 provide  evidence for a 
continuum of disease from infection with MTB to clinically active disease, and potentially 
a long infectious period.213 The estimates for the duration of subclinical disease in the 
aforementioned study were considered when assigning case definitions for prevalent TB in 
XPHACTOR.209 
 
3.6.1. TB case definitions 
A diagnosis of “confirmed TB” was assigned to individuals with a positive result on i) 
Xpert (on sputum sample) or ii) LPA (GenoType MTBDRplus, Hain Lifesciences) performed 
on smear-positive or cultured isolate or iii) M. tuberculosis (MTB) culture, from any sample 
collected within six months of enrolment to the XPHACTOR study.  
A diagnosis of “clinical TB” was assigned to individuals who commenced TB treatment 
within six months of enrolment to XPHACTOR in the absence of microbiological 
confirmation. 
Participants who died within three months of enrolment without fulfilling TB case 
definitions or who were diagnosed with TB more than 6 months after enrolment were 
deemed to have “unclassifiable” TB outcome and excluded from all analyses.  
For evaluating the accuracy of LF-LAM (Chapter 5, Paper 1), the XPHACTOR algorithm, 
and the WHO tool for TB screening in XPHACTOR participants, “not TB” was defined as 
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fulfilling all of the following: absence of criteria for confirmed or clinical TB; alive at least 
3 months after enrolment; and no positive microbiology for MTB (at least 1 MTB culture or 
Xpert result) from any sample within 6 months of enrolment. Participants who did not 
fulfil the case definitions for TB or “not TB” were excluded from these analyses. 
 
3.6.2. Radiological definitions 
“Probable radiological TB” was defined as the presence of i) any of cavitation, 
predominantly upper lobe infiltrates, pleural or pericardial effusion, or clear miliary 
picture on chest radiograph or ii) any of abdominal lymphadenopathy, splenic 
microabscesses, pleural or pericardial effusion on ultrasound scan.  
“Possible radiological TB” was defined as the presence of any of lymphadenopathy (hilar 
or mediastinal), pulmonary nodules or other infiltrates.   
Participants with “probable” or “possible” radiological TB features, but without 
bacteriological confirmation, who started TB treatment within six months of enrolment (or 
within six months of the 3-month visit if participating in the “Causes of TB symptoms” 
aim) were assigned “clinical” TB.  
 
3.7. Sample size 
The sample size for XPHACTOR was based on estimating the sensitivity, with reasonable 
precision, of the study algorithm for undiagnosed TB amongst HIV-positive clinic 
attendees. The sample size calculation assumed a prevalence of bacteriologically-
confirmed undiagnosed TB of 5% amongst HIV clinic attendees. If the sensitivity of the 
algorithm was 95%, 90%, and 85% respectively, then with 150 TB diagnoses, the sensitivity 
could be estimated with 95% confidence intervals respectively of 90.6-98.1%, 84.0-94.3%, 
and 78.6-90.6%. In order to identify 150 TB diagnoses, 3000 HIV-positive clinic attendees 
needed to be recruited, and assuming that 80% were followed up to 3-months, the total 
sample size required was 3750. 
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3.8. Ethical issues due to delaying diagnostic testing 
Ethical issues were discussed with a member of the University of Cape Town (UCT) ethics 
committee when the protocol was being developed and were detailed in the study 
protocol which was approved by LSHTM and local ethics committees. Firstly, the study was 
conducted amongst those who would potentially benefit from the results, as individuals 
attending for HIV care are at high risk of both having undiagnosed TB and are at risk of 
acquiring TB from others with undiagnosed TB in the clinic. Secondly, although in theory 
the study withheld investigation from some individuals who, according to ICF guidelines, 
should have been investigated, experience from these clinics was that these guidelines 
were not being implemented, and were unlikely to be so in resource-limited settings 
because of the high cost. XPHACTOR was considered likely to promote effective screening, 
by generating an evidence-base for rational screening policy, which would ultimately 
benefit HIV clinic attendees. 
There were potential issues around collecting sputum samples and storing them for later, 
rather than immediate testing with Xpert, for participants categorised as “medium” or 
“low” priority at enrolment. The strategy of storing for later testing was important in 
order to evaluate the study algorithm. Participants assigned “low priority” (no TB 
symptoms) at enrolment were highly unlikely to have had TB, so delayed testing of their 
sputum was unlikely to have delayed TB diagnosis in this group who would not have had 
sputum collected under routine circumstances. Delaying testing might have delayed TB 
diagnosis in participants assigned “medium priority”, but research staff always advised 
participants to return to the clinic (who were responsible for their care) if their symptoms 
worsened. Furthermore, these participants were reviewed at monthly intervals, and would 
have undergone investigation with Xpert if they became “high priority”. Any participant 
with cough was always assigned high priority, and therefore would not have had delayed 
testing, and therefore the risk to other patients at the clinic would be minimised.  
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4) XPHACTOR study key results       
This chapter details key results from the XPHACTOR study which provide context for the 
findings of the research papers, and enable comparison with the published literature 
pertaining to TB screening in PLHIV in LMIC. The results presented in this section comprise 
the study profile and baseline characteristics of the participants, the prevalence of TB, 
the performance of the XPHACTOR study algorithm for TB screening, and the frequency of 
WHO tool symptoms.  
 
4.1. Characteristics of study participants 
From September 2012 to February 2014, 3722 participants were enrolled into XPHACTOR 
(2602 on ART, 906 pre-ART, and 214 from HTC services of whom 107 were enrolled from 
antenatal HTC services [ANC]) (Figure 4-1). 3473 (93%) of participants were followed to 3 
months and all the 3-month visits were completed by May 2014.  
Table 4-1 summarises the baseline characteristics of XPHACTOR participants. The median 
CD4 cell counts amongst on ART vs. pre-ART vs. HTC vs. ANC groups were 436 vs. 402 vs. 
248 vs. 379 cells/mm3. In the on ART group the median duration on ART was 4 years 
(interquartile range [IQR] 2-6) and 74.7% had suppressed viral load. At enrolment 
1213/3722 (32.6%) of all participants reported at least one WHO tool symptom (on ART 
30.1%, pre-ART 38.6%, HTC 61.7%, ANC 13.1%). 1997/3722 (53.7%) of participants were 
able to produce a sputum sample at enrolment for testing with Xpert (either immediate 
testing or stored for testing at the end of the study). The most common WHO tool 
symptoms reported were cough 750/3722 (20.2%) and weight loss 544/3721 (14.7%). 
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Figure 4-1. XPHACTOR profile 
 
1 At on ART sites 4956 patients were approached & from one site data is available regarding reasons 1522/3186 declined to be screened (594 not 
interested; 567 no time;151 agreed to screen at next visit; 118 no reason; 92 other), at pre-ART sites all patients were referred by clinic staff and data is 
not available regarding those who declined screening; 2 50 died within 6 months of enrolment (on ART = 23; pre-ART = 25; HTC = 2);  
3 Undertaken at enrolment or during follow-up to 3m visit & participants could have >1 sample positive for MTB;  
4 Routine or for study purposes; 5 1 MTB in pleural fluid; 6 No CXR or TB microbiology 
ANC, New HIV+ enrolled from antenatal services; HTC, New HIV+ enrolled from HIV testing and counselling services; GXP = sputum Xpert; 3m Sp cul = 
Sputum TB culture at 3-month visit; 3m bld cul = Blood TB culture at 3-month visit. 
3722 enrolled 
On ART2 
N=2602 
3851 screened1  
• 114 not eligible  
• 15 did not consent (8 in a hurry or more time needed to decide; 3 not local; 4 other) 
Pre-ART2 
N=906 
HTC2 
N=107 
ANC  
N=107 
TB (79/2602 [3%]) 
Confirmed: 61  
Clinical: 18  
Unclassifiable: 26 
TB (65/906 [7%]) 
Confirmed: 45  
Clinical: 20  
Unclassifiable: 16 
TB (22/107 [21%]) 
Confirmed: 17  
Clinical: 5  
Unclassifiable: 2 
TB (1/107 [1%]) 
Confirmed: 1  
TB investigations3 
GXP4 1340 (51%): Pos 30  
Routine culture 206 (8%): MTB5 10 
3m Sp 2406 (92%): MTB 23  
3m Bld 2427 (93%): MTB 0 
CXR 230 (9%): Probable TB 17, 
Possible TB 69 
No TB Ix6: 104/2602 (4%) 
TB investigations3 
GXP4 722 (80%): Pos 31  
Routine culture 107 (12%): MTB 2 
3m Sp 803 (89%): MTB 10 
3m Bld 822 (91%): MTB: 0  
CXR 144 (16%): Probable TB 14, 
Possible TB 33 
No TB Ix6: 23/906 (3%)   
TB investigations3 
GXP4 86 (80%): Pos 14  
Routine culture 8 (7%): MTB 0 
3m Sp 92 (86%): MTB 3  
3m Bld 94 (88%): MTB 0  
CXR 21 (20%): Probable TB 4, 
Possible TB 8 
No TB Ix6: 3/107 (3%)   
TB investigations3 
GXP4 66 (62%): Pos 0  
Routine culture 3 (3%): MTB 0 
3m Sp 83 (78%): MTB 1  
3m Bld 85 (79%): MTB 0  
CXR 1 (1%): Probable TB 1 
No TB Ix6: 12/107 (11%)  
XPHACTOR study key results 
Page | 100  
 
Table 4-1 Baseline characteristics of XPHACTOR participants N=3722   
 
Characteristic On ART  Pre-ART   HTC ANC 
 N=2602  N=906  N=107  N=107  
Demographics:     
Age, years - Median (IQR)  41 (35-48) 35 (29-42) 35 (30-41) 30 (25-33), N=105 
Female – N (%) 1838 (70.6%) 623 (68.8%) 57 (53.3%) 107 (100%) 
Black African – N (%) 2560 (98.4%), N=2601 904 (99.8%) 105 (98.1%) 107 (100%) 
HIV/TB history     
Duration since HIV diagnosed, months - Median (IQR) 66 (38-99), N=2585 7 (1-30), N=899 N/A N/A 
ART commenced during study follow-up n (%) N/A 396 (43.7%) 57 (53.3%) 8 (7.5%) 
Duration on ART, months - Median (IQR) 50 (28-79), N=2601 N/A N/A N/A 
Previous IPT – N (%) 63 (2.4%), N=2601 167 (18.4%) N/A N/A 
Current IPT – N (%) 19 (0.7%) 172 (19.0%) N/A N/A 
Previous TB treatment – N (%) 1028 (39.5%) 71 (7.8%) 10 (9.4%) 4 (4.7%) 
>1 previous episode of TB treatment – N (%) 166 (6.3%) 7 (0.8%) 0 1 (0.9%) 
CD4 / Viral load / BMI at enrolment   
CD4, cells/mm3 - Median (IQR)   436 (278-621), N=2599 402 (224-555), N=905 248 (106-421), N=103 379 (234-556), N=104 
Viral load suppressed (<20 copies/ml) – N (%) 1624 (74.7%), N=2174 N/A N/A N/A 
BMI, kg/m2 - Median (IQR)  25 (21.6-29.4), N=2598 24.6 (20.9-29.5) 23.4 (20.2-28.6) 29 (26.6-32.8), N=106 
WHO tool positive at enrolment – N (%) 783 (30.1%) 350 (38.6%) 66 (61.7%) 14 (13.1%) 
Cough – N (%) 500 (19.2%) 200 (22.1%) 40 (37.4%) 10 (9.4%) 
Unintentional weight loss – N (%) 295 (11.3%), N=2601 206 (22.7%) 41 (38.3%) 2 (1.9%) 
Night sweats – N (%) 176 (6.8%) 113 (12.5%) 25 (23.4%) 2 (1.9%) 
Fever – N (%) 121 (4.7%) 74 (8.2%) 19 (17.8%) 3 (2.8%) 
>1 WHO tool symptom reported – N (%) 225 (8.6%) 162 (17.9%) 38 (35.5%) 1 (0.9%) 
Reported history of smoking or respiratory disease      
Ex- or current smoker1  – N (%) 586 (22.5%) N=2600 268 (29.6%) 33 (30.8%) 13 (13.1%) 
Chronic respiratory disease (asthma, COPD, silicosis) - N (%)  121 (4.7%) N=2600 33 (3.6%) 3 (2.8%) 4 (3.7%) 
 
BMI, body mass index; COPD, chronic obstructive pulmonary disease; IPT, isoniazid preventive therapy; IQR, interquartile range; HTC, New HIV+ enrolled from HIV testing 
and counselling services; ANC, New HIV+ enrolled from antenatal services; N/A, not applicable; 1 Smoker defined as having ever smoked ≥ 100 cigarettes    
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4.2. Prevalence of TB 
The prevalence of TB, overall and stratified by each group is shown in Table 4-2 for 3678 
participants, having excluding 44 participants with unclassifiable outcome (28 died within 
3 months of enrolment without a TB diagnosis, 15 were diagnosed with TB > 6 months 
after enrolment, 1 participant did not attend for study follow up after enrolment). 
167/3678 (4.5%) of participants fulfilled the study case definitions for TB, and for 153 the 
site of TB was recorded (pulmonary only 133/153 [86.9%], extrapulmonary only 15/153 
[9.8%], and both 5/153 [3.3%]).   
30/3678 (0.8%) of study participants who were diagnosed with TB did not report any WHO 
tool symptoms at enrolment. These comprised 27/124 (21.8%) with confirmed TB and 3/43 
(7.0%) with clinical TB. 
 
Table 4-2 Prevalence of TB in XPHACTOR study 
 
Group Number All TB 
n/N 
% (95% CI) 
Confirmed TB 
n/N 
% (95% CI) 
Clinical TB 
n/N 
% (95% CI) 
On ART  2576 79/2576  
3.1% (2.4, 3.8) 
61/2576 
2.4% (1.8, 3.0) 
18/2576 
0.7% (0.4, 1.1) 
Pre-ART  890 65/890  
7.3% (5.7, 9.2) 
45/890 
5.1% (3.7, 6.7) 
20/890 
2.3% (1.4, 3.4) 
HTC  105 22/105  
21.0% (13.6, 30.0)  
17/105 
16.2% (9.7, 24.6) 
5/105 
4.8% (1.6, 10.7) 
ANC  107 1/107  
0.9% (<0.001, 5.1) 
1/107  
0.9% (<0.001, 5.1) 
0 
Overall 3678 167/3678  
4.5% (3.9, 5.3) 
124/3678 
3.4% (2.8, 4.0) 
43/3678 
1.2% (0.8, 1.6) 
ANC, New HIV+ enrolled from antenatal services; HTC, HIV testing and counselling services 
 
 
4.3. Performance of the XPHACTOR algorithm and the WHO tool 
This analysis was undertaken using XPHACTOR enrolment data. Participants in the HTC and 
ANC groups, and those who were pre-ART with CD4 <200 cells/mm3 at enrolment were 
excluded, because they were all investigated with immediate Xpert at enrolment due to 
their high risk of TB. Participants for whom we did not have microbiological confirmation 
of “not TB” from at least one sample, i.e. a negative TB culture or negative Xpert result; 
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and those currently on IPT were also excluded. The latter were excluded as they were 
likely to have recently undergone investigation for TB, and hence were effectively “pre-
screened” for TB.   
Figure 4-2 details the flow of participants who were included in this analysis. Among 3722 
participants enrolled to XPHACTOR, 604 were excluded as they were either enrolled 
through HTC or ANC (n=214), pre-ART with CD4<200 cells/mm3 at enrolment (n=206), or 
were on IPT at enrolment (n=184). A further 168 participants were excluded due to 
unclassifiable TB outcome (no sputum result for MTB microbiology within 6 months of 
enrolment [135], died within 3 months of enrolment without a TB diagnosis [18], TB 
diagnosis from specimens taken more than 6 months after enrolment [14], did not attend 
for any study follow up [1]), leaving 2950 participants in the analysis (2444 on ART, 506 
pre-ART).   
 
Figure 4-2. Flow chart of participants included in the evaluation of XPHACTOR algorithm  
 
IPT, isoniazid preventive therapy; DNA, did not attend 
ANC, New HIV+ enrolled from antenatal services; HTC, HIV testing and counselling services 
 
916/2950 (31.1%) of participants fulfilled XPHACTOR high priority criteria, and 926/2950 
(31.4%) reported WHO tool symptoms (Figure 4-3). 735/2950 (24.9%) of participants were 
3722 enrolled to 
XPHACTOR 
Not eligible for analysis: 604 
• 214 – Enrolled from HTC or ANC 
• 206 – Pre-ART with CD4<200 at enrolment 
• 184 – On IPT 
Excluded as unclassifiable TB outcome: 168 
• 135 – No sputum TB culture within 6m  
• 18 – Died within 3m without TB diagnosis 
• 14 – TB diagnosed >6m after enrolment 
• 1 – DNA after enrolment 
2950 in analysis 
• 2444 on ART 
• 506 pre-ART 
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both XPHACTOR high priority and reported WHO tool symptoms, amongst whom the most 
commonly reported symptom was cough (n=578).  
 
Figure 4-3. Number of participants who were XPHACTOR high priority vs. number WHO tool 
positive (N=2950) 
 
 
98/2950 (3.3%; 95% CI 2.7, 4.0) of participants in this analysis fulfilled case definitions for 
TB (73 confirmed, 25 clinical). The sensitivity and specificity for TB (confirmed and 
clinical combined) was 69.4% and 70.3% for the XPHACTOR algorithm vs. 72.4% and 70.0% 
for the WHO tool (Table 4-3). The XPHACTOR algorithm had greater sensitivity for TB 
(confirmed and clinical combined) in the on ART vs. pre-ART group (70.9% vs. 63.2%), 
compared with the WHO tool which was less sensitive amongst those on ART vs. pre-ART 
(68.4% vs. 89.5%).  
The performance of the study algorithm, in terms of overall sensitivity and specificity for 
TB, was therefore similar to that of the WHO tool in our study population, and this was 
largely because cough was common and the main driver of both algorithms (Figure 4-3).  
 
    
1843: WHO-Neg & XPHACTOR 
low or medium priority 
181 191 
735 
(Cough: 578) 
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The prevalence of TB, performance of the XPHACTOR algorithm and performance of the 
WHO tool in our study population are discussed and compared with the published 
literature in Chapter 9.   
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Table 4-3 Performance of the XPHACTOR algorithm and WHO tool for TB screening at enrolment 
 
Confirmed and clinical TB (98/2950) 
Sensitivity  
n/N 
% (95% CI) 
Specificity  
n/N 
% (95% CI) 
NPV  
n/N 
% (95% CI) 
PPV  
n/N 
% (95% CI) 
XPHACTOR high priority 68/98 
69.4% (59.3, 78.3) 
2004/2852 
70.3% (68.6, 71.9) 
2004/2034 
98.5% (97.9, 99.0) 
68/916 
7.4% (5.8, 9.3) 
On ART  56/79 
70.9% (59.6, 80.6) 
1652/2365 
69.9% (68.0, 71.7) 
1652/1675 
98.6% (97.9, 99.1) 
56/769 
7.3% (5.6, 9.4) 
Pre-ART  12/19 
63.2% (38.4, 83.7) 
352/487 
72.3% (68.1, 76.2) 
352/359 
98.1% (96, 99.2) 
12/147 
8.2% (4.3, 13.8) 
WHO tool positive  71/98 
72.4% (62.5, 81.0) 
1997/2852 
70.0% (68.3, 71.7) 
1997/2024 
98.7% (98.1, 99.1) 
71/926 
7.7% (6.0, 9.6) 
On ART  54/79 
68.4% (56.9, 78.4) 
1673/2365 
70.7% (68.9, 72.6) 
1673/1698 
98.5% (97.8, 99.0) 
54/746 
7.2% (5.5, 9.3) 
Pre-ART  17/19 
89.5% (66.9, 98.7) 
324/487 
66.5% (62.1, 70.7) 
324/326 
99.4% (97.8, 99.9) 
17/180 
9.4% (5.6, 14.7) 
Confirmed TB1 (73/2925)     
XPHACTOR high priority 48/73 
65.8% (53.7, 76.5) 
2004/2852 
70.3% (68.6, 71.9) 
2004/2029 
98.8% (98.2, 99.2) 
48/896 
5.4% (4.0, 7.0) 
On ART  39/61 
63.9% (50.6, 75.8) 
1652/2365 
69.9% (68.0, 71.7) 
1652/1674 
98.7% (98.0, 99.2) 
39/752 
5.2% (3.7, 7.0) 
Pre-ART  9/12 
75.0% (42.8, 94.5) 
352/487 
72.3% (68.1, 76.2) 
352/355 
99.2% (97.6, 99.8) 
9/144 
6.3% (2.9, 11.5) 
WHO tool positive  49/73 
67.1% (55.1, 77.7) 
1997/2852 
70.0% (68.3, 71.7) 
1997/2021 
98.8% (98.2, 99.2) 
49/904 
5.4% (4.0, 7.1) 
On ART  38/61 
62.3% (49.0, 74.4) 
1673/2365 
70.7% (68.9, 72.6) 
1673/1696 
98.6% (98.0, 99.1) 
38/730 
5.2% (3.7, 7.1) 
Pre-ART  11/12 
91.7% (61.5, 99.8) 
324/487 
66.5% (62.1, 70.7) 
324/325 
99.7% (98.3, >99.9) 
11/174 
6.3% (3.2,11.0) 
 
CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value 
1Clinical TB excluded from analysis  
XPHACTOR study key results 
Page | 106  
 
4.4. “Natural history” of symptoms suggestive of TB in XPHACTOR  
4.4.1. Introduction, aim and objectives 
Published studies in which PLHIV have been systematically screened for TB prior to 
initiation of ART54-56 or IPT214 report a high proportion with symptoms suggestive of TB, 
although most do not have TB. At the time that the XPHACTOR study was commenced 
there was a paucity of published data regarding the prevalence of symptoms suggestive of 
TB amongst individuals established in HIV care.  
The aim of this analysis was to determine the “natural history” of TB symptoms among 
individuals without a final diagnosis of TB, in order to estimate the likely demand for 
repeat diagnostic testing for TB among patients attending for HIV care. 
The objective was, using data collected for the XPHACTOR study (from monthly follow-up 
visits during the entire study duration i.e. October 2012 to May 2014), to describe the 
frequency of WHO tool symptoms reported by individuals attending for HIV care at 
monthly intervals up to the 3-month visit.  
 
4.4.2. Inclusion and exclusion criteria for this analysis 
This analysis was restricted to XPHACTOR study participants who had WHO tool symptom 
data available at both enrolment and 3-month visit. The following individuals were 
excluded from the analysis: i) those without sputum mycobacterial culture results from 
the 3-month visit, in order to ensure there was microbiological confirmation that TB had 
been excluded; ii) all those who fulfilled case definitions for TB at any point during study 
follow-up.   
 
4.4.3. Statistical methods 
Positive WHO tool screen (any of self-reported cough, fever, night sweats or unintentional 
weight loss) and frequency of WHO tool symptoms were summarised at enrolment and at 
each monthly follow up visit. The same variables were summarised in a separate analysis 
restricted to those who reported WHO tool symptoms at enrolment to XPHACTOR.   
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The number of sputum samples collected as part of routine care or for study purposes 
because participants were: i) deemed at high risk of TB (pre-ART with CD4<200 or newly 
diagnosed HIV-positive at enrolment) or XPHACTOR high priority; or ii) WHO tool positive 
at enrolment was summarised.   
 
4.4.4. Results 
Amongst 3722 participants enrolled into XPHACTOR (2602 on ART, 906 pre-ART, and 214 
from HTC services of whom 107 were enrolled from antenatal services), 3-month visit data 
were available for 3473 (93%) of participants. 3202 XPHACTOR study participants fulfilled 
the criteria for this analysis (Figure 4-4), and their characteristics are summarized in 
table 4-4.      
 
 
Figure 4-4. Flow chart of participants in “frequency of symptoms suggesting TB”  
 
1 Positive result on sputum Xpert or TB culture during follow-up, but reinvestigated by clinic as 
asymptomatic and repeat sputum mycobacteriology was negative so not treated for TB 
  
 
3722 enrolled to 
XPHACTOR 
Not eligible for analysis: 
• 249 - No 3-month visit data 
Excluded: 271 
• 161 – Fulfilled case definitions for TB 
• 108 – No sputum TB culture at 3-month visit 
• 2 – Unclassifiable TB outcome1 
3202 in analysis 
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Table 4-4 Characteristics of participants in frequency of symptoms suggestive of TB analysis N=3202 
 
Characteristic On ART  Pre-ART   HTC ANC 
 N=2306 N=743 N=71 N=82 
Demographics:     
Age, years - Median (IQR)  41 (35-48) 35 (29-42) 34 (29-41) 29 (25-32), N=81 
Female – N (%) 1638 (71.0%) 519 (69.9%)  36 (50.7%) 82 (100%) 
Black African– N (%) 2271 (98.5%) 741 (92.5%) 99 (96.1%) 82 (100%) 
HIV/TB history     
Duration since HIV diagnosed, months - Median (IQR) 66 (39-99), N=2290 9 (1-33), N=737 N/A N/A 
ART commenced during study follow-up – N (%) N/A 307 (41.3%) 42 (59.2%) 76 (92.7%) 
Duration on ART, months - Median (IQR) 50 (28-79)  N/A N/A N/A 
Previous IPT– N (%) 51 (2.2%), N=2305 151 (20.3%) N/A N/A 
Current IPT– N (%) 17 (0.7%) 144 (19.4%) N/A N/A 
Previous TB treatment – N (%) 900 (39.0%) 56 (7.5%) 4 (5.6%) 5 (6.1%) 
>1 previous episode of TB treatment – N (%) 142 (6.2%) 4 (0.5%) 0 1 (1.2%) 
CD4 / Viral load / BMI at enrolment   
CD4, cells/mm3 - Median (IQR)   441 (285-626), N=2304 415 (252-561) 271 (151-436), N=69 374 (217-530), N=81 
Viral load suppressed (<20 copies/ml) – N (%) 1463 (75.1%), N=1947 N/A N/A N/A 
BMI, kg/m2 - Median (IQR)  25.2 (21.8-29.5), N=2303 25.3 (21.5- 30.0) 24.7 (21.3-29.0) 29.4 (26.6-32.8) 
WHO tool positive at enrolment – N (%) 653 (28.3%) 255 (34.3%) 37 (52.1%) 12 (14.6%) 
Cough – N (%) 413 (17.9%) 146 (19.7%) 21 (29.6%) 9 (11.0%) 
Unintentional weight loss – N (%) 226 (9.8%), N=2305 135 (18.2%) 23 (32.4%) 1 (1.2%) 
Night sweats – N (%) 141 (6.1%) 76 (10.2%) 11 (15.5%) 1 (1.2%) 
Fever – N (%) 101 (4.4%) 52 (7.0%) 9 (12.7%) 1 (1.2%) 
>1 WHO tool symptom reported – N (%) 168 (7.3%) 105 (14.1%) 18 (25.3%) 0 
Reported history of smoking or respiratory disease      
Ex- or current smoker1 – N (%)   522 (22.7%), N=2304 211 (28.4%) 21 (29.6%) 11 (13.4%) 
Chronic respiratory disease (asthma, COPD, silicosis) – N (%)  108 (4.7%), N=2305 23 (3.1%) 1 (1.4%) 3 (3.7%) 
 
BMI, body mass index; COPD, chronic obstructive pulmonary disease; IPT, isoniazid preventive therapy; IQR, interquartile range; HTC, New HIV+ enrolled from HIV testing 
and counselling services; ANC, New HIV+ enrolled from antenatal services; N/A, not applicable 
1 Smoker defined as having ever smoked ≥ 100 cigarettes
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Characteristics of participants 
Amongst 3202 participants included in this analysis, at enrolment 2306 (72%) were on ART 
for a median of 4 years (interquartile range [IQR] 2-6), 743 (23%) were pre-ART, 71(2%) 
and 82 (3%) were newly diagnosed HIV-positive from HTC and ANC respectively. Overall 
957/3202 (30%) were WHO tool positive at enrolment, of whom 291/957 (30%) reported 
more than one symptom. The most common WHO tool symptoms reported were cough 
589/3202 (18%) and weight loss 385/3201 (12%).  
 
Frequency of TB symptoms during study follow-up 
At 1, 2, and 3-month visits respectively, 325/2148 (15%) vs. 273/2017 (14%) vs. 325/3202 
(10%) of participants reported at least one WHO tool symptom. The 3-month visit was 
undertaken at median 85 days (IQR 84-110; N=3196) from enrolment. At all visits the most 
commonly reported symptoms were cough and weight loss (Figure 4-5). A similar pattern 
was seen when the analysis was restricted to participants who were established on ART at 
enrolment (N=2306, Figure 4-6) or those not on ART at enrolment (N=896, Figure 4-7).  
 
Figure 4-5. Overall percentage with WHO tool symptoms during follow-up (N=3202) 
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Figure 4-6. WHO tool symptoms during follow-up amongst those on ART (N=2306) 
 
  
 
Figure 4-7. WHO tool symptoms during follow-up amongst those not on ART (N=896) 
 
 
 
When the analysis was restricted to 957 participants who were symptomatic at enrolment, 
although the percentage reporting any WHO tool symptom reduced at each follow-up visit, 
16% remained symptomatic at the 3-month visit, with again cough and weight loss the 
most commonly reported symptoms (Figure 4-8).  
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Figure 4-8. Evolution of symptoms amongst those symptomatic at enrolment (N=957) 
 
 
 
Sputum samples tested with Xpert 
1243/3202 (39%) of participants had an Xpert on sputum within 90 days of enrolment, 
either because they were WHO-tool positive at enrolment, XPHACTOR high priority, or as 
part of routine care. 316/3202 (10%) had more than one sample tested. Amongst those in 
the on ART vs. pre-ART vs. HTC vs. ANC groups respectively, 770/2306 (33%) vs. 364/743 
(49%) vs. 55/71 (78%) vs. 54/82 (66%) had at least one sputum sample tested with Xpert, 
and 213/2306 (9%) vs. 95/743 (13%) vs. 7/71 (13%) vs. 1 (1.2%) had more than one sample 
tested. 
Amongst participants who were reported WHO tool symptom(s) at enrolment, 786/957 
(82%) had at least one sputum tested with Xpert during study follow-up. The proportions 
having one, two, three, or greater than four samples tested were 548/957 (57%), 155/957 
(16%), 64/957 (7%), and 19/957 (2%) respectively.   
 
4.4.5. Discussion  
This analysis, from which participants diagnosed with TB were excluded, demonstrates 
that individuals attending for HIV care were highly symptomatic (30% WHO tool positive at 
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enrolment). Cough and weight loss were the most commonly reported symptoms. 
Unsurprisingly we found that those newly diagnosed from HTC services were the most 
symptomatic; these individuals often present to services because they are unwell. The 
data presented span a duration of more than a year, i.e. are not confined to winter. We 
have previously shown, by linking symptom frequency to national sentinel influenza 
surveillance data that influenza-like illness (ILI) appears unlikely to be a major contributor 
to reported cough.132 (Appendix 10.6) There are no other published data, to the best of 
my knowledge, which report the natural history of WHO tool symptoms on repeated 
screening amongst PLHIV who have had TB excluded. However, data from household TB 
prevalence surveys and studies which have screened clinic attendees for TB in sub-Saharan 
Africa are available, and provide comparitors in the general community and clinic settings 
for our reported frequency of WHO tool symptoms. These studies are discussed below. 
 
Comparison with studies reporting frequency of symptoms suggestive of TB 
In the 2013-2014 Zambian national TB prevalence survey adult (aged > 15 years) household 
members from 66 randomly-selected clusters across all provinces were systematically 
screened for TB, using both a symptom screen and chest radiography, and offered HTC.215 
Individuals with abnormal chest radiographs or those reporting ≥ 2 weeks duration of 
either cough, fever or chest pain underwent sputum smear and TB culture. Eighty-four 
percent of those eligible participated, around 46,000 individuals, amongst whom 10% 
reported symptoms suggestive of TB. Two-thirds of participants underwent HIV testing, 
amongst whom the prevalence of HIV was 7%. Most (92%) of the participants who fulfilled 
the criteria for requesting sputum submitted at least one sample, amongst whom 4% 
(265/6123) had bacteriologically-confirmed TB.  
The 2016 Kenyan national TB prevalence survey was also a nationwide household survey of 
adults aged > 15 years from 100 randomly selected clusters.216 All participants underwent 
symptom and chest radiograph screening, with sputum requested from those with cough > 
2 weeks or abnormal chest radiography, or from those who did not undergo chest 
radiography. Sputum samples underwent microscopy, culture and testing with Xpert. 
Eighty-three percent of those eligible participated, around 63,000 individuals, amongst 
whom 38% reported symptoms suggestive of TB (cough [15%], night sweats [12%], fever 
[8%], weight loss [3%]; N= 63,050). Most (94%) of the participants who fulfilled criteria for 
requesting sputum submitted samples, amongst whom 305/9715 (3%) had 
bacteriologically-confirmed TB. HTC was undertaken only for participants with confirmed 
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TB, amongst whom 17% (41/245) were HIV-positive. However, half of all the prevalence 
survey participants knew their HIV status, amongst whom 5% (1627/32386) reported they 
were HIV-positive.217 The aforementioned national prevalence surveys, in which very few 
participants had bacteriologically-confirmed TB, and the majority were HIV-negative, 
indicate that the prevalence of symptoms suggestive of TB in the community at large 
ranges from 10-38%.215, 216 This range includes our finding that overall 30% of participants 
reported WHO tool symptom(s) at enrolment and the proportion reporting cough in the 
Kenyan national TB prevalence survey (15%)216 was very similar to ours (18%). It is possible 
that some TB diagnoses were missed in both of the aforementioned national surveys as 
only those with persistent symptoms and/or abnormal chest radiographs underwent 
investigation, but the prevalence of TB in community-based surveys in which all 
participants have undergone mycobacterial culture on sputum is generally low.134, 208 
Therefore it appears that significant proportions of individuals in the general community 
also report symptoms suggestive of TB and in particular cough. 
Ssemmondo et al undertook symptom-based TB screening in rural Uganda during mobile 
multidisease community health campaigns (CHC) which incorporated HIV testing.218 Their 
study was undertaken between 2013-2014 in seven out of thirty-two previously 
enumerated communities participating in a cluster-randomised trial of universal HIV 
testing and treatment in Kenya and Uganda. CHCs were undertaken over a two-week 
period, one month after the baseline study census enumeration of all residents, at 
convenient locations within each community. TB screening comprised enquiring about 
current cough and sputum was requested for microscopy for AFB if cough had been present 
for > 2 weeks. The authors reported that 74% (27,214) of all adults (age ≥ 15 years old) 
enumerated in the baseline census attended the campaigns, of whom 99% underwent HIV 
testing and 3.5% (941/26813) were HIV-positive with median CD4 cell count of 474 
cells/mm3. Twenty-one percent of adults reported current cough and 11% reported cough 
> 2 weeks. The proportion of participants reporting prolonged cough increased with age 
and was greater in HIV-positive (17%) compared with HIV-negative (10%) adults. Only 38% 
(1099/2876) of participants with cough > 2 weeks were able to produce a sputum sample 
and ten had smear-positive TB, of whom three were HIV-positive. Individuals attending the 
campaigns are more likely to have attended because they were unwell and thus 
symptomatic. Therefore, the proportion of adults reporting cough is likely to be biased, 
and most likely an overestimation of the proportion of adults with cough in the 
community. It is also likely that some TB diagnoses were missed because investigation was 
restricted to those with prolonged cough and the majority of those requiring investigation 
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could not produce sputum. However their data also indicate that a significant proportion 
of adults participating in this rural community health campaign reported cough.   
Owiti et al retrospectively analysed programme data collected from individuals attending 
for routine HIV care in Kenya between 2015 and 2016.219 In this setting patients should 
have been screened for TB at every clinical encounter using a standardized form which 
was subsequently electronically captured. Amongst around 90,000 individuals, the 
majority (>75%) were aged over 19 years and on ART, median follow-up time was 1.5 
years, and the median number of clinical encounters per individual was eight. The authors 
reported documentation of TB screening at almost 90% of all encounters, with 96% of 
PLHIV never reporting symptoms, and 3.6% and 0.4% of PLHIV reporting symptoms at only 
one encounter and at more than one encounter respectively. The most commonly reported 
symptom was cough, but only 7% of symptomatic individuals had documentation of 
investigation for TB (sputum microscopy or chest radiograph). The authors did not report 
the prevalence of TB. The proportion of PLHIV reporting symptoms in this study was much 
lower than amongst XPHACTOR study participants on ART. This may be due to the 
limitations of the retrospective design of the analysis which relied on routinely collected 
programme data. Forms might not have been completed fully due to lack of time in busy 
clinics, or the lack of symptoms might reflect a more mature population who had been on 
ART for a longer duration than those in XPHACTOR, although this was not ascertainable as 
the median CD4 cell count and duration on ART were not reported.  
Adelman et al, as already discussed in the literature review (Chapter 2) systematically 
screened HIV clinic attendees in Ethiopia, of whom 90% were on ART, and reported the 
presence of WHO tool symptoms in 39% of attendees.147 The authors did not investigate all 
participants with symptoms for TB and therefore could not exclude them from the 
proportion reporting symptoms, and this might explain the higher proportion reporting 
symptoms in their study compared with XPHACTOR. Chihota et al provide some data from 
primary health clinics (PHCs).43 The authors screened consecutive adults leaving PHCs 
participating in the XTEND trial in order to ascertain the proportion of those reporting 
symptoms suggestive of TB who had sputum requested by HCW. The authors reported that 
about 50% (4098/8104) of those approached were eligible for their study, i.e. reported at 
least one of the WHO tool symptoms. This figure appears exceptionally high for PHC 
attendees and may reflect a heightened awareness of TB symptoms and willingness to 
report these at a research trial site, or perhaps those with no symptoms were missed.  
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Even amongst our participants who were established on ART, 28% reported WHO tool 
symptoms at enrolment, and 10% at the 3-month visit. Of note, in this group, amongst 
those for whom viral load data were available, only 75% had viral load suppression. The 
proportion of those on ART reporting symptoms at enrolment is slightly lower than from 
comparable studies screening individuals established in HIV care (33-39%).142, 146-148 This 
probably reflects the exclusion of individuals diagnosed with TB from this analysis, 
whereas the aforementioned studies reported data from all enrolled.142, 146-148 Furthermore 
16% of our 957 participants who reported WHO tool symptoms at enrolment also reported 
symptoms at the 3-month follow-up visit. Amongst these participants 25% (238/957) had 
more than one sputum sample tested using Xpert during study follow-up. These data 
provide an indication of the volume of testing with Xpert that may arise as a result of 
regular screening in this population using the WHO tool. Our findings highlight the 
potential resource implications in LMIC settings of screening using a tool that lacks 
specificity and generates a large proportion of patients requiring a diagnostic test for TB. 
This might in part explain variations in adherence to TB screening guidelines.68 There are 
no other published studies of the evolution of WHO tool symptoms at subsequent clinic 
visits amongst those symptomatic at enrolment who have had TB excluded.  
 
Potential reasons for high frequency of reported cough 
Cough was the most frequently reported symptom overall, both at enrolment and follow-
up visits. Potential reasons for reported cough other than TB include non-communicable 
diseases such as asthma and COPD, smoking, use of biomass fuels and post-tuberculous 
chronic lung disease. A significant proportion of our study participants were either ex- or 
current smokers, i.e. around 25% of those established in HIV care, 30% of those from HTC 
and 13% of those from ANC. This is comparable with data from South Africa’s 2016 
demographic and health survey (DHS) which reported amongst adult (> 15 years old) males 
38% were current tobacco smokers and 6% ex-smokers compared with adult females 
amongst whom 7% were current smokers and 2% were ex-smokers.220 Smoking itself may 
increase the risk of TB infection.221 At the time the study was undertaken nicotine 
replacement therapy and other interventions to assist smoking cessation were not 
available in the public sector, the only option was advice and signposting to pharmacies. 
In resource-limitted settings, even if smoking cessation aids are now available in the 
public sector, it is unlikely that these are provided free-of-charge.  
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In the 2016 DHS asthma symptoms were reported by 3%-4% of adults and COPD symptoms 
by 2% of adults, which is comparable to our findings of 1-5% reporting chronic respiratory 
disease.220 However less than 1% of DHS participants reported using any medications for 
these conditions. The use of wood as a cooking fuel was more common in rural vs. urban 
households (32% vs. 2%) in the DHS, but our study was conducted in an urban setting and 
therefore here the current use of biomass fuel is less likely to have been responsible for 
cough. The prevalence of previous TB treatment in our study participants was high, 
ranging from 6% in the HTC group to 39% in the on ART group (amongst whom 6% reported 
more than one previous episode of TB treatment). Therefore post-TB chronic lung disease 
may have been responsible for cough in some participants and better criteria are needed 
to identify this condition and to guide management. The large proportion of individuals 
reporting cough also highlights the need for better access to pulmonary function testing at 
PHC level or simpler tests such as the six-minute walk test, and if appropriate treatments 
such as inhalers or pulmonary rehabilitation.222 
 
Strengths and limitations 
In keeping with other studies which enrolled ANC attendees, which report 16145-19%141 with 
WHO tool symptoms, we found those newly diagnosed from ANC were less symptomatic 
(15% WHO tool positive), although the number in this group was small. As discussed in the 
literature review (Chapter 2) a limitation of the WHO tool is that pregnancy itself may 
impact on the presence of TB symptoms, and in particular on reported weight loss. In this 
population measured weight loss, failure to gain weight appropriate to the trimester of 
pregnancy, or MUAC require further evaluation. 
A strength of our study was that the WHO tool was administered systematically by trained 
research staff, in the preferred language of the participant using standardized 
translations, thus ensuring that symptom screening questions were asked in a consistent 
manner.  
 
Conclusions 
Given the burden of symptoms suggestive of TB clear guidelines for further evaluation and 
management of the underlying cause of these symptoms, providing TB is excluded, are 
needed. The high prevalence of previous TB in this population highlights the need for 
guidelines to assist with the indentification and optimal management of post-TB chronic 
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lung disease and to differentiate active TB from previous TB in those who have had 
treatment in the past. This is particularly important with task-shifting and differentiated 
models of ART delivery, and given that cough appears to predominate, consideration 
should be given to developing simpler tests of pulmonary function and better access to 
respiratory specialists in primary care. The Practical Approach to Lung Health in South 
Africa (PALSA) guideline was developed from the WHO Practical Approach to Lung Health 
strategy to assist management by primary care nurses of adults with respiratory 
symptoms.223 The syndromic algorithms presented in the guideline equip primary care 
nurses, who are often the first port of call for patients and have limited access to doctors, 
to make diagnoses other than TB and enable them to manage common respiratory 
diseases. The Integrated Management of Adolescent and Adult Illness (IMAI) manuals 
provide similar but higher level guidance aimed at district level clinicians.224 Sufficient 
time and human resources are needed to follow these guidelines, but both are too often 
lacking in resource-limited settings.  
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6.3. Material provided as supplementary online appendices 
 S1 Table. Characteristics of eligible participants and missing values (N=1065) 
Characteristic Derivation dataset (N=525) Validation dataset 
(N=540) 
 Value Missing 
values 
Value Missing 
values 
 N (%) N (%) N (%) N (%) 
Demographics       
Age, years  Median (IQR) 41 (34,48) 0 41 (34,48) 0 
Sex Female 353 (67.2) 0 382 (70.7)  0 
Alcohol history Never 1  315 (60) 0 360 (66.7) 0 
Smoking history Never 2 361 (68.8) 0 389 (72.0) 0 
HIV/TB history     
Participant category On ART 3 377 (71.8) 0 387 (71.7) 0 
Duration since HIV diagnosed, 
months  
Median (IQR) 56 (21,95) 10 (2) 51 (6,97) 2 (0.4) 
Duration on ART, months Median (IQR) 55 (26,85)  1/377(0.3) 51 (28,83)  0 
Ever had IPT Yes 51 (9.7) 0 19 (3.5) 0 
Ever had CPT Yes 378 (72.0) 0 360 (66.7) 0 
Previous TB treatment Yes 205 (39.1) 0 202 (37.4) 0 
WHO symptoms at enrolment     
 Cough 308 (58.7) 0 354 (65.6) 0 
 Weight loss 238/524(45.4) 1 (0.2) 224 (41.5) 0 
 Night sweats 133 (25.3) 0 132 (24.4) 0 
 Fever 99 (18.9) 0 89 (16.5) 0 
Number of symptoms  1 (1,2)  0 1 (1,2) 0 
Duration of WHO symptoms4, 
days  
Median (IQR) 30 (8,94) 5 (1) 28 (7,84) 4 (0.7) 
CD4 / BMI at enrolment     
CD4, cells/mm3    Median (IQR) 379 (228,543) 2 (0.4) 335(168,559) 1 (0.2) 
Time from CD4 to enrolment, 
days   
Median (IQR) 147 (43,259) 2 (0.4) 118 (27,267) 6 (1) 
BMI, kg/m2   Median (IQR) 24.0(20.6,28.5) 1 (0.2) 24.1(20.3,28.4) 2 (0.4) 
TB diagnoses      
 Total 52 (9.9) 0 60 (11.1) 0 
 Confirmed TB 36 (6.9) 0 41 (7.6) 0 
 Clinical TB 16 (3.1) 0 19 (3.5) 0 
Time from enrolment to TB 
diagnosis 5, days 
Median (IQR) 7 (0,31) 0 13 (0,83) 1 (0.2) 
Follow up     
Time from enrolment to most 
recent of last study / clinic 6  
visit, days 
Median (IQR) 281 (203,347) 1 (0.2) 181 (133,231) 1 (0.2) 
Alive 6 months after 
enrolment 7 
Yes 487 (98) 
(N=497) 
28 (5.3) 469 (98) 
(N=479) 
61(11.3) 
 
1 compared with any alcohol in last 1 year; 2 compared with ever/ex-smoker; 3 compared with pre-ART 
group; 4 duration WHO tool positive;5 defined as earliest of positive TB test or date TB treatment 
started; 6 Most recent clinic visit at time of clinic file review; 
7 Amongst participants with most recent study/clinic visit <6 months from enrolment, if participant had 
valid South African ID number and demise not reported by Department of home affairs / participant-
nominated contacts / clinic staff within 6 months of enrolment, participant assumed to be alive at 6 
months after enrolment. 
 
IPT=isoniazid preventive therapy; CPT=cotrimoxazole preventive therapy   
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  S2 Table. Hosmer-Lemeshow test for calibration of final model (model A)   
 
 Derivation dataset 1 Validation dataset 2 
   TB   TB 
Decile N Cut off3 Observed  Predicted  N Cut off3 Observed  Predicted 
1 52 0.0126 0 0.4 54 0.0098 1 0.3 
2 51 0.0220 2 0.9 53 0.0186 1 0.7 
3 52 0.0308 0 1.4 53 0.0288 2 1.3 
4 51 0.0448 2 1.9 54 0.0450 4 2.0 
5 52 0.0611 2 2.7 53 0.0627 4 2.9 
6 51 0.0805 5 3.6 53 0.1024 5 4.2 
7 52 0.1078 7 4.9 54 0.1478 6 6.6 
8 51 0.1604 5 6.6 53 0.2044 8 9.3 
9 52 0.2681 12 10.6 53 0.3346 6 13.8 
10 51 0.5963 17 19.0 53 0.6479 21 23.7 
 515  52 52 533  58 64.8 
 
1 Hosmer-Lemeshow p=0.65    
2 Hosmer-Lemeshow p=0.31 
3 Upper boundary of predicted risk 
Observed = observed number with TB 
Predicted = expected number with TB predicted by model 
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 S3 Table: Model A Multivariable logistic regression analysis in derivation dataset after exclusion of all clinical TB 
(N=499) 
Predictor Patients with TB Unadjusted  P value Adjusted 3 P value Adjusted β  
N=36/499 odds ratio (Wald) odds ratio coefficient 
 n/N (%) (95% CI)  (95% CI)  (log [adjusted OR]) 
      (95% CI) 
Age 1, years     1.00 (0.96, 1.03) 0.89    
Sex Male 16/163 (9.8%) 1     
 Female 20/336 (6.0%) 0.59 (0.29, 1.15) 0.12    
Smoking status Never smoked 20/346 (5.8%) 1     
 Current or ex-smoker 16/153 (10.5%) 1.90 (0.96, 3.78) 0.07    
Alcohol status Current 15/199 (7.5%) 1     
 None in last 1 year 21/300 (7.0%) 0.92 (0.46, 1.84) 0.82    
ART status On ART ≥ 3 months 18/341 (5.3%) 1  1  0 
 Pre-ART / ART <3 months 18/158 (11.4%) 2.31 (1.17, 4.57) 0.02 1.84 (0.87, 3.89) 0.11 0.61 (-0.14, 1.36) 
Ever had CPT No / don’t know 12/138 (8.7%) 1     
 Yes 24/361 (6.7%) 0.75 (0.36, 1.54) 0.43    
Previous history of TB No 25/306 (8.2%) 1     
 Yes 11/193 (7.7%) 0.68 (0.33, 1.41) 0.30    
Number of WHO symptoms  1 symptom 11/334 (3.3%) 1  1  0 
 > 1 symptom 25/165 (15.2%) 5.24 (2.51, 11.00) <0.001 4.33 (2.02, 9.23) <0.001 1.46 (0.70, 2.23) 
Duration of WHO tool symptoms <1 week 2/96 (2.1%) 1     
 ≥ 1 week 34/403 (8.4%) 4.33 (1.02, 18.35) 0.05    
BMI 1,2, kg/m2   0.87 (0.80, 0.94) 0.001 0.88 (0.81, 0.96) 0.004 -0.12 (-0.21, -0.04) 
CD4 1,2, cells/mm3     0.997 (0.995, 0.998) <0.001 0.998 (0.996, 0.999) 0.012 -0.002 (-0.004, -
0.0005) 
 
1 Age, BMI and CD4 count were modelled as continuous variables 
 
2 In the multivariable analysis BMI and CD4 count were modelled as continuous variables, a linear relationship with the outcome was found to be adequate after modelling 
using fractional polynomials.  
 
3 Adjusted for all variables shown. 100 unit increase in CD4 corresponds to reduction in adjusted odds ratio (aOR) of TB of 0.78 (95% CI 0.64, 0.95); 5 unit increase in BMI 
corresponds to reduction in aOR of TB of 0.54 (95% CI 0.35, 0.82).  
Intercept (log odds) for multivariable model is 0.21. In the multivariable model we found no statistically significant interaction between remaining variables and “ART status”. 
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S4 Table. Model B: Multivariable logistic regression analysis in derivation dataset (N=515)  
Predictor Patients with TB Unadjusted  P value Adjusted 3 P value Adjusted β coefficient 
 N=52/515 odds ratio (Wald) odds ratio Model B (Wald) (log [adjusted OR]) 
 n/N (%) (95% CI)  (95% CI)  (95% CI) 
Age 1, years     1.00 (0.97, 1.03) 0.96    
Sex Male 23/170 (13.5%) 1     
 Female 29/345 (8.4%) 0.59 (0.32, 1.05) 0.07    
Smoking status Never smoked 28/354 (7.9%) 1     
 Current or ex-smoker 24/161 (14.9%) 2.04 (1.14, 3.64) 0.02    
Alcohol status Current 23/207 (11.1%) 1     
 None in last 1 year 29/308 (9.4%) 0.83 (0.47, 1.48) 0.53    
ART status On ART ≥ 3 months 24/347 (6.9%) 1  1  0 
 Pre-ART / ART <3 months 28/168 (16.7%) 2.69 (1.51, 4.80) 0.001 2.07 (1.07, 4.01) 0.03 0.73 (0.06, 1.39) 
Ever had CPT No / don’t know 19/145 (13.1%) 1     
 Yes 33/370 (8.9%) 0.65 (0.36, 1.18) 0.16    
Previous history of TB No 33/314 (10.5%) 1     
 Yes 19/201 (9.5%) 0.89 (0.49, 1.61) 0.70    
Cough No 16/211 (7.6%) 1  1  0 
 Yes 36/304 (11.8%) 1.64 (0.88-3.03) 0.12 2.96 (1.50, 5.85) 0.002 1.08 (0.40, 1.77) 
Fever No 38/418 (9.1%) 1     
 Yes 14/97 (14.4%) 1.69 (0.87-3.25) 0.12    
Night sweats No 31/384 (8.1%) 1  1  0 
 Yes 21/131 (16.0%) 2.17 (1.20-3.94) 0.01 1.99 (1.02, 3.89) 0.04 0.69 (0.02, 1.36) 
Unintentional weight loss No 12/280 (4.3%) 1  1  0 
 Yes 40/235 (17.0%) 4.58 (2.34-8.96) <0.001 4.08 (1.96, 8.49) <0.001 1.41 (0.67, 2.14) 
BMI 1,2, kg/m2   0.88 (0.82, 0.94) <0.001 0.90 (0.84, 0.97) 0.005 -0.10 (-0.17, -0.03) 
CD4 1,2, cells/mm3     0.997 (0.995, 0.998) <0.001 0.997 (0.996, 0.999) 0.009 -0.002 (-0.004, -0.0005) 
 
1 Age, BMI and CD4 count were modelled as continuous variables 
2 BMI and CD4 count were modelled as continuous variables, a linear relationship with the outcome was found to be a good approximation after assessment of nonlinearity 
using fractional polynomials.  
3 Adjusted for all variables shown. 100 unit increase in CD4 corresponds to reduction in adjusted odds ratio (aOR) of TB of 0.81 (95% CI 0.69, 0.95); 5 unit increase in BMI 
corresponds to reduction in aOR of TB of 0.61 (95% CI 0.43, 0.86).   
In the multivariable model we tested for interactions between “ART status” and CD4 cell count, “ART status” and BMI, “ART status” and cough, “ART status” and night sweats, 
“ART status” and weight loss. Interaction term with p<0.05:  ART status and cough. 
Intercept (log odds) for multivariable model is 0.32 
In derivation vs. validation datasets: Hosmer-Lemeshow statistic p=0.81 vs. p=0.01, AUROC 0.82 (95% CI 0.76-0.88) vs.  AUROC 0.75 (95% CI 0.69-0.82) 
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S1 Fig. Boxplot illustrating distribution of clinical score in individuals with and without 
TB   
  
N=515 in derivation dataset with 52 TB diagnoses; N=535 in validation dataset with 58 TB diagnoses 
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9) Discussion and conclusions 
9.1. Introduction 
This thesis examined TB screening and investigation strategies for adults attending routine 
HIV care in a LMIC setting with an HIV-associated TB epidemic. The research was 
undertaken at a time when the TB diagnostic landscape was rapidly evolving and CD4 
count determined eligibility for ART. The rollout of new diagnostic tools in the “real 
world” raised questions around resource prioritisation and how to use them most 
efficiently. Contrary to expectations, the advent of Xpert has not resulted in greater 
numbers of individuals starting TB treatment, but the proportion of bacteriologically-
confirmed diagnoses has increased, and when Xpert is positioned at point-of-care TB 
treatment is started faster.101, 181, 225-227 The role of LF-LAM is very limited.112  
Since this research was undertaken the gap between the number of TB diagnoses notified 
to national programmes and the number estimated by the WHO each year remains large.2 
Now, more sensitive versions of the diagnostic tests used in this research are either 
available,90 or being developed;114, 228, 229 immediate ART is recommended for all PLHIV; 
and different models of ART delivery are in place. The recommended screening tool for 
intensified TB case finding in PLHIV remains the same, developed using data largely from 
the pre-ART era, in order to enable rapid scale-up of IPT. The performance of a screening 
test will differ when it is used in different settings and different populations from that in 
which it was originally developed. This is illustrated by the performance of the WHO tool 
for TB screening in individuals on ART amongst whom the tool is less sensitive but more 
specific for TB.42 In the future if more PLHIV are on ART and for longer periods of time, 
consequently undergoing repeated rounds of TB screening, which is also known to reduce 
the sensitivity of the tool, then more TB diagnoses will be missed by the tool. The 
improved specificity will however generate fewer false-positives on screening, thus 
reducing the numbers undergoing unnecessary diagnostic testing. The hoped-for decline in 
the burden of HIV-related TB will also reduce the PPV of the WHO tool, so that an even 
smaller proportion of those who report symptoms will actually have TB. Nevertheless, 
screening PLHIV for TB remains an important strategy in the goal of ending the global TB 
epidemic, as well as on an individual level to reduce suffering. World leaders pledged only 
last year to regularly screen all PLHIV and to finding the missing people with TB.38   
This chapter summarises the main findings from the research undertaken, making 
comparison with the published literature; discusses the implications arising from this 
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work, its strengths and limitations; and makes recommendations for HIV programmes and 
future research. It also considers the possible impact on these research findings of the 
aforementioned changes in HIV care and “next-generation” TB diagnostics. Now that ART 
is started irrespective of CD4 cell count, the entity of pre-ART care for those waiting to 
reach a predetermined CD4 threshold for ART initiation should no longer exist. Therefore, 
the discussion will focus more on the findings in the on ART group, as this is of more 
relevance to HIV programmes.   
The flow of the discussion will follow the pathway depicted in Figure 1-2 (the aims of the 
thesis), which reflects the journey PLHIV attending for routine care may undergo following 
TB screening.  
 
9.2. Summary of findings and comparison with published studies    
9.2.1. Options for screening for TB among people attending for HIV care 
WHO 4-symptom TB screening tool 
The XPHACTOR study enabled a prospective evaluation of the performance of the WHO 
tool in the era of ART, uniquely, and of particular relevance since the advent of treat-all, 
in a large cohort established on ART. At enrolment, almost one-third of those on ART 
reported WHO tool symptom(s), most commonly cough and weight loss, and 3.1% (95% CI 
2.4, 3.8) fulfilled our case definitions for clinical and confirmed TB combined. In the on 
ART group the sensitivity and specificity of the WHO tool for clinical and confirmed TB 
combined was 68.4% (95% CI 56.9, 78.4) and 70.7% (95% CI 68.9, 72.6) respectively. The 
sensitivity was slightly lower for bacteriologically-confirmed TB (62.3%, 95% CI 49.0, 74.4), 
but the specificity was unchanged.   
Most published studies which have investigated the performance of the WHO tool for TB 
screening have focussed on populations comprising those newly diagnosed HIV-positive,73, 
79 those preparing to initiate ART,54, 56, 72 or those screened prior to IPT.75, 77 Studies which 
have screened individuals on ART using the WHO tool have excluded large numbers of 
participants because they could not produce sputum or were missing data,138, 143 or 
included individuals who had already been extensively pre-screened for TB.143 These 
factors would have generated biased estimates of sensitivity (probably underestimations) 
and limit the generalisability of their findings to routine HIV care settings. Furthermore, 
compared to XPHACTOR, PLHIV in these aforementioned studies had been on ART for a 
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shorter length of time (1-2 years), and had lower median CD4 cell counts. Ours was a more 
“mature” population, reflected by their longer duration on ART (median 4 years) and 
higher median CD4 count (436 cells/mm3). This also explains the lower prevalence of 
confirmed TB in our on ART group of 2.4%, compared with 5.4-5.9% in comparable 
studies.138, 143 Our study findings are likely to provide a better indication of the workload 
associated with, and the diagnostic yield from intensified TB case-finding in the future, 
among HIV-positive individuals attending for routine care. These individuals will probably 
have higher CD4 cell counts at ART initiation, have been taking ART for longer, and should 
have been repeatedly screened for TB.   
 
Prevalence of WHO tool symptoms in XPHACTOR 
In XPHACTOR, one-third of those on ART reported WHO tool symptoms at enrolment, and 
this reduced to just over one-quarter if those diagnosed with TB were excluded. This is in 
accordance with studies conducted in HIV clinic or MCH settings, in which 33-39% of 
participants who were on ART reported WHO tool symptoms at study enrolment.142, 147, 148 
TB screening studies which have excluded individuals unable to expectorate sputum are 
likely to have overestimated the prevalence of cough.138, 143, 154 We did not exclude 
participants who were unable to produce sputum at enrolment, and therefore our findings 
are more generalisable to HIV care settings. We also found that cough was the most 
commonly reported symptom. Even when the same participants were screened over a 3-
month period using the WHO tool at monthly intervals, and having excluded those who 
were diagnosed with TB, cough remained the most common symptom reported on 
screening. Recurrent or persistent cough will impact on the quality of life of sufferers, and 
therefore capacity is needed at all levels of healthcare to enable timely evaluation, 
diagnosis, and provision of appropriate treatment for these patients.  
We found that 10% of XPHACTOR participants in the on ART group reported WHO tool 
symptoms on screening at the 3-month visit, and this was after excluding individuals who 
had been diagnosed with TB during the course of the study. Extrapolating our findings to 
ART programmes suggests that a large volume of confirmatory diagnostic testing will be 
required when the WHO tool is used as intended, to screen the same population at every 
clinical encounter. To the best of my knowledge there are no other published data which 
report the evolution of WHO tool symptoms when the same individuals are repeatedly 
screened. 
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Performance of the WHO tool in XPHACTOR dataset 
We found that the WHO tool was less sensitive (62.3% vs. 91.7%) but more specific (70.7% 
vs. 66.5%) for confirmed TB in the on ART compared with the pre-ART group. NPV was high 
(>98%) for both groups at confirmed TB prevalence of 3.1%, and at prevalence of 
confirmed and clinical TB combined of 7.3%, but PPV was <10%. Therefore the WHO tool 
worked well, as designed, for ruling out TB in both groups, but the vast majority of those 
reporting symptoms did not have TB and would have required unnecessary diagnostic 
testing for TB. (Table 4-3) If the TB prevalence falls in HIV clinic settings, as is hoped for 
with PLHIV initiating ART at higher CD4 cell counts, the PPV of the WHO tool will be 
further reduced. Therefore, in resource-constrained settings the rollout of treat-all may 
require alternative TB screening and diagnostic strategies to the WHO tool followed by a 
diagnostic test. Failing this, HCWs may be even less likely to adhere to TB screening and 
investigation algorithms in heavily pressurised LMIC settings.68  PLHIV may tire of 
repeatedly undergoing investigation after screening with a tool that lacks specificity. One 
could speculate that they might even prefer not to disclose the presence of WHO tool 
symptoms when repeatedly screened, to avoid the associated obligatory reattendances for 
test results and follow-up. 
In our pre-ART group the XPHACTOR algorithm was less sensitive than the WHO tool (75.0% 
[95% CI 42.8, 94.5] vs. 91.7% [95% CI 61.5, 99.8]) and more specific (72.3% [95% CI 68.1, 
76.2] vs. 66.5% [95% CI 62.1, 70.7]) for confirmed TB. Sensitivity and specificity were 
similar for both the WHO tool and the XPHACTOR algorithm in the on ART group. These 
findings are unsurprising given that the XPHACTOR algorithm was intended to improve the 
specificity for TB by “tightening” WHO criteria, i.e. requiring duration of fever, or 
evidence of weight loss; and as expected this was at the expense of sensitivity. The WHO 
tool was designed to maximise sensitivity and developed in a dataset comprising a pre-ART 
population. 
XPHACTOR data afforded the opportunity to prospectively evaluate the performance of 
the WHO tool in a population attending for HIV care who had been previously screened for 
TB. In the original meta-analysis which developed the WHO tool, the sensitivity of the 
WHO tool amongst those previously screened for TB was 40.5% (95% CI 16.6, 69.9), the 
wide confidence intervals reflecting the small numbers in that group.80 When combining 
our pre- and on ART groups, who were established in care and therefore should have been 
previously screened for TB, we found the sensitivity of the WHO tool for confirmed TB was 
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greater, 67.1% (95% CI 55.1, 77.7). This reflects our study population being more 
representative of HIV clinic attendees, who are more likely to be symptomatic and at 
higher risk of TB than participants in the studies providing this data for the meta-analysis, 
who were mainly enrolled from community-based surveys.134, 135 It therefore provides a 
more accurate reflection of WHO tool performance amongst those previously screened for 
TB in clinic settings.  
 
Limitations of the WHO tool 
Strategies to find the missing millions with TB also need to address how best to identify 
asymptomatic individuals with microbiologically-confirmed TB, and individuals with 
extrapulmonary TB. A symptom-based TB screening tool will obviously not identify 
asymptomatic TB, and extrapulmonary TB is less likely to be identified by a screening tool 
which was developed using a reference standard of culture-confirmed TB from sputum 
samples. These issues are discussed below. 
Asymptomatic Tuberculosis 
Two studies in South Africa, which systematically screened PLHIV for pulmonary TB just 
prior to ART initiation230 or as part of pre-ART care,231 reported prevalences of 
asymptomatic TB of 4% in the larger study (28/654)230 and 8.5% (18/213) in the smaller 
study.231 In these studies, individuals with asymptomatic TB had an intermediate degree of 
immunosuppression, as suggested by median CD4 counts of 136-249 cells/mm3 being in 
between those of PHLIV with active TB (68-148 cells/mm3) and those with negative TB 
microbiology who did not require TB treatment (249-322 cells/mm3).230, 231 56% of these 
individuals developed TB symptoms within a median of 28 days. When compared with a 
group of PLHIV with symptomatic TB enrolled from a TB clinic in the same setting, those 
with asymptomatic TB were more likely to be smear-negative.231 The numbers with 
asymptomatic TB in both of these studies were small, but the phenomenon of 
asymptomatic bacteriologically-confirmed TB is well described when PLHIV are 
systematically screened using sensitive diagnostic tests.56, 232, 233  
In XPHACTOR, all study participants were asked to provide a sputum sample at enrolment, 
which was tested with Xpert immediately or stored for later testing. 0.7% (27/3678) of our 
participants fulfilled the case definition for confirmed TB but reported no WHO tool 
symptoms at enrolment, suggesting that asymptomatic TB might be less common in 
populations established in HIV care. The proportion of individuals with asymptomatic TB 
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may change over time as the characteristics of people attending for HIV care changes, 
hopefully shifting towards people with higher CD4 cell counts, whom the aforementioned 
studies indicate are less likely to have asymptomatic TB. 230, 231 
A model of TB as a continuum of disease from infection with MTB to clinically active 
disease is currently considered more appropriate than the traditional binary concept of an 
individual switching directly from latent TB infection to active TB disease.234 Alternative 
screening modalities to the WHO tool are needed to identify asymptomatic disease. 
However, one could postulate that repeatedly screening PLHIV using a symptom screen, 
should first identify (and treat) those who are most unwell. Those with asymptomatic TB 
will hopefully passively present for care if they do develop symptoms, or if disease has 
progressed, will be identified at the next round of screening. There is currently 
insufficient data on survival outcomes in PLHIV with asymptomatic TB who do not receive 
TB treatment to suggest that they fare any worse than those without TB, so this 
phenomenon might not be clinically important.230 
Extrapulmonary Tuberculosis 
20/153 (13%) of XPHACTOR study participants who fulfilled the case definitions for TB and 
had the site of disease recorded had evidence of extrapulmonary disease, of whom 15 only 
had extrapulmonary disease. In Research Paper 4 (“Causes of TB symptoms in HIV-
positive adults”) over half (8/14) of participants initiating TB treatment did so based on 
the results of investigations for extrapulmonary TB (abdominal ultrasound, 6; LNA; 1; 
lumbar puncture, 1). Although the number of participants investigated in this study was 
small, most (65%) had submitted sputum samples for mycobacteriology prior to enrolment. 
In actual fact, all should already have undergone investigation as part of the XPHACTOR 
main study procedures, because everyone was asked to provide sputum for testing with 
Xpert (immediately or stored for later testing) at enrolment, and a further sample was 
requested at the 3-month visit for mycobacterial culture. We found that only 1997/3722 
(53.7%) of study participants were able to produce a sputum sample at enrolment. This 
highlights the limitation of sputum-based diagnostics, in terms of difficulties in collecting 
sputum and for diagnosing extrapulmonary TB, and the need for access to other 
investigation modalities.  
The studies included in the WHO metanalysis mainly collected sputum samples for 
mycobacterial culture, i.e. the WHO tool was developed using a reference standard of 
bacteriologically-confirmed pulmonary TB.80 This reflects the reality of investigating TB in 
LMIC and the data that were available at the time the meta-analysis was undertaken, 
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when there was an urgent need for a simple TB screening tool to facilitate rollout of IPT. 
Individuals with extrapulmonary disease are also likely to present with cough, fever, 
unintentional weight loss and night sweats. However, it may be that extrapulmonary TB is 
more likely to be missed when screening is undertaken using the WHO tool because of the 
reference standard used to develop the tool. Extrapulmonary disease is more common in 
individuals with advanced HIV disease, and may become less common as PLHIV initiate ART 
at higher CD4 counts, although those who drop out of HIV care may present at a later 
stage with advanced immunosuppression.   
 
Alternative TB screening and diagnostic algorithms examined in this thesis 
This thesis looked at alternatives to the recommended algorithm of WHO symptom screen, 
followed by Xpert if WHO tool symptoms were reported; and if Xpert-negative but 
symptomatic, then further investigation in line with the WHO smear-negative pathway 
(mycobacterial culture, chest x-ray, and if indicated a trial of antibiotic). This research, 
uniquely, was undertaken in the context of active case finding for TB amongst PLHIV 
established in HIV care, in contrast to most other published studies that have focussed on 
screening individuals prior to ART initiation or at new HIV-positive diagnosis.  
In summary we found that the sensitivity of LF-LAM, when used to screen study 
participants with CD4 cell count < 200 cells/mm3, was too low to be useful as a screening 
test and certainly could not be recommended to replace the WHO tool (Chapter 5 - 
Research Paper 1, “TB Screening with LAM in an HIV Clinic”). When a grade 2 cut-off 
was used, which is equivalent to the current recommended designation for a positive test, 
sensitivity was only 5.4% (95% CI 1.1, 14.9) for confirmed and clinical TB combined. There 
were only three positive LF-LAM results using this cut-off amongst 56 individuals who 
fulfilled these TB case definitions, so we could not explore the sensitivity of LF-LAM in 
those with CD4 <100 cells/mm3.   
In Research Paper 2 (Chapter 6 - “Clinical Score for TB in HIV-positive adults in South 
Africa”) a triage tool was developed to prioritise individuals reporting WHO tool symptoms 
for diagnostic testing for TB. The score was designed to be simple, using information 
readily available at primary healthcare level; and was derived from a clinical prediction 
model developed using multivariate analysis. The clinical score comprised ART status 
(categorised as on ART > 3 months vs. pre-ART or ART < 3 months), BMI (<18.5 vs. 18.5-24.9 
vs. ≥25 kg/m2), CD4 cell count (<200 vs. 200-349 vs. ≥350 cells/mm3), and number of WHO 
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tool symptoms (1 vs. >1 symptom). Prioritising a diagnostic test for symptomatic 
individuals with a cut-off score of ≥3 would have avoided one-third of the volume of Xpert 
tests required in our study population, at the expense of missing 3% of TB diagnoses in 
those not tested. 
Research Paper 3 (Chapter 7 - “Investigating TB if initial Xpert is negative”) looked at 
the diagnostic yield from undertaking a repeat Xpert test on a fresh sputum sample 
amongst individuals with an initial negative test result. The sputum sample was collected 
at attendance for the result of the initial Xpert. This study was restricted to individuals at 
highest risk of TB, defined by CD4 <200 cells/mm3 or those newly diagnosed HIV-positive, 
in order to ensure sufficient TB diagnoses to enable comparison with the Xpert-negative 
algorithm. Amongst 27/227 TB diagnoses in this study, only five were identified by the 
repeat Xpert test, and the remainder started TB treatment during study follow-up mainly 
on the basis of compatible imaging (10) or mycobacteriology (culture-positive for MTB [4], 
further Xpert positive [4]). This highlights the need for good access to imaging, both chest 
radiograph and ultrasound scan. Furthermore, in those at high risk of TB, further 
investigation for TB should not be halted following an initial negative Xpert result.   
 
Published studies reporting other TB screening options    
Alternative TB screening options can be subdivided into i) methods to replace the WHO 
tool; ii) a second step to triage WHO-tool-positive individuals for investigation with Xpert 
(sequential screening); and iii) methods which include the WHO tool in order to improve 
algorithm sensitivity (parallel screening).235 Sequential screening strategies, by virtue of 
further screening only those who test positive by the initial test, will lose sensitivity but 
improve upon both the specificity and PPV compared to the first screening test. Parallel 
screening strategies, whereby all individuals have multiple screening tests, and screen 
negative only if all tests are negative, lose specificity but improve upon sensitivity 
compared with the individual screening tests.71  
Screening tests perform differently in different settings and the selected screening 
strategy is determined not just by financial constraints, but also by the prevalence of TB, 
the setting and the potential risks of failing to identify TB. In a community-level setting, 
where the prevalence of TB is lower, individuals are also less likely to be symptomatic and 
less likely to have TB. A screening test designed in a hospital setting, where the 
prevalence of TB is likely to be higher and attendees are also more likely to be unwell and 
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more symptomatic, will have lower specificity in a community based setting. This will 
result in large numbers of individuals undergoing unnecessary diagnostic tests for TB. 
Table 9-1 summarises alternative screening strategies pertinent to the research 
undertaken for this thesis, i.e. replacements for the WHO tool and triage tools for those 
reporting WHO tool symptoms. The studies presented in table 9-1 have been evaluated in 
ambulatory PLHIV, or are currently used instead of the WHO tool, and largely published 
either following the 2010 recommendation to use the WHO tool or after this research was 
commenced.    
 
WHO high priority target product profile (TPP) for a triage test84 
The need for a triage test has been identified, ideally for use at community-level or as a 
minimum at primary or higher level healthcare, to reduce the volume of diagnostic testing 
required for TB. The role of the triage test is to identify, amongst symptomatic 
individuals, those most likely to have TB who should therefore be prioritised for diagnostic 
testing.84 A test that needed minimal training and infrastructure, and required sputum or 
non-sputum based samples was envisaged. Minimum product requirements were agreed, 
by consensus: sensitivity (>90%) and specificity (>70%) for bacteriologically confirmed 
pulmonary TB; cost <US$2; availability of results within 30 minutes; and with ease of 
access to a confirmatory test deemed a prerequisite. According to the WHO report,84 this 
product was not intended to be used as a TB screening tool, but rather to triage 
individuals attending because of symptoms suggestive of TB for diagnostic testing, or for 
anyone attending for care with a risk factor for TB such as HIV. The latter is confusing as it 
suggests that the triage test could be used as a TB screening tool for PLHIV attending for 
care, even though the report stipulates that separate TPPs for a screening test (which 
requires higher sensitivity) still need to be agreed upon. Investigators have applied these 
minimum criteria of sensitivity and specificity when evaluating alternative screening 
algorithms to the WHO tool; to date only POC CRP, as discussed below, fits these 
criteria.236 
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Table 9-1 Alternative TB screening and investigation options for ambulatory PLHIV in LMIC  
 
Role Method Population 
Median CD4 
Author year 
 TB case 
definition 
TB prevalence Sensitivity Specificity Comment 
Replacement for 
WHO tool  
LF-LAM HTC 
CD4 213 
Drain151 2016 
Sputum C+ 123/675 (18.2%) 31% 92.0% Pre-2014 Gd 1 cut off used, 
overestimates sensitivity + 
underestimates specificity  
Sensitivity better in CD4<100107  
 Prior to ART 
CD4 211 
Balcha104 2014 
Sputum or LNA 
C+ or GXP+; or 
clinical TB 
128/757 (16.9%) 
confirmed 
148/757 (19.6%) 
clinical + confirmed 
25.8% for confirmed 
TB 
92.8% Pre-2014 Gd 1 cut off  
Sensitivity better in CD4<100 
“Not TB” required negative TB culture 
& no TB Rx 
Followed to 6 months 
Bias and not generalisable as did not 
enrol those unable to produce sputum 
 Prior to ART 
CD4 170 
Lawn105 2012 
Sputum C+ 85/516 (16.4%) 28.2% 98.6% Pre-2014 Gd 1 cut off  
Sensitivity better in CD4<100 
 ANC 
CD4 437 
(54% on ART) 
LaCourse141 2016 
Sputum C+ 7/288 (2.4%) 0/7 95.1% Pre-2014 Gd 1 cut off used 
Possible selection bias as high refusal 
rate for participation 
CRP HTC 
CD4 306 
Shapiro237 2018 
Sputum C+ 42/425 (10%) CRP >5: 90.5% 
CRP >10: 78.6% 
CRP >5: 58.5% 
CRP >10: 72.3% 
Specificity greater if CD4>200 
Lab based CRP 
Retrospective design, verification bias 
 Prior to ART 
CD4 171 
Lawn238 2013 
Sputum C+ 
 
81/496 (16.3%) CRP ≥5: 90.1% 
CRP ≥10: 85.2% 
CRP ≥5: 43.9% 
CRP ≥10: 57.6% 
Lab based CRP 
 Prior to ART 
CD4 165 
Yoon236 2017 
Sputum C+ 163/1177 (13.8%) CRP ≥5: 92·6% 
CRP ≥8: 90.2% 
CRP ≥10: 89·0% 
CRP ≥5: 59·7% 
CRP ≥8: 69·6% 
CRP ≥10: 72·1% 
GXP+ C-ve deemed not TB 
“Not TB” required negative TB culture  
POC CRP 
CXR New enrolees to HIV 
clinic 
58% on ART 
CD4 336 
Nguyen142 2016 
Sputum C+ 28/397 (7.1%) CXR suggestive of 
active PTB: 71% 
 
71% Excluded those who did not complete 
all evaluations – selection bias 
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Role Method Population 
Median CD4 
Author year 
 TB case 
definition 
TB prevalence Sensitivity Specificity Comment 
 Attending PHC for HIV 
care 
50% on ART 
CD4 215 
Gounder239 2011 
C+ or SM+ or 
histology on 
sputum / LNA / 
blood 
30/422 (7%) CXR suggestive of 
active PTB: 95% 
 
47% Convenience sample140 – selection 
bias, overestimates sensitivity, not 
generalisable 
 Prior to ART 
CD4 100 
Bassett54 2010 
Sputum C+ 158/825 (19%) Any abnormality on 
CXR: 83% 
35%  
 Prior to ART 
CD4 120 
Hanifa55 2012 
Sputum C+ 64/300 (21%) Any abnormality on 
CXR: 85.5% 
CXR suggestive of 
active PTB: 77.4% 
48.1% 
 
 
63.4% 
Followed to 3-6 months 
Alternative symptom 
screen 
ID-TB/HIV 
 
Prior to ART 
CD4 242 
Cain72 2010 
C+ on sputum / 
urine / blood / 
stool / LNA 
267/1748 (15%) 93% 36% Contributed to WHO meta-analysis.  
Age > 6yrs 
Used in SE. Asia   
In preceding 4 wks: Any cough or 
fever or NS >3w 
Triage test if 
WHO-tool 
positive   
Clinical Score 
 
Prior to ART 
625 WHO tool positive 
CD4 212 (N=791) 
Balcha176 2014 
Sputum or LNA 
C+ or GXP+; 
115/625 (18.6%) Score ≥2: 96/116 
(83%) 
 
Score ≥4: 
19/116 (16%) 
291/509 (57%) 
 
 
 
494/509 (97%) 
Followed to 6 months 
“Not TB” required negative TB culture 
& no TB Rx 
Score (each assigned 1 point): cough, 
Karnofsky score ≤80, MUAC <20 cm, 
lymphadenopathy, HB <10 
Not enrolled if unable to produce 
sputum (same population as 104) 
 CRP  HTC 
All WHO tool positive 
CD4 268 
Shapiro237 2018 
Probable TB = 
TB Rx / GXP+ / 
C+ / Sm+ within 
3 m  
78/749 (10.4%) CRP ≥5: 98·7% 
 
CRP ≥5: 48.3% 
 
Retrospective analysis 
Case definition applied retrospectively  
TB investigation only if clinician 
requested – verification bias 
Lab based CRP on stored samples 
 
ANC, antenatal clinic; ART, antiretroviral therapy; C+, culture-positive MTB; C-, culture-negative for MTB; CRP, C-reactive protein mg/L; CXR, chest radiograph; GXP+, Xpert-positive; HB, 
haemoglobin g/dL; HTC, HIV testing and counselling services; LNA, lymph node aspirate; MUAC, mid upper arm circumference; PHC, Primary health clinic; POC, point of care; SM, TB 
microscopy; TB Rx, TB treatment 
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Alternative screening methods to replace the WHO tool 
Methods replacing the WHO tool include LF-LAM, POC CRP, chest radiograph, and the ID-
TB/HIV algorithm which is used in Southeast Asia.72 In addition, screening using sputum 
Xpert or mycobacterial culture has been examined and advocated in all PLHIV prior to ART 
initiation in settings with HIV-associated TB epidemics.54, 56, 188 2017 South African HIV 
clinicians society guidelines recommend, if feasible, sputum mycobacterial culture for all 
individuals with CD4 count <200 cells/mm3 as part of TB screening prior to IPT initiation.62 
I will not discuss further the strategy of “investigating all”, as it is impractical and too 
expensive to use for the regular TB screening of PLHIV established in care in LMIC. The 
research undertaken in this thesis sought to prioritise use of limited resources in a 
population established in HIV care.  
Published studies examining alternative screening methods have in general been 
undertaken at very specific milestones in an HIV-positive individual’s journey through 
care, i.e. at new HIV diagnosis, or prior to ART or IPT initiation, when the likelihood of 
active TB and the negative impact of a missed TB diagnosis are greatest. These studies are 
summarised in Table 9-1 and discussed in further detail below. 
 
LF-LAM   
We found LF-LAM was too insensitive for use as a TB screening tool for individuals 
attending for routine HIV care, even when restricted to those with CD4 count <200 
cells/mm3. Sensitivity was only 7.5% and specificity was 98.6% for bacteriologically 
confirmed TB using a grade 2 cut-off on the pre-January 2014 manufacturer’s reference 
card (equivalent to the grade 1 cut-off on the current reference card). The urine samples 
in our study were frozen, but stored and processed in accordance with manufacturer’s 
recommendations and other studies.105 The WHO guidance (to which our data contributed) 
and a recent Cochrane review advise against the use of LF-LAM for TB screening, as 
already discussed in the literature review.103  
Studies presented in Table 9-1 report a higher sensitivity of LF-LAM for TB than we found. 
This is likely due to the different populations investigated in these studies, i.e. individuals 
preparing to initiate ART or those newly diagnosed HIV-positive.137 Their study participants 
would have been more unwell and at greater risk of TB than our participants, who were 
established in HIV care, as reflected by the much higher prevalence of TB reported in 
these studies. These studies also used the more sensitive, but less specific, grade 1 cut-off 
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in the pre-2014 reference card to define a positive LF-LAM result. The only study which 
did include individuals on ART enrolled participants from antenatal care, so is not 
generalisable to routine HIV care settings.141 20% of those approached declined to 
participate in the aforementioned study, and selection bias is likely to have impacted on 
the sensitivity of LF-LAM, which was negative for all seven participants who fulfilled the 
study case definitions for TB. 
Urine is generally considered to be a relatively easy sample to collect, but in XPHACTOR, 
20% of those eligible for the LF-LAM study did not produce a urine sample. In contrast 
other studies which have evaluated LF-LAM as a screening test for TB in PLHIV in 
outpatient settings reported that very few individuals were unable to produce urine 
(Table 9-1).104, 105, 151 It is possible that individuals who were unable to produce urine 
declined to participate in these studies in the first place, or were not enrolled. Inpatient 
studies report ease in collection of samples and this is to be expected with a “captive” 
population. In crowded HIV clinics adequate access to a toilet might not always be 
feasible. Even in higher income countries with better access to outpatient toilet facilities 
on-demand urine samples are not always forthcoming. Newer diagnostic tests therefore 
need to use samples that a healthcare worker can collect and complete all testing on 
during the consultation itself, e.g. finger prick blood or saliva.  
 
Point-of-care CRP 
POC CRP currently appears the most attractive option for replacing the WHO tool, because 
of superior sensitivity and specificity for TB, but it has only been evaluated in a population 
preparing to initiate ART, i.e. at high risk of TB.236  It costs less than $2 per test and 
provides results within three minutes. Yoon et al evaluated the diagnostic accuracy of POC 
CRP for culture-confirmed pulmonary TB at ART initiation in a hospital-based ART clinic in 
Uganda.236 The study was undertaken at a time when ART was provided when the CD4 
count was <350 cells/mm3.236 In this study consecutive adults were prospectively enrolled 
and all were systematically screened for TB using the WHO tool, POC CRP and two sputum 
samples were collected (one induced if necessary) for one Xpert and two TB cultures on 
solid and liquid media. The reference standard used for analyses was culture-confirmed 
TB, but those who were Xpert-positive but culture-negative were designated as not TB. A 
diagnosis of not TB was assigned if there were at least two negative sputum cultures, as is 
appropriate for a diagnostic accuracy study. However, excluding all individuals who were 
unable to produce two sputum samples will bias the sensitivity estimates for POC CRP. A 
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large number of individuals were excluded from this study because of missing sputum 
culture results (5% of those enrolled, and more so amongst those with CRP <10 mg/L). 
TB prevalence in this population with a median CD4 count of 165 cells/mm3 was 14%.236 
The great majority (87%) of participants reported WHO tool symptoms, reflecting an 
unusual definition of WHO tool positivity which allowed for symptoms reported within the 
30 days prior to enrolment. Positive POC CRP defined as ≥8 mg/L had sensitivity and 
specificity of 90% and 70% respectively, compared with 96% and 14% for the WHO tool, 
thus fitting the TPP criteria for a triage test for pulmonary TB. The very high sensitivity 
and poor specificity of the WHO tool arise from the expanded definition for WHO tool 
symptoms. The sensitivity of POC CRP is likely to be biased and overestimated because of 
the large number of participants who were excluded due to missing results or failure to 
produce two sputum samples. Individuals who could produce two sputa are more likely to 
have been unwell, probably because they had TB. TB diagnoses may have been missed due 
to the failure to collect extrapulmonary samples, the lack of prospective follow-up, and 
Xpert-positive culture-negative TB being deemed “not TB”, the rationale for which is not 
provided. The authors’ findings cannot be generalised to HIV-positive individuals attending 
for routine care, as 63% of their participants were new to HIV care. CRP is likely to be less 
sensitive for TB screening in individuals stable on ART, who are less likely to be unwell or 
to have TB.137   
In a later study, which included some of those enrolled in the above study, Yoon et al 
compared POC CRP-based screening algorithms to the WHO tool followed by Xpert prior to 
ART initiation.240 In this study enrolment procedures were identical to those detailed 
above, but in addition a urine sample was collected for testing with LF-LAM. The authors 
compared the yield from algorithms which started with CRP-based screening (instead of 
the WHO tool) and were followed by confirmatory testing with 1) urine LF-LAM if CD4 
count < 100 cells/mm3, and Xpert on sputum if CD4 ≥ 100 cells/mm3 or LF-LAM negative; or 
2) as per 1) but followed by sputum mycobacterial culture if the Xpert result was 
negative. Amongst 1245 participants 88% were WHO tool positive, 40% fulfilled CRP 
screening criteria (≥8 mg/L), median CD4 count was 153 cells/mm3, and TB prevalence 
was 16%. CRP ≥8 mg/L followed by Xpert had a comparable yield to WHO tool followed by 
Xpert (sensitivity 59% vs. 56% respectively), but fewer Xpert tests were required per TB 
diagnosis. A large number of those enrolled (15%) were excluded from analyses because of 
incomplete sputum culture results for purposes of assigning TB case definitions. The 
sensitivity of this algorithm is therefore also likely to be biased and again probably 
overestimated. For the reasons  already discussed above, the findings from this study may 
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not translate into improved diagnostic yield when used for intensified case finding in a 
population stable in HIV care.  
 
Chest x-ray and ID-TB/HIV algorithm 
Screening for TB using chest radiography at every clinical encounter is clearly not 
practical, feasible, or even desirable because of the amount of radiation exposure 
entailed. Studies undertaken in which at least 50% of enrolees were on ART have reported 
sensitivities of chest radiograph findings suggestive of active pulmonary TB ranging from 
71%142 to 95%.239 The latter reported sensitivity was from a study which enrolled a 
convenience sample and participants were highly symptomatic. The estimate is therefore 
biased and it is highly likely that those who participated did so because they were unwell 
and more likely to have had TB. Khan et al reported improved sensitivity for 
bacteriologically-confirmed TB in individuals on ART using an algorithm comprising either 
WHO tool positive or any abnormality on chest x-ray vs. WHO tool alone (52% vs. 77%).138 
The limitations of this study have been detailed in the literature review, in particular a 
large number of exclusions from the study which will bias the estimate of sensitivity. 
The ID-TB/HIV algorithm has already been discussed in the literature review.72 It is used in 
Southeast Asia prior to ART initiation, and its performance has been evaluated in Kenya in 
a population newly enrolling in HIV care. Their symptom screen had a sensitivity of 72.5% 
for bacteriologically confirmed TB, which was similar to the performance of the WHO tool 
in this setting.    
 
Triage test to prioritise PLHIV with WHO tool symptoms for Xpert 
Two methods have been investigated to prioritise PLHIV reporting WHO tool symptoms for 
confirmatory diagnostic testing. Shapiro et al237 investigated the diagnostic accuracy of 
CRP amongst individuals at HIV-positive diagnosis in South Africa who reported WHO tool 
symptom(s).237 The authors used a composite reference standard of clinical and 
bacteriologically-confirmed TB. A cut-off of ≥5 mg/L attained the TPP minimum target for 
sensitivity (99%), but lacked specificity (48%). Limitations of this study include its 
retrospective design, and verification bias because participants did not undergo 
standardised investigation for TB at enrolment, which was instead dependant on a 
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clinician’s assessment at enrolment. Hence the sensitivity reported is likely to be biased 
and probably overestimated. 
Balcha et al176 derived a clinical score to determine the risk of bacteriologically-confirmed 
TB, using data collected as part of a prospective cohort study screening clinic attendees in 
Ethiopia prior to ART initiation. Their final model is discussed in the literature review 
(Table 2-7). Although their score is intended to be simple to use, the inclusion of the 
Karnofsky score and haemoglobin levels do not make for ease of use in busy primary care 
settings. The parent study from which the data were derived enrolled only participants 
who could produce sputum, greatly limiting generalisability, and probably resulted in an 
overestimation of the sensitivity of the score. Those who could produce sputum were 
probably more unwell, and therefore more likely to have had TB. A clinical score of ≥2 
(maximum score 5) to trigger diagnostic testing in individuals with WHO symptoms, 
enabled 53% (414/784) of all participants vs. 20% (159/784) if only the WHO tool had been 
used to avoid a diagnostic test. This strategy missed 7.2% (30/414) of TB diagnoses in 
those who were not investigated, compared with using the WHO tool alone, which missed 
6.3% (10/159). Their prediction model has not yet undergone any form of validation and 
does not fulfil the minimum TPP for a triage test (Table 9-1). 
The clinical score derived using XPHACTOR study data (Research Paper 2, Chapter 6) was 
designed for the same purpose as that of the aforementioned study by Balcha et al.176 Our 
tool is simpler to use and has been internally validated. A cut-off score of ≥3 (maximum 
score 16) did exceed the 90% minimum sensitivity for a triage test, but it lacked 
specificity. It did, however, miss a smaller proportion of TB diagnoses in those who were 
not tested (3% [9/331]) compared with Balcha et al.176 However, the study populations are 
not comparable, ours was a population established in HIV care, with a much lower 
prevalence of confirmed TB (3.4%), compared with their participants who were screened 
for TB prior to ART initiation and had a much higher prevalence of TB (16.9%).  
 
 
Summary  
Alternative options to the WHO tool followed by confirmatory testing with Xpert have 
been investigated for PLHIV prior to ART initiation and at new HIV diagnosis. These are  
LF-LAM, CRP, chest radiography, an alternative clinical algorithm, and a clinical score to 
triage symptomatic individuals for confirmatory testing. Only POC CRP at cut-off ≥8 mg/L 
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attains the minimum sensitivity and specificity requirements stipulated by the WHO for a 
triage test, or for use in anyone attending for care with a risk factor for TB such as HIV. 
This test has only been evaluated in a population at very high risk of TB, those newly 
diagnosed HIV-positive, who should arguably all be investigated for TB. These studies are 
limited by a large number of exclusions, which is likely to have resulted in biased 
estimates of sensitivity, and their findings cannot be generalised to other patient 
populations. Other than the clinical score derived in this thesis, no other algorithms have 
been evaluated for TB screening in a population established in HIV care.   
 
9.2.2. Alternative pathways following a negative initial Xpert result   
In Research Paper 3, we reported limited utility from repeating Xpert on a fresh sputum 
sample for individuals with an initial negative test result. We found that only 5/28 
participants with an initial negative Xpert result who fulfilled our study case definitions 
for TB were identified by the repeat Xpert. Studies evaluating the incremental yield from 
repeating Xpert suggest that testing more than one sample does improve the diagnostic 
yield of Xpert. Studies investigating factors that impact on the yield of Xpert from sputum 
suggest that early morning,187 induced,189 and mucopurulent186 sputum provide a better 
diagnostic yield. These studies, which are discussed in the literature review, collected 
samples from participants attending because of TB symptoms or prior to ART initiation, 
and mainly collected multiple samples at enrolment. The increased yield may simply 
reflect the much greater proportion of participants in these studies who did actually have 
TB, compared with that reported in research paper 3. Our repeat sputum sample was 
collected from participants who had already had an initial Xpert result, so if they did have 
TB they were more likely to have paucibacillary disease which would be harder to detect. 
We did not induce sputum, and collected a spot rather than a morning sample for the 
repeat sputum, to better reflect what happens in real life, and this might have impacted 
on our reported yield from the repeat Xpert test. We froze the repeat sputum sample for 
later testing with Xpert, but the storage, testing and processing are all in accordance with 
that reported from other published studies.56  
The study population in research paper 3 was at high risk of TB, but not typical of those 
who would traditionally follow this pathway, i.e. firstly identified by the WHO tool as 
symptomatic and subsequently following the Xpert-negative pathway because they 
remained symptomatic. We included participants from whom we collected sputum 
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samples, irrespective of the presence of WHO tool symptoms, because they were deemed 
at high risk of TB, i.e. those pre-ART with CD4 count <200 cells/mm3, and all enrolled 
from HTC services. This was in order to ensure sufficient TB diagnoses to enable a 
comparison to be made. These individuals, if asymptomatic but later diagnosed with TB, 
are likely to have been less unwell at the time that the initial and repeat samples were 
collected, and had paucibacillary disease which would have been missed by Xpert. 
Irrespective of the strategy used, repeat Xpert or Xpert-negative pathway, both require 
multiple clinic attendances for patients. In XPHACTOR we found considerable drop out 
along the cascade of care for this pathway, in terms of attendance for chest radiograph or 
review of response to antibiotic trial, and more efficient strategies need to be considered. 
One potential strategy is the upfront collection of two sputum samples from all 
symptomatic individuals, with testing of the second sample determined by the result of 
the initial Xpert. Another strategy is the diagnostic algorithm derived using CART analysis 
by Cain et al in the pre-Xpert era, in which empiric TB treatment is commenced based on 
chest radiography and CD4 cell counts whilst awaiting sputum TB culture results.72 
  
9.2.3. Other causes for TB symptoms  
Research Paper 4 describes a small number of individuals with persistent symptoms 
suggestive of TB whom we extensively evaluated using simple tests which should generally 
be available within primary or secondary level settings in LMIC. The most common criteria 
for entry to this study were measured weight loss and cough. The most common final 
diagnoses were weight loss due to severe food insecurity, TB, other respiratory tract 
infections and post-TB lung disease.  
This study is the first to systematically evaluate patients established in HIV care with 
persistent or recurrent symptoms suggestive of TB, and with an initial negative Xpert 
result among those able to produce sputum, for a broad spectrum of diagnoses. The only 
other comparable study is from Munyati et al who investigated primary care attendees 
with chronic cough and also identified a high proportion of non-communicable disease 
diagnoses, in particular post-tuberculous disease, asthma and heart failure. We also found 
post-TB chronic lung disease to be a relatively common diagnosis; better criteria to 
distinguish it from active TB and to guide optimal management are needed. 
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9.3. Implications of this research  
The journey an HIV-positive individual takes through care can be divided into the initial 
diagnosis, ART initiation with or followed by IPT, and subsequent routine attendances for 
HIV care (to monitor treatment success and collect medication), all interspersed with 
attendances for other medical conditions, which may or may not be HIV-related. 
Differentiated care delivery models are encouraged with task-shifting to enable ART pick-
up for stable patients at more convenient times, locations and frequencies. The definition 
of “stable” individuals can vary from the WHO criteria of someone who has received ART 
for at least one year with evidence of treatment success (based on viral load suppression, 
or if not available, on rising CD4 count); in South Africa viral load suppression after 3-6 
months suffices.241 Since 2010 HIV care in South Africa has been routinely provided by 
nurses in primary health clinics, rather than at hospital-based clinics. The rollout of treat-
all risks overloading these clinics and strategies to reduce workload, such as reducing the 
frequency of visits, are required. 
Ongoing heightened risk of TB in PLHIV mandates screening at each of the aforementioned 
encounters. However, the risk of TB and/or negative consequences of missing TB are 
arguably greatest at initial HIV diagnosis, prior to ART initiation, during the first few 
months of ART, and prior to IPT initiation. Further investigation and the exclusion of TB in 
individuals who are WHO tool positive should enable the diagnosis and treatment of the 
actual disorder responsible for these symptoms. Other considerations arising from the TB 
screening pathway which cannot be ignored are the negative sequelae and impact of a 
false-positive diagnosis resulting in unnecessary TB treatment,242 and the inconvenience of 
repeated visits for further investigations and test results in those false-positives identified 
on screening.  
We have shown that the WHO tool is less sensitive but more specific for screening 
individuals on ART for TB, and in our study the prevalence of confirmed TB in the on ART 
group was half (2.4%) that of the pre-ART group (5.1%). Screening a population established 
on ART using the WHO tool will therefore miss more TB diagnoses than if the tool were 
used in a pre-ART population. The higher specificity in those on ART will result in fewer 
people undergoing unnecessary diagnostic testing, but one-third of this group (who should 
all have been previously screened for TB) reported WHO tool symptoms at enrolment and 
therefore required investigation for TB. The PPV of the WHO tool in the on ART group for 
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confirmed TB was very low (5%), so the vast majority of those identified by the tool will 
not have TB. The NPV was very high, enabling TB to be reliably ruled out and IPT provided. 
The volume of confirmatory diagnostic testing needed as a result of using the WHO tool at 
every clinical encounter for individuals established on ART, which will become the case for 
all PLHIV as treat-all is implemented, will be large (potentially one-third of all attendees). 
Individuals who are stable on ART should have previously been screened for TB and if 
indicated investigated for TB; hence if they are later diagnosed with TB they are more 
likely to have been less unwell at previous screening, and probably had paucibacillary 
disease. Repeated rounds of screening should identify (and treat) first those who are most 
symptomatic and those with the highest bacillary load. Therefore, in a resource-limited 
setting individuals who are stable on ART, particularly those with higher CD4 cell counts or 
those on IPT who are likely to have been recently investigated for TB, could be screened 
at less frequent intervals. This is probably inevitable in the future if longer supplies of ART 
are provided and to reduce the workload at overstretched clinics, and PLHIV need to be 
aware of the importance of attending for investigation if they become unwell in between 
scheduled clinic attendances. Additionally, a different screening and investigation 
algorithm could be considered, such as a triage test to prioritise investigation amongst 
those who are WHO tool positive, or POC CRP instead of the WHO tool. These strategies 
require further evaluation in populations established in HIV care, and different 
investigation pathways for different groups of PLHIV may prove too complicated to 
implement. Alternative algorithms to the Xpert-negative pathway are also needed, as 
there is a high potential for drop out due to the number of visits and investigations 
needed. Simply repeating the Xpert does not appear useful, in contrast with WHO 
recommendations.127 
This thesis focussed on individuals established in HIV care at a time when a division was 
present between those in pre-ART care, who received CD4 monitoring and TB preventive 
therapy, and those on ART. Most of our on ART group had been so for more than one year, 
so are likely to have fulfilled the criteria for “stable”, although we do not have the data 
to confirm this. Therefore, the findings from this large cohort of patients stable on ART, 
one-third of whom reported WHO tool symptom(s) is of particular relevance in the era of 
treat-all to HIV care programmes. There is a great need for a better tool for TB screening 
in the context of active case finding for those stable in HIV care, and alternatives to the 
onerous Xpert-negative pathway. Diagnostic tools are not the only answer, as the rollout 
of Xpert has proven, and good health systems infrastructure is also needed. 
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Impact of recent changes in HIV care and TB diagnostics on this research 
This research commenced in 2012 and subsequent changes in HIV care, in particular treat-
all, the recommendation for viral load rather than CD4 count monitoring, and next-
generation diagnostics will impact upon our findings. Treat-all should realise ART initiation 
at higher CD4 counts, so PLHIV should become less symptomatic, the prevalence of TB 
should become lower in this population, and there should be less extrapulmonary disease. 
The characteristics of individuals attending for HIV care are likely to change over time 
with treat-all, and therefore the performance of the WHO tool in this population will 
differ from the pre-ART population in which it was originally developed; it is likely to be 
less sensitive and more specific. The PPV of any TB screening tool will reduce as the 
prevalence of TB declines. A lower PPV will generate a greater number of false-positives, 
and a larger number of people to be screened in order to identify one TB diagnosis. 
Differentiated ART delivery models may result in fewer clinic visits for routine HIV care 
and therefore a longer interval between rounds of TB screening, or screening by 
alternative cadres of healthcare worker e.g. pharmacists or lay community health care or 
peer group workers. The clinical score derived in research paper 2 requires ART status and 
CD4 cell count; in the future viral load should also be considered for incorporation in this 
model, as CD4 counts may be measured less frequently.  
The arrival of Ultra, which is more sensitive but less specific than Xpert, may reduce the 
proportion of indivduals requiring chest radiograph and sputum culture along the Xpert-
negative pathway. However, a negative Ultra or Xpert result in a PLHIV who remains 
symptomatic should not halt further evaluation along the Xpert-negative pathway, as this 
risks missing TB diagnoses. On the other hand, false-positive diagnoses arising from the 
lower specificity of Ultra may result in unnecessary TB treatment being provided, 
particularly in those previously treated for TB; and strategies to address this phenomenon 
are required. The next-generation LAM test, which improves on sensitivity, may make it 
more suitable as a screening test, providing it remains a simple test suitable for point-of-
care use. 
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9.4. Limitations and strengths   
9.4.1. Limitations  
The main limitations of this study are in the selection of participants for research papers 3 
and 4, which limit the generalisability of study findings, and in the development of the 
clinical prediction model. These are discussed below in greater detail. 
In retrospect, the dataset used for developing the clinical prediction model was too small 
to use the split sample method for derivation then validation. It would have been better 
to use the entire dataset to develop the prediction model. Imputing missing values might 
have enabled development of a model more relevant to the era of treat-all, which could 
include viral load. Internal validation should have been undertaken using a resampling 
technique such as bootstrapping. Univariate analysis was used to preselect some of the 
candidate predictors, and the EPV was less than 10, i.e. the model is likely to have been 
overfitted; statistical methods for developing prediction models when there are few 
events should have been considered.243 The model requires external validation before it 
can be utilised in practice. 
We enrolled participants to the repeat Xpert study (Research Paper 3) based on risk of 
TB, rather than on symptoms, and in fact some participants were asymptomatic at 
collection of both the initial and the “repeat” sputum samples. In reality patients would 
only follow the Xpert-negative pathway if they still had symptoms following an initial 
negative Xpert. Our comparator to the repeat Xpert was pragmatic and in line with routine 
clinical practice. The components of the Xpert-negative pathway could not always be 
performed on the same day as collection of the sputum sample for repeat Xpert, but 
rather in a sequential manner reflecting “real-life”. One could argue that it was unfair to 
compare Xpert on a sputum sample collected one week following the initial Xpert test 
with potentially multiple different investigations during the course of study follow-up. The 
negative repeat Xpert in this scenario might just reflect paucibacillary disease, and indeed 
we did have participants who were diagnosed with TB by Xpert on a sputum sample 
collected later during study follow-up.   
For Research Paper 4, if we had required the presence of the same symptom(s) reported 
both at enrolment to XPHACTOR and at the 3-month visit for inclusion in this study, we 
would have enrolled very few participants. Therefore, in order to ensure sufficient 
participants, we defined persistent weight loss as objectively measured significant weight 
loss, which was subjectively confirmed as unintentional weight loss by the patient at the 
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3-month visit. Consequently, weight loss and cough were the most common symptoms 
based on which we enrolled to this substudy, and our final diagnoses may not be 
representative of findings from other HIV care settings. We were also limited in terms of 
the extent of investigation that we were able to undertake, but these do reflect 
investigations commonly available at primary or secondary care level in LMIC. 
Our study population was mainly individuals established in HIV care, but in reality, 
amongst those in the pre-ART group who were exclusively enrolled from CHCs, a 
proportion had only received their HIV-positive diagnosis a few weeks previously. This is 
reflected in the IQR for the median time in HIV care for this group of 7 months (IQR 1-30).  
In our assessment of the diagnostic accuracy of the XPHACTOR algorithm and the WHO tool 
we excluded all unclassifiable TB outcomes. Although this did not entail many exclusions, 
it might have been better to either impute these values, or present “best” or “worst” case 
scenarios, by computing diagnostic accuracy after including the individuals as firstly 
having TB and then subsequently as not having TB. 
 
9.4.2. Strengths  
Strengths of this study include its prospective design, collection of sputum from all 
participants at enrolment (irrespective of symptoms) for testing with Xpert (immediate or 
stored for later testing). All participants were followed for a period of around three 
months, with repeat TB screening and investigation if indicated. At the 3-month visit all 
participants had sputum and blood collected for mycobacterial culture; our study 
retention rates were high. We also facilitated the Xpert-negative pathway in those with an 
initial negative Xpert. Thus, we are unlikely to have missed many TB diagnoses. We did 
not exclude participants who were unable to produce sputum, limiting bias and ensuring 
generalisability. 
As already discussed, our study is unique in its characterisation of a large cohort of 
individuals established in HIV care, with a large proportion on ART; and therefore relevant 
in the era of treat-all. This study population provides a good indication of the frequency of 
reporting WHO tool symptoms and the likely need for confirmatory diagnostic testing if 
the WHO tool is used as recommended, at every clinical encounter.  
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9.5. Conclusions and recommendations   
For a population established in HIV care, the current screening and diagnostic algorithm 
generates a large number of individuals who require a diagnostic test for TB. This is not 
feasible in resource limiting settings, and may impede intensified TB case finding. There is 
evidence that TB screening and investigation algorithms are not adhered to in these 
settings, and particularly with the rollout of treat-all there is a great need for alternative 
strategies. Amongst those at highest risk of TB or negative sequelae of missing TB, i.e. 
those newly initiating ART or prior to IPT, screening with the WHO tool followed by Xpert 
probably remains the best strategy; if resources allow then all should be investigated with 
mycobacterial culture or Xpert. In those stable on ART, who are less likely to have TB than 
those prior to ART or prior to IPT, perhaps a clinical score to triage individuals who have 
WHO tool symptoms, a biomarker such as CRP used as a POC screening test, or simply 
screening at less frequent intervals could be considered to preserve limited resources. 
This would rely on patients having a high level of awareness to present passively if they 
developed any symptoms of TB. At present no published tools, except for POC CRP, fulfil 
the WHO TPP for a triage test, and all strategies require further evaluation in a population 
established on ART, as most studies were undertaken prior to ART initiation or IPT. 
The Xpert negative pathway is onerous on both patients and healthcare workers, with 
patients being lost along the diagnostic cascade, and alternative strategies are needed. 
However, it is important to keep looking for TB in individuals with symptoms, using all 
available modalities. With the advent of treat-all, and PLHIV established on ART for longer 
periods of time, it is also important to identify non-communicable disease related causes 
if they have persistent symptoms suggestive of TB but negative TB investigations. Post-
tuberculous lung disease requires better criteria to distinguish it from active TB, and 
respiratory physicians need to be more easily accessible at primary care level to help 
better diagnose and manage this condition and also cough which we found was the most 
commonly reported WHO tool symptom.  
Future research is needed to externally validate our clinical score for TB; evaluate POC 
CRP as an alternative to screening using the WHO tool in populations established on ART 
(although even <US$2 per test may be too expensive if a large volume of testing is 
required); and derive speedier options to the Xpert-negative pathway.  
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10) Appendices 
10.1. Ethical approvals 
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10.2. XPHACTOR participant information sheet and consent form 
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10.3. XPHACTOR enrolment questionnaire 
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10.4. Standard operating procedures for clinician assessment for “Causes of 
TB symptoms” study 
 
A. Purpose: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ting Procedure is to establish a safe and non-invasive method of induction and 
processing of sputum 
 
 
 
  
 
To outline the following 
1) Clinical evaluation performed by research clinician at initial assessment of participants enrolled 
to Aim 3 including: 
a) Assessment of all participants  
b) Assessment specific to those reporting cough 
c) Assessment specific to those with ≥5% measured unintentional weight loss since enrolment   
d) Assessment specific to those reporting fever / night sweats 
2) On-going evaluation by research clinician of participants enrolled to Aim 3 
3) Assignment of final diagnosis 
 
B. Scope: 
Applies to all staff involved in the follow-up of participants at XPHACTOR study sites. 
 
 
C. Responsibilities: 
The Project Manager is responsible for: 
• Ensuring that sites are appropriately resourced to perform XPHACTOR study procedures  
 
The Research Clinicians are responsible for: 
• Ensuring adherence to this SOP 
Laboratories: 
Centre for Tuberculosis (CTB), National Institute for Communicable Diseases 
1) TB culture (sputum, urine, stool) and may undertake TB microscopy and culture from FNA if 
requested. 
 
Centre for Respiratory Diseases and Meningitis (CRDM), National Institute for Communicable 
Diseases 
• PCR and culture for pertussis and atypical bacteria, and sputum for MC&S. 
 
Clinical Lab Services (CLS), Spencer Lister Building, NHLS Complex 
2) All other Aim 3 samples, unless the responsible clinic physician requests these are sent via the 
routine clinic system 
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1.  Research 
Clinician  
 
Overview of initial assessment by research clinician 
The research clinician (RC) will assess ALL participants enrolled in study 
Aim 3 at an appointment arranged by the research team at the 3-month 
visit (see SOP XPH-015). The assessment should occur within 2 weeks of 
the 3-month visit. 
This assessment will include: 
1) Performing a clinical assessment using case report form (CRF) 
AIM3_002. 
2) Reviewing the participant’s study file and clinic notes and completing 
CRF AIM3_File Review. 
3) Arranging a standard set of investigations according to the 
participant´s symptomatology, medical history and previous 
investigations. 
4) Prescribing treatment and providing lifestyle advice, appropriate to the 
suspected diagnosis, in collaboration with the responsible clinic 
physician.   
5) Organising referral for a specialist opinion, when clinically appropriate, 
in collaboration with the responsible clinic physician.  
6) Facilitating admission to hospital if participant is acutely unwell. 
2.  Research 
Clinician  
 
Initial evaluation of ALL participants enrolled in Aim 3  
The RC will 
1) Review the participant’s file and clinic records, for symptom frequency 
and duration, major diagnoses, investigations and results (including all 
TB investigations sent as part of XPHACTOR study or by clinic 
physicians), last cervical smear (if applicable), and treatment to date 
including detailed ART history; and complete CRF AIM3_File Review. 
 
2) Take a history which will include detailed assessment for cough, fever, 
night sweats and unintentional weight loss, review of current 
medications, systems review, and past medical history, date and result 
of last cervical smear (if applicable).  
a) Cough assessment will include: duration, nature and frequency of 
cough; history of preceding respiratory infection; associated 
symptoms and trigger factors; diurnal variation, smoking status 
and environmental exposures; and use of ACE inhibitors. 
b) Assessment for unintentional weight loss will include: direct 
enquiry regarding symptoms suggestive of acute or chronic 
infection, endocrine disease, malignancy, systemic disease, loss 
of appetite or difficulty eating (odynophagia), malabsorption, drug 
or alcohol misuse, psychological illness, loss of body fat since 
starting ART and ART history. 
c) Assessment for fever and/or night sweats will include: duration and 
pattern, assessment for possible focus of infection, malignancy, 
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connective tissue / endocrine / blood disorder, travel history, 
alcohol and drug history, and if female assess for peri-menopause 
/ menopause. 
 
3) Screen / evaluate all participants for the following using validated tools: 
a) Anxiety and depression 
b) Household food insecurity 
 
4) Perform a physical examination, including: 
a) Assessment for lymphadenopathy. 
b) Measurement of temperature (see SOP XPH-015).  
c) Respiratory, cardiovascular and abdominal examination. 
d) Ear, nose and throat examination. 
e) Skin, oropharynx, and palate (e.g. for Kaposi sarcoma, 
candidiasis, and other lesions). 
i) If clinically indicated, refer for biopsy of skin lesion(s). 
f) Urine dipstick for protein, glucose, blood, nitrites, leucocytes; send 
for microscopy, and culture if abnormal and cytology if clinically 
indicated. 
g) Further examination as indicated by history, e.g. for focus of 
infection / neurological / rectal examination / breast examination / 
vaginal examination. 
 
5) If applicable, review of temperature chart that participant has 
completed (thermometers are given at 3-month visit for those who 
report fever or night sweats, for twice daily temperature and 
temperature at time feels feverish / night sweats). 
 
6) Review most recent chest radiograph (CXR) and report, and facilitate 
further management of abnormal CXR findings. All Aim 3 participants 
without CXR in preceding 6 weeks will have had CXR arranged at the 
3-month visit. 
 
7) Arrange the following investigations:    
a) If measured temperature (see 3b) is >38.3: aerobic and anaerobic 
blood cultures will be taken. Blood culture for TB will have already 
been taken at the 3-month visit.  
b) If axillary or cervical lymph nodes display features requiring further 
investigation (see below), RC will facilitate fine needle aspiration 
(FNA). The aspirate will be sent for TB microscopy and cytology 
and, if feasible, also for TB culture.  
If lymph node is exuding caseous material via a fistula, then 
material will be sent for TB microscopy and, if feasible, also for TB 
culture.  
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Features indicating need for FNA are: 
i) large (> 2 cm diameter) or rapidly growing lymph nodes 
ii) asymmetrical lymphadenopathy 
iii) tender/painful lymph nodes not associated with local infection 
iv) matted/fluctuant lymph nodes 
c) If pleural effusion is present on CXR, RC will facilitate diagnostic 
pleural aspiration. The aspirate will be inspected and sent for ADA 
(adenosine deaminase), protein, TB microscopy and culture, 
MC&S (microscopy, culture and sensitivity), cytology and LDH.        
d) Send sputum, stool and urine samples collected by  the participant 
on the day of the assessment for TB culture (CTB) 
3.  Research 
Clinician  
Initial assessment of COUGH: 
CXR will have already been requested for all Aim 3 participants at 3-month 
visit, if no CXR from the preceding 6 weeks (see SOP XPH-015). The 
participant will attend the assessment with this CXR. 
1) FOR ALL participants reporting cough at 3-month visit: 
a) Sputum for TB culture. One sample is sent for all Aim 3 participants 
(early morning sample collected by participant on day of 
appointment with clinician) on the day of Clinician Assessment 
(see above), - this should be induced if participant is unable to 
expectorate spontaneously and there are no contraindications to 
sputum induction. At the three-month visit PN will have also sent a 
sputum sample for TB culture. 
b) Sputum for bacterial culture (MC&S and atypical bacteria). This 
sample was sent at 3-month visit (see SOP XPH-015). 
c) Nasopharyngeal swab and oropharyngeal swabs for PCR 
(pertussis and atypical bacteria). These samples were sent at 3-
month visit (see SOP XPH-015). 
 
2) For participants reporting acute cough (≤3 weeks):  
a) Sputum samples for MC&S, atypical bacteria, and TB investigation 
already sent (see above). 
b) If pneumonia suspected (cough and at least one of new focal chest 
signs, fever > 4 days or dyspnoea / tachypnoea, pulse>100, and 
without other obvious cause): 
i) Send blood for FBC and differential, CRP. 
ii) Arrange CXR if no CXR since onset of cough. 
iii) Take aerobic and anaerobic blood cultures.  
iv) If feasible send blood for serology for atypical bacteria 
(Mycoplasma pneumoniae, Chlamydophila pneumonia, 
Legionella spp, and Coxiella).    
 
3) For participants reporting subacute cough (>3 to <8 weeks) 
a) Ensure that two spontaneous and one induced (if feasible and 
there are no contraindications to induction [see SOP XPH-008]) 
sputum sample have been sent for TB culture within the last 2 
weeks. 
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b) If cough has not followed an obvious preceding respiratory tract 
infection, then investigate further as per chronic cough. 
 
4) For participants reporting chronic cough (≥8 weeks):  
a) Ensure that two spontaneous and one induced (if feasible and 
there are no contraindications to induction – [see SOP XPH-008]) 
sputum samples have been sent for TB culture within the last 2 
weeks. 
b) Send blood for FBC, differential and CRP, if no recent result (within 
last 1 month). 
c) Refer all for spirometry pre- and 20 minutes post- 400mcg inhaled 
salbutamol via large volume spacer / 5mg nebulised salbutamol 
(or 10mg  nebulised terbutaline / 500mcg terbutaline via large 
volume spacer), unless contraindicated. A referral letter is required 
to the respiratory clinic / spirometry provider. Spirometry should 
not be requested for patients who have had any of the following 
within last 3 months:  
i) Unstable  cardiovascular status: 
(1) Myocardial infarction / unstable angina 
(2) Pulmonary embolism 
(3) Uncontrolled hypertension 
ii) Surgery: 
(1) Hernia repair 
(2) Eye surgery 
(3) Thoracic / abdominal / other major surgery 
iii) Pneumothorax. 
iv) Ear Infection 
v) Haemorrhagic cerebrovascular event 
vi) 3rd Trimester pregnancy 
vii) Haemoptysis of unknown origin 
 
Preparation instructions for spirometry should be given to 
participant, i.e. avoid   
i) a large meal 2 hours pre-testing  
ii) smoking for 24 hours pre-testing 
iii) drinking alcohol 2 hours pre-testing 
iv) taking short acting bronchodilators 6 hours pre-testing  
v) taking long acting bronchodilators for 12 hours pre-testing 
vi) taking sustained release theophyllines 24 hours pre-testing 
d) Assess cough severity using visual analogue scale (VAS, 0-
100mm). 
 
5) For participants with features suggestive of cardiac failure 
(orthopnoea / paroxysmal nocturnal dyspnoea / exertional dyspnoea / 
peripheral oedema): measure serum natriuretic peptides. 
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6) If Pneumocystis jiroveci pneumonia is likely, i.e. participant has the 
following: 
a) CD4 <200 cells/µl and 
b) fever / exertional dyspnoea / tachypnoea, with or without  
c) characteristic chest radiograph features (bilateral diffuse/mid-zone 
symmetrical ground-glass or interstitial shadowing) 
Discuss referral to hospital / for admission with responsible clinic 
physician and if feasible arrange the following investigations: 
i) Bronchoalveolar lavage (BAL) fluid (induced sputum if BAL not 
available) for cytology for Pneumocystis jirovecii cysts.  
ii) Serum for 1,3-β-D-glucan 
iii) Exercise oximetry 
 
Initial management plan for cough: 
1) TB likely: Facilitate TB treatment if positive sputum results (Xpert or 
AFB/TB culture). If negative or pending microbiology and CXR features 
of active TB, facilitate TB treatment (discuss first with responsible clinic 
physician). 
 
2) If any red flags (see Appendix 1): Persistent haemoptysis in smokers 
or ex-smokers who are ≥40 years or a chest X-ray suggestive of lung 
cancer: refer urgently to chest physician for assessment (including CT 
scan of chest or bronchoscopy as deemed clinically appropriate). 
Consider FBC and differential at same time as arranging referral. 
 
3) Pneumocystis jiroveci pneumonia likely: Participant should be 
managed by responsible clinic physician, as admission is likely to be 
required, although mild cases might be managed on an outpatient 
basis with high dose trimethoprim-sulfamethoxazole for 21 days and 
prednisolone.   
 
4) Acute cough (≤ 3 weeks) 
a) Suspect common cold if: nasal congestion / discharge, postnasal 
drip, sneezing and sore throat. Advise symptomatic treatment. 
b) Suspect influenza if: fever with ≥1 of headache, myalgia, cough 
and sore throat. Advise symptomatic treatment. 
c) Suspect community acquired pneumonia (CAP) if:  cough and 
at least one of new focal chest signs, fever > 4 days or dyspnoea 
/ tachypnoea, pulse>100, and without other obvious cause. 
Definite CAP if above supported by CXR findings of lung 
shadowing that is likely to be new.  
i) Prescribe antibiotics (amoxicillin first-line, and tetracycline or 
macrolide in case of hypersensitivity), and review response to 
treatment. Advise patient to return if no clinical improvement 
in 3 days or any deterioration, or if symptoms take longer than 
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3 weeks to resolve. Discuss admission with responsible clinic 
physician if CRB-65 severity score>0 (1 point for each of the 
following). 
(1) Confusion 
(2) Respiratory rate ≥30/min 
(3) Systolic BP<90 or diastolic BP≤60 mm Hg 
(4) Age ≥ 65 years 
 
d) Suspect acute bronchitis if:  
i) Cough associated with at least one of sputum production / 
dyspnoea / wheeze / chest discomfort or pain, and  
ii) No evidence of pneumonia (clinical or radiographic), and  
iii) Common cold, acute asthma, and exacerbation of COPD have 
been ruled out. 
Usually viral in origin, and hence antibiotics are not routinely 
indicated. Bronchodilators may be useful if wheezing present. 
e) Suspect exacerbation of pre-existing condition if:  
i) History of bronchiectasis and acute deterioration, with 
worsening cough (with increased sputum volume, viscosity, 
or purulence; with or without increasing wheeze, 
breathlessness, or haemoptysis) and/or systemic upset. 
(1) Ensure sputum has been sent for culture and sensitivity, 
and discuss with responsible clinic physician regarding 
appropriate antibiotic prescription and other 
recommended treatment / admission 
ii) History of asthma and acute dyspnoea / wheeze / chest 
tightness 
(1) If admission is not required arrange bronchodilator and 
prednisolone prescription. 
iii) History of COPD and increasing dyspnoea / purulent sputum / 
clinical signs of pneumonia 
(1) advise increased frequency of bronchodilator use 
(2) prescribe oral steroids if significant increase in 
breathlessness 
(3) prescribe antibiotics if purulent sputum or signs of 
pneumonia 
 
f) Suspect pertussis if:  
i) Suspected case: acute cough lasting for ≥14 days, without an 
apparent cause plus one or more of the following 
(1) Paroxysms of coughing  
(2) Post-tussive vomiting  
(3) Inspiratory whoop and 
(4) Absence of laboratory confirmation  
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ii) Confirmed case: signs and symptoms of pertussis with B 
pertussis isolated from respiratory sample or confirmed B. 
pertussis PCR positive in a respiratory clinical specimen 
• Provide antibiotic therapy if within 3 weeks of onset of illness: 
azithromycin 500mg od for 3 days / clarithromycin 500mg for 
7 days / if pregnant erythromycin 500mg qds for 7 days / if 
macrolide contraindicated cotrimoxazole 960mg bd for 7 days 
(not in pregnancy). 
 
5) For chronic cough  
a) Suspect bronchiectasis if chronic cough with copious sputum 
production and/or suggestive chest x-ray, discuss with 
responsible clinic physician regarding referral to chest physician 
for CT scan of chest and further management. 
b) Suspected heart failure:  
i) If serum natriuretic peptides raised or high facilitate 
echocardiogram 
(1) High levels:  BNP > 400 pg/ml (116 pmol/litre) or 
NTproBNP > 2000 pg/ml (236 pmol/litre) 
(2) Raised levels: BNP 100–400 pg/ml (29–116 pmol/litre) or 
NTproBNP 400–2000 pg/ml (47–236 pmol/litre)   
ii) Arrange further management according to clinical symptoms 
and echocardiogram findings, in collaboration with clinic 
physician. If no access to echocardiogram, arrange 
electrocardiogram. 
c) If spirometry performed: 
i) Ensure quality control (see Reference 4. Levy et al): 
(1) Within-manoeuvre criteria - individual spirograms are 
acceptable if: 
(a) They are free from artefacts i.e. free from: 
(i) Cough during first second of exhalation 
(ii) Glottis closure that influences measurement  
(iii) Early termination or cut-off 
(iv) Effort that is not maximal throughout 
(v) Leak or obstructed mouthpiece 
(b) They have good starts: 
(i) Extrapolated volume <5% of FVC or 0.150 L, 
whichever is greater 
(c) They show satisfactory exhalation 
(i) Duration ≥6s for adults or plateau in volume time 
curve or 
(ii) If patient cannot or should not continue to exhale 
 
(2) Between-manoeuvre criteria, -apply the following tests 
after three acceptable individual spirograms have been 
obtained: 
(i) Two largest values of FVC must be within 0.150 L 
of each other, & 
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(ii) Two largest values of FEV1 must be within 0.150 
L of each other 
 
If the above criteria are not met then testing should be 
continued until both criteria are met, or total of eight 
tests have been performed, or patient cannot / should 
not continue. 
Three satisfactory manoeuvres should be saved. 
ii) If FEV1/FVC <0.7 and >400ml improvement in FEV1 after 
bronchodilator, treatment trial for asthma (200mcg inhaled 
beclomethasone twice daily for 6 weeks, or oral prednisolone 
30mg daily for 2 weeks) and review clinical response. 
iii) If FEV1/FVC <0.7 and FEV1< 80% predicted, age>35yr and 
smoking history (or history of exposure to air pollution, e.g. 
wood burning stove), without >400ml improvement in FEV1 
after bronchodilator, treat for COPD for 6-8 weeks and review 
clinical response. 
 
d) If spirometry is not available and high probability of asthma 
(see features listed below), start treatment trial for asthma, and 
review clinical response. 
(1) >1 of cough, wheeze, breathlessness, chest tightness 
especially if symptoms are: 
(a) worse at night and in early morning 
(b) in response to exercise, allergen exposure and cold 
air 
(c) after taking aspirin or beta blockers 
(2) History of atopy 
(3) Family history of atopy or asthma 
(4) Widespread wheeze 
(5) Otherwise unexplained eosinophilia 
 
e) If participant complains of frequent gastrointestinal 
symptoms suspect gastro-oesophageal reflux disease 
(GORD): Symptoms include daily heartburn (sensation of 
discomfort or burning behind the sternum rising up to the neck) or 
regurgitation (effortless return of stomach contents into the 
pharynx), cough worse with or after meals/stooping, cough on 
phonation, dysphonia, and abatement of cough during sleep.   
If any red flag symptoms (Appendix 1) facilitate urgent referral 
for endoscopy:  
i) Dyspepsia in patient aged ≥55 years with onset of dyspepsia 
<1yr previously / continuous symptoms since onset 
ii) Dysphagia at any age 
Appendices 
Page | 259  
 
D. SOP Text 
 Step Responsibility Activity 
iii) Dyspepsia at any age with any of: anaemia, persistent 
vomiting or weight loss  
iv) Dyspepsia with any of: family history upper GI cancer in >2 
first-degree relatives, Barrett's oesophagitis, pernicious 
anaemia, peptic ulcer surgery >20 years previously, known 
dysplasia, atrophic gastritis, intestinal metaplasia, jaundice, or 
upper abdominal mass 
 
If no red flags treat as GORD: 
• Provide diet and lifestyle advice: Reduce weight if overweight, 
stop smoking, reduce alcohol and aggravating foods (fat, 
chocolate, citrus), raise the head of the bed, and avoid eating 
during the three hours before going to bed. 
• Provide trial of PPI (e.g. omeprazole 20mg twice daily) for 8 
weeks (30 minutes before food) and review response. If no 
improvement discuss with responsible clinic physician 
regarding referral for upper gastrointestinal endoscopy. 
 
f) If upper airways symptoms predominate suspect upper 
airways disease: Symptoms include post nasal drip (sensation of 
having something drip down into throat), persistent nasal 
discharge / congestion, and recurrent need to clear throat).  
 
Differential diagnoses include: 
i) Allergic rhinitis: suggested by sneezing and itching eyes / ears, 
and may be seasonal or perennial. Provide steroid nasal spray 
/ antihistamine and review response at 8 weeks. 
ii) Post-viral: suggested by preceding upper respiratory tract 
infection (URTI). Provide antihistamine and review response 
at 8 weeks. 
iii) Secondary to chronic sinusitis: suggested by symptoms > 12 
weeks of facial discomfort (often unilateral and worse when 
bending forwards) or pain; nasal obstruction or (purulent) 
nasal discharge or postnasal drip; and decreased or absent 
sense of smell. Provide steroid nasal spray for 12 weeks and 
review response. Consider ENT referral. 
iv) Anatomic abnormality e.g. deviated nasal septum / nasal 
polyp. Refer for ENT opinion (unilateral polyp may be a sign of 
malignancy).   
v) Rhinitis medicamentosa most commonly due to long-term use 
of topical decongestant. Withdraw offending agent one nostril 
at a time.     
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g) If on ACE inhibitor, discuss replacing this (e.g. with angiotensin 
receptor blocker or other alternative) with responsible clinic 
physician. If replaced, review response at 4 weeks and 12 weeks 
as ACE inhibitor-induced cough may linger for up to 3 months in a 
subgroup of individuals. 
 
6) If current smoker: Provide smoking cessation advice, and review 
response at 8 weeks post-cessation: 
a) Ask about smoking. 
b) Advise participant to quit smoking unless there are exceptional 
circumstances. 
c) If participant is interested in quitting provide advice, which may 
include attending a smoking cessation service if available, or 
discussing pharmacotherapy (not available within public sector in 
South Africa). 
d) If participant is not ready to quit ask him/her to consider the 
possibility and encourage seeking help in the future.  
 
SECOND LINE if no clear diagnosis for COUGH identified 
1) Suspected TB: after discussion with responsible clinic physician treat 
for TB and review response to treatment.   
 
2) Referral to respiratory physician for further respiratory investigation 
e.g. bronchoscopy if deemed appropriate 
4.  Research 
Clinician   
Initial assessment of UNINTENTIONAL WEIGHT LOSS: 
Defined as: ≥ 5% measured weight loss since enrolment. 
For ALL: 
1) Complete lipodystrophy assessment CRF 
2) Blood tests:  
a) FBC and differential count, renal function, liver function, HbAlc, 
thyroid function.  
3) Repeat CXR if no CXR in last 4 weeks. 
4) Abdominal ultrasound scan 
5) If diarrhoea (loose or liquid stools more than three times daily) 
reported:  
a) Stool for microscopy, bacterial culture and parasitology.  
b) Test for clostridium difficile toxin if history of antibiotic prescription 
in last 12 weeks. 
c) Arrange further management if any of the above tests are positive. 
 
6) If any red flags are present discuss with responsible clinic physician 
and refer for as appropriate urgent gastroscopy, gastroenterology / 
surgical / gynaecological opinion and pap smear (review last result if 
available): 
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a) Change in bowel habit, rectal bleeding, dyspepsia, dysphagia, 
melaena, persistent vomiting, unexplained iron deficiency 
anaemia, abdominal or rectal mass, jaundice, see above for 
suspected GORD red flags) 
i) Ensure digital rectal examination if: 
(1) Unexplained lower gastrointestinal tract symptoms 
(2) Male patient with any features suggestive of prostate 
cancer 
ii) Ensure breast examination if patient complains of breast 
symptoms 
b) Intermenstrual bleeding, postmenopausal bleeding, postcoital 
bleeding, alteration in vaginal discharge. Patient requires full pelvic 
examination.  
 
Second line investigations for unintentional weight loss 
1. Blood tests: lactate (if other symptoms of hyperlactataemia or on D4T), 
and discuss with responsible clinic physician. 
5.  Research 
Clinician   
Initial assessment of FEVER / NIGHT SWEAT 
For ALL 
1) Assess for likely focus of infection and travel history (as detailed above 
in “Initial assessment for all”) and arrange further investigation as 
indicated history and examination. 
2) Review participant’s temperature record. 
3) If likely focus of infection identified then: 
a) Respiratory tract infection: evaluate as per section above for 
cough. 
b) Urinary symptoms / abnormal urine dipstick:  MSU for microscopy 
and culture. 
c) Diarrhoea reported (loose or liquid stools more than three times 
daily): stool for microscopy, bacterial culture, and parasitology, test 
for clostridium difficile toxin if history of antibiotic prescription in last 
12 weeks. 
d) Malaria film if indicated by travel history. 
e) Cellulitis / skin lesions (sores / ulcers / oozing lesions) or 
discharging ear: swab if possible and send for microscopy and 
culture.  
f) Abscess identified: refer for incision and drainage, and if feasible 
send sample for MC&S. 
g) Tonsillitis likely, consider throat swab.  
h) Pelvic infection likely (lower abdominal pain, deep dyspareunia, 
abnormal vaginal bleeding, purulent vaginal discharge): facilitate 
cervical swabs for chlamydia and gonorrhoea. 
i) Sexually transmitted infection likely: facilitate appropriate 
investigation. 
j) Acute abdomen: refer to hospital for further investigation and 
management. 
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k) Meningitis likely (headache, stiff neck, altered mental state, shock, 
focal neurological deficit): refer to hospital for further investigation 
(CT brain, lumbar puncture) and management 
l) Endocarditis suspected ([Risk factors: valvular heart disease, 
valve replacement, structural congenital heart disease, 
hypertrophic cardiomyopathy, previous endocarditis, recreational 
drug abuse, invasive vascular procedures] and [Features: non-
specific symptoms, murmur, petechiae, splinter haemorrhages, 
clubbing, arthritis, Osler’s nodes, Janeway’s lesions, congestive 
cardiac failure]): discuss referral to hospital with responsible clinic 
physician for further investigation and management. 
m) Osteomyelitis / septic arthritis suspected: refer to hospital for 
investigation and further management. 
n) If appropriate, arrange further imaging (e.g. CT scan or sinus 
radiography) after discussion with responsible clinic physician 
 
4) No likely focus of infection identified: 
a) If measured temperature is >38.3: aerobic and anaerobic blood 
cultures.  
b) FBC + differential, CRP, renal and liver function, HbAlc, glucose 
and thyroid function. 
i) Discuss with responsible clinic physician if blood film should 
be arranged through routine system for suspected 
haematological cancer. 
c) Send urine for microscopy and culture. 
d) Repeat CXR if no CXR since onset of symptoms, or no CXR in last 
4 weeks. 
e) Abdominal ultrasound scan 
f) If measured fever: consider CT scan abdomen. 
g) If measured fever: consider sinus radiograph. 
5) If female < 45 years of age and symptoms suggestive of early 
menopause (hot flushes, night sweats, and irregular menstrual cycle):  
consider measurement of follicle-stimulating hormone (FSH) levels. 
 
Initial management plan for fever / night sweats: 
1) If focus of infection identified and participant does not require referral 
to hospital (mild (37.2-38) or moderate pyrexia (38.1-40) and not 
acutely unwell) then facilitate prescription for appropriate treatment for 
infection.  
2) Facilitate referral to hospital (discuss with responsible clinic physician) 
for further evaluation if: 
a) Acutely unwell 
b) High fever (>40) at assessment 
c) Hospital management required (e.g. surgery or further 
assessment)   
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3) If no measured or recorded fever discuss with responsible clinic 
physician. 
 
SECOND LINE if no clear diagnosis for fever / night sweats identified 
Discuss with responsible clinic physician regarding whether the following 
investigations are deemed clinically appropriate and can be arranged 
through clinic or by referral to specialist, for patients with measured fever 
or reported night sweats and no focus of infection identified. 
1) Autoimmune screen (antinuclear antibody [ANA], Rheumatoid factor) 
2) Abdominal CT scan 
3) Bone marrow aspiration 
6.  Research 
Clinician   
Participants will be reviewed at scheduled monthly follow up with the 
research team (or more frequently if clinically indicated).  
Follow up will include: 
1. Sputum to be sent for TB culture if cough reported 
2. If persistent cough, repeat CXR and ensure 3 sputa for TB culture (of 
which one induced, if feasible, and no contraindication to sputum 
induction [see SOP XPH-008]) 
3. Follow up of results of investigations 
4. Follow up of evolution of symptoms 
5. Follow up of outcome of specialist referrals  
6. Follow up of response to any treatments prescribed 
7.  Research 
Clinician   
Assignment of final diagnosis: 
Will be based assigned at 6 months based on results of investigations and 
response to any trials of treatment. 
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10.5. Evaluation of WHO 4-Symptom Tool to Rule Out TB: Data from the XPHACTOR Study (Poster) 
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10.6. Frequency and seasonal variation of TB symptoms amongst people 
taking antiretroviral therapy in South Africa (Poster) 
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